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ABSTRACT 
A series of pseudodipeptide-based chiral 1,3,4,5-tetrasubstituted-2-oxopiperazines has been 
designed and synthesized as potential PAR1 antagonists. These highly functionalized 
piperazines were synthesized from aromatic and basic amino acid derived 
[CH(CN)NH]pseudodipeptides through a four step pathway that involves reduction of the 
cyano group to build the 2-oxopiperazine ring, followed by selective functionalization at the 
N4-,  N1-positions, and at the exocyclic moiety at position C5. This regioselective 
functionalization required the fine tuning of reaction conditions. All new compounds were 
screened as inhibitors of human platelet aggregation induced by the PAR1 agonist SFLLRN 
and as cytotoxic agents in human cancer cell lines. Some of the compounds displayed 
moderate PAR1 antagonist activity, while, others were cytotoxic at M concentration. No 
correlation was observed between both types of activities. 
Keywords: PAR1 antagonists; Peptidomimetics; 2-Oxopiperazines; -Amino nitriles; Platelet 
antiaggregant activity; Cytotoxicity. 
 
1. Introduction 
Thrombin induces multiple effects on a variety of cells, such as: platelets [1-4], endothelial 
and smooth muscle cells [1, 4, 5], neurons and astrocytes in the nervous system [1, 4-10], 
immune and inflammatory cells [4, 11, 12], and tumor cells [13-18]. These effects are 
mediated by the activation of the protease-activated receptor 1 (PAR1) [19]. This activation 
requires the thrombin-catalyzed cleavage of the N-terminal extracellular domain of PAR1 at 
the Arg
41
/Ser
42
 peptide bond, which unveils the recognition sequence SFLLRN that acts as a 
tethered activation ligand.  
                                                          
*
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As PAR1 is mainly expressed in platelets, where its activation induces aggregation, it has 
been proposed that PAR1 antagonists could be good antithrombotic agents without the 
hemorrhagic drawbacks of thrombin inhibitors. Based on this suggestion, PAR1 antagonists 
have been searched almost exclusively in relation to the cardiovascular system up to now [2, 
3, 20].  However, numerous studies have shown that PAR1 is overexpressed in invasive and 
metastatic tumors and that its expression levels directly correlate with the degree of 
invasiveness of the cancer [17, 21-28]. Based on these facts, this receptor is starting to be also 
considered a promising target for cancer therapy [19].  
The first potent PAR1 antagonists were SFLLRN-based peptidomimetic ureas, represented 
by the optimized antagonist RWJ-58259 (Figure 1) [29], where an indazole ring is used as 
scaffold to assemble three key pharmacophoric groups (an aromatic and two amines). Later, 
several laboratories have reported a few series of antagonists obtained from HTS of diverse 
libraries of non-peptide small molecules, followed by optimization [20, 30], such SCH-
530348 (named vorapaxar, Figure 1) [31], currently in Phase III clinical trials [32-34].  
Mutagenesis, X-ray, and NMR studies have shown that the first thrombin/PAR1 
interaction is produced between the exosite I of thrombin and the hirudin-like sequence of 
PAR1 (K
51
YEPF
55
), and that this first interaction is essential and determinant for high 
thrombin/PAR1 affinity [35-46]. These studies have also indicated that the hydrophobic 
residues F34, I82, L65 and Y76, and the basic residues R67 and R73, of the exosite I of 
thrombin are important for high affinity. This knowledge prompted us to initiate a project 
directed to the search of new PAR1 antagonists based on the hot spots of the exosite I of 
thrombin for PAR1. As these hot spots are discontinuous and are not localized in a defined 
secondary structure, we decided to use a diversity oriented synthesis (DOS) strategy for the 
search of peptidomimetics. To this aim, we planned the synthesis of diverse small directed 
libraries of different scaffolds able to assemble, at least, one or two aromatic groups and one 
or two basic groups at variable distances and orientations. As a first result of this project, we 
have recently reported a library of ureas and thioureas of general formula A. Some of these 
derivatives showed moderate antiaggregant activity in a screen of inhibitors of human platelet 
aggregation induced by the PAR1 agonist SFLLRN [47]. 
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Fig. 1. Selected PAR1 antagonists and proposed 2-oxopiperazine derivatives B. 
 
We now describe the synthesis and biological evaluation of a library of pseudodipeptide-
based 2-oxopiperazine derivatives of general formula B, which could be considered as 
conformational restricted analogues of the urea derivatives A. The 2-oxopiperazine skeleton 
was selected as central core taking into account our synthetic experience in this heterocycle 
[48, 49] and that the piperazine ring is included among privileged scaffolds in medicinal 
chemistry. Actually, there are 165 drug entries for this heterocycle in the DrugBank database 
[50]. As in the series of urea derivatives A the side chain protection of the basic amino acid 
was necessary for their biological activity, the 2-oxopiperazine derivatives B were designed 
maintaining this protection. These piperazine derivatives have been screened as human PAR1 
antagonists in a platelet aggregation assay and as cytotoxic agents in human cancer cell lines. 
 
2. Results and discussion  
2.1. Synthesis 
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As shown in the retrosynthetic Scheme 1, a molecular diversity generation strategy in four 
steps was devised for the synthesis of the 2-oxopiperazine derivatives B, which started from 
the aromatic and basic amino acid derived [CH(CN)NH]pseudodipeptides E. This scheme 
consist of reduction of the cyano group, with subsequent in situ lactamization to give the 2-
oxopiperazines D, followed by selective functionalization at the N4 (C) and N1 positions, and 
at the exocyclic moiety at position C5 (R
4
). Phenylalanine and tryptophan were selected as 
aromatic amino acids and lysine and arginine as basic amino acids. 
Scheme 1.  Retrosynthesis of the 2-oxopiperazines B. 
 
The starting pseudodipeptides 4a,b and 5a (Scheme 2) were obtained by applying our 
methodology for the synthesis of [CH(CN)NH]pseudodipeptides [51], which involves a 
modified Strecker reaction of the protected -amino aldehydes Boc-Trp(Boc)-H (1) and Boc-
Phe-H (2) with the methyl esters of the side chain protected basic -amino acids 3a and 3b at 
-20 ºC for 1 h, followed by in situ reaction with TMSCN at 0 ºC for 24 h. In this way, 4a,b 
and 5a were obtained as (RS)-epimeric mixtures at the cyano-bearing stereocenter, which 
could not be chromatographically resolved. In the tryptophan derivatives (RS)-4a,b, the 
(R)/(S) epimer ratio was (1:2), while in the phenylalanine derivatives (RS)-5a, this ratio was 
(1:1). The Ni Raney catalyzed hydrogenation of these epimeric mixtures at room temperature 
and 1 atm of H2 pressure, with in situ lactamization, led to the corresponding 2-
oxopiperazines (RS)-6a,b and -7a in 60-80% overall yield, which were chromatographically 
resolved in the respective (R)- and (S)-epimers.  
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 Scheme 2.  Synthesis and configuration assignment of the 2-oxopiperazine derivatives 6a,b and 7a. 
 
Signal overlapping of the 3-H and 5-H protons in the 
1
H NMR spectra of (R)- and (S)-6a,b 
and -7a did not allow the NOE-based assignment of relative configuration at C5 with respect 
to that at C3. As the C3 chiral center came from the starting basic amino acid, its configuration 
was known. Therefore, with the aim of ascertaining the C5 configuration, the Arg derivatives 
(R)- and (S)-6a and -7a were transformed into the corresponding 3,6-
dioxooctahydroimidazo[1,5-a]pyrazine derivatives (R)- and (S)-8a and -9a by Boc-removal, 
followed by reaction with bis(trichloromethyl)carbonate in the presence of TEA. As shown in 
Scheme 2, the NOE effect between 1-H and 8a-H protons observed in the NOESY 1D spectra 
of (R)-8a and -9a were indicative of a relative cis disposition and, therefore, a (R)-
configuration at C8a, and, therefore, a (R)-configuration at C5 in (R)-6a and -7a. Similarly, the 
NOE effect between 5-H and 8a-H observed in the NOESY 1D spectra of (S)-8a and -9a were 
indicative of a trans relative disposition, and a (S)-configuration at C8a in these compounds, 
and at C5 in (S)-6a and -7a. The comparison of the 
1
H NMR data of each pair of epimers of 
these Arg derived 2-oxopiperazines 6a and 7a showed that in the (R)-epimers both 6-H were 
anisochronous (  0 ppm), while in the (S) they were isochronous ( = 0 ppm). 
Furthermore, 5-H appeared at a lower field (0.05-0.07 ppm) in the (R)-epimers than in the (S). 
On the other hand, it was observed that C3 and C5 appeared 2.5-3.8 ppm at higher field in the 
(R)-epimers than in the (S) in the 
13
C NMR spectra. These differences between epimers were 
used for the tentative configuration assignment in the lysine derived 2-oxopiperazines 6b, 
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where the selective transformation into 3,6-dioxooctahydroimidazo[1,5-a]pyrazine derivatives 
without removal of the Boc group at the side chain was not possible. 
The regioselective functionalization of the N4 and N1 positions of the 2-oxopiperazine ring 
of 6a,b and 7b was approached through alkylation reactions, by firstly applying the reaction 
conditions recently set up for related 2-oxopiperazine derivatives [49]. Thus, benzylation of 
(R)-7a was attempted by reaction with 1.1 equivalents of benzyl bromide in the presence of 
K2CO3 as base, under argon in CN3CN solution at 60 ºC. After 24 h of reaction, the HPLC-
MS analysis of the crude reaction showed 28% of the 4-benzyl derivative (R)-11a (Scheme 3) 
along with 72% of the starting compound (R)-7a (Table 1, entry 1). An increase of BnBr from 
the beginning of the reaction led to dirtier reactions. Therefore, to minimize side reactions an 
additional equivalent of BnBr and base was added each 24 h. In this way, after 3 days (Table 
1, entry 3), 68% of (R)-11a was obtained. The starting material completely disappeared with 
4.1 equivalents of reagents and 4 days of reaction, but, the reaction was significantly dirtier, 
to give only a 40% of the 4-benzyl derivative (R)-11a (entry 4). NaH, Cs2CO3 and 
diisiopropylethylamine (DIEA) were also tried as bases (Table 1, entries 5-10). Both NaH, 
Cs2CO3 led to very dirty reaction crudes. However, with DIEA the reactions were cleaner 
than with K2CO3, to provide 85% of (R)-11a by adding 4.1 equivalents of reagents (entry 10). 
These reaction conditions were also applied to the N4-benzylation of the 2-oxopiperazines 
(S)-7a and 6a,b, as well as for their N4-alkylation with tert-butyl bromoacetate (Scheme 3). In 
general, (R)-epimers gave higher yields (65-80%) than their respective (S)-isomer (50-80%). 
In the 
1
H NMR spectra the 6-H protons appeared as anisochronous, except for the (R)-epimer 
of the tryptophan derived N4-tert-butoxycarbonylmethyl-2-oxopiperazines (R)-12a,b, where 
these protons appeared as isochronous, indicating high conformational flexibility. 
 
Scheme 3.  N4-Alkylation of the 2-oxopiperazines 6a,b and 7a. 
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Table 1  
Optimization of the N4-benzylation conditions for (R)-7a 
Entry Base BnBr and base eq. t (days) 
Yield (%)
a
 
(R)-7a (R)-11a 
1 K2CO3 1.1 1 72 28 
2
b
 K2CO3 2.1 2 40 48 
3
b
 K2CO3 3.1 3 10 68 
4
b
 K2CO3 4.1 4 0 40 
5 NaH 1.1 1 47 3 
6 Cs2CO3 1.1 1 53 7 
7 DIEA 1.1 1 70 30 
8
b
 DIEA 2.1 2 41 59 
9
b
 DIEA 3.1 3 26 74 
10
b
 DIEA 4.1 4 0 85 
a 
Determined by HPLC-MS analysis [Sunfire C18 (4.6×50 mm, 3.5 m)]. 
b
Addition of 1 equiv. each 24 h. 
 
After the regiospecific alkylation at the N4-position, benzylation at N1 was studied by using 
the Phe and Arg derived 2-oxopiperazine (R)-11a for the setup of reaction conditions. 
Initially, this benzylation was attempted by applying previously described conditions 
developed for 2-oxopiperazine analogues [49], that is MW-activated reaction with BnBr in 
CH3CN at 150 ºC, using Cs2CO3 as base (Table 2, entry 1). This attempt revealed the 
simultaneous alkylation at the guanidino group of arginine, in spite of being protected with 
the Pbf group. Thus, as shown in Scheme 4, the HPLC-MS analysis of the crude reaction 
mixture showed the formation of three products, of which that benzylated at N1 and at the 
guanidino group (R)-19a (33%) was the major product. In view of this result, we decided to 
optimize the selective alkylation at N1 by minimizing the alkylation at the guanidino group. 
Different solvents, bases, reagent stoichiometries, temperatures and reaction times were tried, 
whose results are summarized in Table 2. It was not possible to completely avoid the 
alkylation at the guanidino group and the best results were obtained when the benzylation was 
performed in (9:1) THF/DMF mixture at 0 ºC, adding 0.5 equivalents of BnBr and 1 
equivalent of NaH in 1 h intervals during 3 h. In this way, the product of selective benzylation 
at N1 (R)-17a was isolated in 58% yield, while, the product of dibenzylation at N1 and at the 
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guanidino group (R)-19a was isolated in 20%. These reaction conditions were applied to the 
other N4-sustituted-2-oxopiperazines (R)- and (S)-(10a-13a). Although the products resulting 
from monobenzylation at the guanidino group (R)- and (S)-(15a, 18a, 21a and 24a) were 
identified in the HPLC-MS analysis of the crude reaction mixtures, they could not be isolated 
for their complete characterization. 
 
Scheme 4.  Benzylation of the arginine derived 4-substituted-2-oxopiperazines 10a-13a.  
Table 2  
Optimization of the N1-benzylation conditions for (R)-11a 
Entry Solvent Base (eq.) BnBr eq. T (ºC) t (h) 
Yield (%)
a
 
(R)-17a (R)-18a (R)-19a 
1 CH3CN Cs2CO3 (1) 1.1 150
b
 0.5 5 14 33 
2 THF NaH (2) 1.1 rt 1 14 5 3 
3 THF/DMF (9:1) NaH (2) 1.1 rt 1 32 1 30 
4 THF/DMF (9:1) NaH (2) 1.1 -20 1 11 0 5 
5 THF/DMF (9:1) NaH (2) 1.1 0 1 48 2 25 
6
c
 THF/DMF (9:1) NaH (3) 1.5 0 3 58 2 20 
a 
Determined by HPLC-MS analysis [Sunfire C18 (4.6×50 mm, 3.5 m)]. 
b
MW heating. 
c
Addition of 0.5 eq. of 
BnBr and 1 eq. of NaH each hour. 
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The assignment of the benzylation position was based on 
1
H,
1
H COSY and 
1
H,
13
C HSQC 
and HMBC correlation spectra. The benzyl methylenic protons at N1 in the piperazine ring 
and at the guanidino group appeared overlapped in 
1
H NMR and their assignment was carried 
out based on their HMBC correlation with the lactamic carbon C2, at 170-172 ppm, and with 
the guanidine carbon at 154-156 ppm, respectively. Furthermore, these methylenic protons at 
the N1 position appeared as an AB system, with a geminal coupling constant of 14-15 Hz. 
However, the methylenic protons at the guanidine group appeared as a doublet or doublet of 
doublets coupled to a NH, with a coupling constant of 5-6 Hz, which moved varying the 
spectra temperature, and disappeared after stirring with D2O. These data helped us to assign 
the structure of the trisubstituted guanidine group in 16a, 19a, 22a and 25a, with the Pbf 
protecting group attached to the C=N bond, as described for sulfaguanidines [52].  The 
HPLC-MS chromatograms of these benzylguanidylated compounds showed two overlapped 
peaks with the same mass in a (2:1) ratio, which could not be resolved. In spite of the signal 
overlapping and problems of resolution due to dynamic exchange, two isomers in the same 
ratio were also observed in the 
1
H NMR spectra of these compounds in (CD3)2CO, which 
were attributed to the interconverting E- and Z-isomers at the guanidino group [53, 54]. This 
interconversion could explain the low resolution of the 
1
HNMR spectra. 
The application of the benzylation conditions of entry 6 in Table 2 to the lysine derived N1-
unsubstituted-2-oxopiperazines (R)- and (S)-(10b and 12b) led to the corresponding N1-
benzyl derivatives (R)- and (S)-(26b and 27b) (Scheme 5), which were isolated in 70-80% 
yields, without observing benzylation at the lysine protected side chain.   
Scheme 5.  N1-Benzylation of the lysine derived 4-substituted-2-oxopiperazines 10b and 12b. 
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In the arginine derived 1,4-dibenzyl-2-oxopiperazines (R)- and (S)-(14a and 17a), where 
the selective removal of the Boc protections without removal of the protection at the basic 
amino acid side chain was possible, the Boc-HN group of the exocyclic moiety at C5 was 
replaced by a benzyl-ureido group. Thus, as shown in Scheme 6, removal of the Boc groups, 
by treatment with 3N solution of HCl in EtOAc, followed by reaction with benzyl isocyanate 
in the presence of TEA, gave the corresponding ureas (R)- and (S)-(28a and 29a) in 50-85% 
yield. In all cases, the Arg protection Pbf was not affected by the reactions.  
Scheme 6.  Synthesis of 2-oxopiperazine derived benzyl-ureas. 
 
It is interesting to note that in the 
1
H NMR spectra of the (S)-epimer of the N1-benzyl-N4-
tert-butoxycarbonylmethyl-2-oxopiperazine derivatives 21a, 22a, 24a, 25a and 27b, as well 
as of the urea derivatives 28a and 29a, the 6-H protons appeared as isochronous, indicative, as 
above commented, of high conformational flexibility in the piperazine ring.  
With the aim of studying the influence of the substituent R
4
 at position 5 of the 2-
oxipiperazines upon the biological activity, aralkyl analogues (R
4 
= H) were also synthesized 
following a similar synthetic strategy to that commented for the tryptophan and phenylalanine 
derivatives. As in the biological screening of these derivatives, compounds containing the 
arginine side chain had given better results than those containing the lysine side chain, the 
new analogues were focused only on those containing arginine. Thus, as shown in Scheme 7, 
the modified Strecker reaction of aldehydes 30 and 31 with H-Arg(Pbf)-OMe (3a) gave the 
corresponding epimeric mixtures of -amino nitriles (RS)-32a and -33a in a (1:1) ratio, which 
could not be separated. The Ni Raney catalyzed hydrogenation of these -amino nitriles led to 
the respective 2-oxopiperazine derivatives (R)- and (S)-34a and -35a, but in yields lower than 
40%, due to retro-Strecker and cyano removal side reactions. After studying other catalysts 
11 
 
and hydrogenation conditions, it was deduced that the best reduction conditions were 
hydrogen transfer from hydrazine monohydrate using Ni Raney as catalyst under refluxing 
MeOH for 10 min [47]. In this way, the epimeric mixtures  34a and 35a were obtained in 55-
86% yield and were chromatographically resolved into the (R)- and (S)-epimers. 
Scheme 7.  Synthesis and configuration assignment of the 2-oxopiperazine derivatives 34a and 35a. 
 
NOE effects between  the 3-H and 5-H protons were not observed in the NOESY 1D 
spectra of both epimers of the 2-oxopiperazines 34a and 35a in different solvents [CDCl3 or 
(CD3)2CO] to be used for assignment of configuration at C5. However, after the removal of 
the Arg side chain protection Pbf in the 5-phenethyl derivatives 34a, by treatment with TFA 
in the presence of triisopropylsilane (TIPS), the NOE effects observed in the NOESY 1D 
spectra of (R)- and (S)-36a in D2O [Scheme 7, NOE between 3-H and 5-H in (R)-36a and 
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between 3-H and 5-CH2 in (S)-36a] allowed the indirect assignment of configuration for both 
epimers in 36a and in 34a. In the comparison of the HPLC-MS and NMR data for the pair of 
epimers 34a, it was observed that the (S)-epimer showed higher tR than the (R) and that the 3-
H proton, as well as C3 and C5, appeared at a lower field in the (S)-epimer than in the (R). 
These differences between the pair of epimers were used for the tentative assignment of the 
analogue 2-oxopiperazines containing the N-Boc-indol-3-yl moiety 35a. 
The application of the reaction conditions previously set up for the regioselective 
alkylation of the 2-oxopiperazines 7a to (R)- and (S)-(34a and 35a) allowed first the 
preparation of the 4-benzyl-2-oxopiperazine derivatives (R)- and (S)-(37a and 38a) (Scheme 
8), and later that of the 1,4-dibenzyl-2-oxopiperazines (R)- and (S)-(39a and 42a) (40-50%), 
along with the tribenzylated derivatives (R)- and (S)-(41a and 44a), as minor products (8-
14%). As above commented, these tribenzylated derivatives also appeared as two inseparable 
mixture of E-and Z-benzylguanidyl derivatives in HPLC-MS and NMR. As in the case of the 
2-oxopiperazines 15a, 18a, 21a and 24a, the compounds resulting from benzylation at the N4-
position in the piperazine ring and at the guanidine group 40a and 43a, although were 
detected in the HPLC-MS spectra analyses, they could not be isolated and completely 
characterized.  
 Scheme 8.  Regioselective benzylations of the 2-oxopiperazines 34a and 35a. 
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2.2. Biological evaluation 
2.2.1. PAR1 antagonist activity 
Since PAR1 is mainly expressed in platelets, to evaluate the PAR1 antagonist activity, all 
new compounds were screened as inhibitors of human platelet aggregation induced by a 30 
µM concentration of the PAR1 agonist SFLLRN. The antagonist RWJ-58259 was used as a 
reference. At a 10 M concentration this antagonist inhibited 98% the platelet aggregation. 
All compounds were tested at an initial concentration of 0.1 mg/mL (≈ 150 M). None of the 
lysine derived 2-oxopiperazines 6b, 10b, 12b, 26b and 27b inhibited the platelet aggregation 
in this assay. However, as shown in Fig. 2, most of the arginine derived 1-benzyl-4-
substituted-2-oxopiperazines showed significant % of inhibition. The low range of variability 
in the inhibition percentages did not allow to establish clear structure-activity relationships. 
Thus, the type of aromatic moiety did not significantly affect the inhibition, except for the 
derivatives containing a benzyl-urea at the exocyclic substituent R
4
, wherein the Phe 
derivatives 29a were better than the respective Trp derivatives 28a. In fact, the (S)-epimer 
(S)-29a, with a 57% of inhibition was the best of the series. Neither the substituent at N4 (R
2
) 
nor the stereochemistry at C5 showed a clear influence upon the activity. In the case of 
stereochemistry, its low influence on the activity could be related to the already commented 
high flexibility of the 2-oxopiperazine ring, observed in the NMR spectra of most compounds. 
The comparative analysis of the platelet aggregation inhibition results of this series of 2-
oxopiperazine derivatives of general formula B with those of our previously reported series of 
urea analogues A [47], shows that the conformational restriction of the 2-oxopiperazine ring 
does not affect the binding of the compounds to PAR1, as the best compounds of both series 
displayed similar activity values. 
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Fig. 2. Inhibition (%) of human platelet aggregation induced by a 30 M concentration of SFLLRN. 
 
2.2.2. Antitumor activity  
All new compounds herein described were evaluated as antitumor agents in a HTS 
programme, which included evaluation of cytotoxicity on three representative human cancer 
cell lines: breast (MDA-MB-231), lung (A549), and colon (HT-29), using doxorubicin as 
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positive control and according to the National Cancer Institute (NCI) protocols. The three cell 
growth parameters: GI50 (concentration that produces 50% growth inhibition), TGI 
(concentration that produces total growth inhibition), and LC50 (concentration that produces 
50% of cellular death) were determined from the data analysis, automatically generated by the 
HTS laboratory information management system. The GI50 results of the compounds that 
displayed values lower than the highest 100 μM concentration are shown in Table 3.  
 
Table 3  
GI50 values of the cytotoxicity screening 
 
Compound Ar 
Conf. 
 (*) R
1
 n R
2
 R
3
 
GI50 (M) 
Breast 
MDAMB-231 
Lung 
A549 
Colon 
HT-29 
(R)-10a Ind(Boc) (R) C(NH2)=N-Pbf 3 Bn H 4.44 4.89 3.78 
(S)-10a Ind(Boc) (S) C(NH2)=N-Pbf 3 Bn H 4.55 5.55 3.78 
(R)-11a Ph (R) C(NH2)=N-Pbf 3 Bn H 6.83 1.24 5.26 
(S)-11a Ph (S) C(NH2)=N-Pbf 3 Bn H 6.04 5.39 3.29 
(R)-12a Ind(Boc) (R) C(NH2)=N-Pbf 3 CH2CO2
t
Bu H 4.54 3.25 4.98 
(S)-12a Ind(Boc) (S) C(NH2)=N-Pbf 3 CH2CO2
t
Bu H 4.87 7.68 2.92 
(R)-6b Ind(Boc) (R) Boc 4 H H 5.56 >10 5.43 
(S)-6b Ind(Boc) (S) Boc 4 H H 5.31 9.75 5.43 
(R)-10b Ind(Boc) (R) Boc 4 Bn H 2.92 4.86 4.58 
(S)-10b Ind(Boc) (S) Boc 4 Bn H 4.58 5.56 4.45 
(R)-12b Ind(Boc) (R) Boc 4 CH2CO2
t
Bu H 2.29 4.57 3.09 
(S)-12b Ind(Boc) (S) Boc 4 CH2CO2
t
Bu H 6.72 8.60 5.78 
(R)-26b Ind(Boc) (R) Boc 4 Bn Bn 3.33 >10 >10 
(S)-26b Ind(Boc) (S) Boc 4 Bn Bn 1.48 >10 3.83 
(R)-27b Ind(Boc) (R) Boc 4 CH2CO2
t
Bu Bn 1.56 >10 4.44 
Doxorubicin
a
       0.09 0.07 0.10 
a
Reference drug 
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As shown in Table 3, the N1-unsubstituted arginine derivatives (R
3
 =H) 10a-12a, as well as 
most of the tryptophan-lysine pseudodipeptide derived 2-oxopiperazines, displayed M 
cytotoxicity in the three cell lines. None of the compounds without the Boc-NH group at the 
aralkyl moiety at C5 showed cytotoxicity at the highest assayed concentration of 100 μM. 
Among the cytotoxic compounds, it is noteworthy to comment the selectivity of the lysine 
derived 1-benzyl-2-oxopiperazines (R)-, (S)-26b and (R)-27b against breast cancer cells 
MDAMB-231, for which they were the best compounds of the series. There was not any 
coincidence between the cytotoxic compounds with those active in the platelet aggregation 
assay. The lack of correlation between both two types of activities in this series of compounds 
seems to indicate independent mechanisms of action. 
 
3. Conclusions 
A series of pseudodipeptide based chiral 1,3,4,5-tetrasubstituted-2-oxopiperazines has been 
designed and synthesized as potential PAR1 antagonists by applying a DOS strategy. These 
highly functionalized piperazine derivatives are prepared through a versatile scheme in four 
steps from aromatic and basic amino acid derived [CH(CN)NH]pseudodipeptides. This 
route involves reduction of the cyano group to build the 2-oxo-piperazine ring, followed by 
selective functionalization at the N4-,  N1-positions, and at the exocyclic moiety at position 
C5. The selective functionalization at N4- and N1-positions, via alkylation, has required the 
fine tuning of the reaction conditions, particularly those of alkylation at N1-position in the 
arginine derivatives, in order to minimize the simultaneous alkylation at the protected 
arginine guanidino group. In spite of the wide screening of reaction conditions, it has not been 
possible to completely avoid this side reaction.  
To evaluate the PAR1 antagonist activity, all new synthesized compounds have been 
screened as inhibitors of human platelet aggregation induced by the PAR1 agonist SFLLRN. 
In this screening, most of the arginine derived 1-benzyl-4-substituted-2-oxopiperazines 
showed moderate antiaggregant activity. The low range of variability in the platelet inhibition 
percentages does not allow to establish clear structure-activity relationships. Besides, taking 
into account our interest in PAR1 antagonists in the field of antitumor agents, all compounds 
have also been included in a HTS programme for that activity. In this screening some of the 
N1-unsubstituted arginine derivatives and most of the tryptophan-lysine pseudodipeptide 
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derived 2-oxopiperazines, displayed M cytotoxicity in breast, lung, and colon human cancer 
cell lines. There is no correlation between the results of PAR1 antagonism and cytotoxicity of 
the compounds. Therefore, in this series of compounds the mechanisms responsible of both 
types of activity seems to be independent.   
 
4. Experimental 
4.1. General 
All reagents were of commercial quality. Solvents were dried and purified by standard 
methods. Analytical TLC was performed on aluminum sheets coated with a 0.2 mm layer of 
silica gel 60 F254. Silica gel 60 (230-400 mesh) was used for flash chromatography. Analytical 
RP-HPLC was performed on a Sunfire C18 (4.6×150 mm, 3.5 μm) column, with a flow rate of 
1 mL/min, using a tunable UV detector set at 214 and 254 nm and gradients of CH3CN 
(solvent A) and 0.05 % TFA in H2O (solvent B) as mobile phase. HPLC-MS was performed 
on a Sunfire C18 (4.6×50 mm, 3.5 μm) column at 30°C, with a flow rate of 1 mL/min. 
Gradients of CH3CN with 0.08% of formic acid (solvent A) in 0.1% of formic acid in H2O 
(solvent B) were used as mobile phase. Electrospray in positive mode was used for ionization. 
Melting points were taken on a Mettler Toledo M170 apparatus and are uncorrected. 
Elemental analyses were obtained on a CH-O-RAOID apparatus. Optical rotations were 
determined in a Perkin Elmer 141 polarimeter. NMR spectra were recorded using Varian 
Inova 300, Varian Inova or Mercury 400, and Varian Unity 500 spectrometers. NMR spectra 
assignment was based on COSY, HSQC, and HMBC spectra. NOESY 1D spectra were 
carried out at 400 MHz, using a gradient duration of 0.0005 s and mixing times of 0.5 s and 
0.70 s. MW experiments were performed in a MW reactor Emrys
TM
 Synthesizer (Biotage 
AB). 
4.2. General procedure for the synthesis of the Boc-Xaa[CH(CN)NH]Yaa-OMe 
pseudodipeptides (RS)-4a,b and -5a 
TEA (1.1 mL, 7.96 mmol) was added to a solution of H-Lys(Boc)-OMe·HCl or H-
Arg(Pbf)-OMe·HCl (7.96 mmol) in MeOH (40 mL). After 15 min of stirring at room 
temperature, the mixture was cooled to -20 ºC and ZnCl2 (542 mg, 3.98 mmol) was added, 
followed by the addition of the corresponding aldehyde Boc-Xaa-H (Xaa = Phe [55] or 
Trp(Boc) [56]) (992 mg, 3.98 mmol). The solution was stirred for 1 h at -20 ºC, and the 
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reaction was heated to 0 ºC. Then, TMSCN was added (896 μL, 7.16 mmol) and the mixture 
was stirred at 0ºC during 24 h. The solvent was removed under reduced pressure and the 
residue was dissolved in EtOAc (50 mL). The solution was washed with H2O (225 mL) and 
brine (25 mL), dried over Na2SO4, and evaporated to dryness. The residue was purified by 
flash chromatography, using EtOAc in hexane gradient as mobile phase to obtain the epimeric 
mixtures of pseudodipeptides (RS)-4a, (RS)-4b and (RS)-5a.  
4.2.1. Boc-Trp(Boc)[CH(CN)NH]Arg(Pbf)-OMe [(RS)-4a] 
Foam [4.80 g, 72%, (R:S) = (1:2)]; HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 60-100% 
gradient of solvent A in B, 30 min] tR  14.24 min; 
1
H NMR [400 MHz, (CD3)2CO]. (R)-4a δ 
(ppm): 1.34 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.67 [s, 9H, Boc (Ind)], 1.68 [m, 2H, -H 
(Arg)], 1.79 [m, 2H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, 
CH3 (Pbf)], 2.84 (m, 1H, NH), 2.97 [s, 2H, CH2 (Pbf)], 3.04 (m, 1H, 3-H), 3.24 [m, 2H, -H 
(Arg)], 3.28 (m, 1H, 3-H), 3.58 [m, 1H, α-H (Arg)], 3.68 (s, 3H, OMe), 4.01 (m, 1H, 1-H), 
4.18 (m, 1H, 2-H), 6.34 (d, 1H, J = 9.5 Hz, NHBoc), 6.47 [m, 3H, NHC(NH2)=N], 7.25 (d, 
1H, J = 7.5 Hz, Ind), 7.32 (d, 1H, J = 7.5 Hz, Ind), 7.58 (m, 1H, Ind), 7.62 (d, 1H, J = 7.5 Hz, 
Ind), 8.13 (d, 1H, J = 7.5 Hz, Ind). (S)-4a δ (ppm): 1.34 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 
(Pbf)], 1.67 [s, 9H, Boc (Ind)], 1.68 [m, 2H, -H (Arg)], 1.79 [m, 2H, -H (Arg)], 2.04 [s, 3H, 
CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.75 (m, 1H, NH), 2.96 [s, 2H, 
CH2 (Pbf)], 3.04 (m, 1H, 3-H), 3.24 [m, 2H, -H (Arg)], 3.28 (m, 1H, 3-H), 3.41 [m, 1H, α-H 
(Arg)], 3.70 (s, 3H, OMe), 3.95 (m, 1H, 1-H), 4.24 (m, 1H, 2-H), 6.44 (m, 1H, NHBoc), 6.47 
[m, 3H, NHC(NH2)=N], 7.25 (d, 1H, J = 7.5 Hz, Ind), 7.32 (d, 1H, J = 7.5 Hz, Ind), 7.58 (m, 
1H, Ind), 7.62 (d, 1H, J = 7.5 Hz, Ind), 8.13 (d, 1H, J = 7.5 Hz, Ind); 
13
C NMR (100 MHz, 
(CD3)2CO). (R)-4a δ (ppm): 12.5, 18.1, 19.5 [3CH3 (Pbf)], 27.0 (C3), 27.2 [Cγ (Arg)], 28.3 
[3CH3 (Boc)], 28.5 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 31.0 [Cβ (Arg)], 41.4 [Cδ (Arg)], 43.6 
[CH2 (Pbf)], 52.1 (Ome), 53.3 (C2), 54.4 (C1), 59.7 [Cα (Arg)], 79.4, 84.1 [2C (2Boc)], 86.9 
[C (Pbf)], 115.6 [CH (Ind)], 117.5 [C (Pbf)], 117.6 [C (Ind)], 119.5 (CN), 119.9, 123.3, 124.8, 
125.1 [4CH (Ind)], 125.3 [C (Pbf)], 131.6 [C (Ind)], 132.8, 135.6 [2C (Pbf)], 136.3 [C (Ind)], 
138.7 [C (Pbf)], 150.2, 156.3 [2CO (2Boc)], 157.3 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 
174.3 (CO2). (S)-4a δ (ppm): 12.5, 18.1, 19.5 [3CH3 (Pbf)], 26.9 (C3), 27.0 [Cγ (Arg)], 28.3 
[3CH3 (Boc)], 28.5 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 31.2 [Cβ (Arg)], 41.4 [Cδ (Arg)], 43.6 
[CH2 (Pbf)], 52.0 (Ome), 53.8 (C2), 54.0 (C1), 61.2 [Cα (Arg)], 79.4, 84.1 [2C (2Boc)], 86.9 
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[C (Pbf)], 115.6 [CH (Ind)], 117.5 [C (Pbf)], 117.7 [C (Ind)], 119.6 (CN), 119.9, 123.3, 124.8, 
125.1 [4CH (Ind)], 125.3 [C (Pbf)], 131.4 [C (Ind)], 132.8, 135.6 [2C (Pbf)], 136.3 [C (Ind)], 
138.7 [C (Pbf)], 150.2, 156.5 [2CO (2Boc)], 157.3 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 
174.8 (CO2); ES-MS m/z 838.7 [M+1]
+
; Anal. calcd. for C42H59N7O9S: C, 60.20; H, 7.10; N, 
11.70. Found: C, 60.11; H, 6.95; N, 11.94. 
4.2.2. Boc-Trp(Boc)[CH(CN)NH]Lys(Boc)-OMe [(RS)-4b] 
Foam [4.60 g, 87%, (R:S) = (1:2)]; HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 70-100% 
gradient of solvent A in B, 30 min] tR 11.00 min [(R)-4b] and 11.36 min [(S)-4b]; 
1
H NMR 
[400 MHz, (CD3)2CO]. (R)-4b δ (ppm): 1.35 (s, 9H, Boc), 1.38 [s, 9H, Boc (Lys)], 1.49 [m, 
2H, -H (Lys)], 1.52 [m, 2H, -H (Lys)], 1.67 [m, 9H, Boc (Ind)], 1.81 [m, 2H, -H (Lys)], 
2.82 (m, 1H, NH), 3.06 (m, 1H, 3-H), 3.08 [m, 2H, ε-H (Lys)], 3.31 (dd, 1H, J = 3 and 15 Hz, 
3-H), 3.58 [dd, 1H, J = 6.5 and 12 Hz, α-H (Lys)], 3.71 (s, 3H, OMe), 4.02 (m, 1H, 1-H), 4.20 
(m, 1H, 2-H), 5.94 [m, 1H, NHBoc (Lys)], 6.34 (d, 1H, J = 9 Hz, NHBoc), 7.26 (m, 1H, Ind), 
7.32 (m, 1H, Ind), 7.59 (m, 1H, Ind), 7.64 (d, 1H, J = 7.5 Hz, Ind), 8.14 (d, 1H, J = 7.5 Hz, 
Ind). (S)-4b δ (ppm): 1.35 (s, 9H, Boc), 1.38 [s, 9H, Boc (Lys)], 1.49 [m, 2H, -H (Lys)], 1.52 
[m, 2H, -H (Lys)], 1.67 [m, 9H, Boc (Ind)], 1.73 [m, 2H, -H (Lys)], 2.74 (m, 1H, NH), 3.01 
(m, 1H, 3-H), 3.08 [m, 2H, ε-H (Lys)], 3.24 (dd, 1H, J = 4.5 and 15 Hz, 3-H), 3.40 [dd, 1H, J 
= 8 and 15.5 Hz, α-H (Lys)], 3.72 (s, 3H, OMe), 3.98 (m, 1H, 1-H), 4.25 (m, 1H, 2-H), 5.94 
[m, 1H, NHBoc (Lys)], 6.45 (d, 1H, J = 8.5 Hz, NHBoc), 7.26 (m, 1H, Ind), 7.32 (m, 1H, 
Ind), 7.59 (m, 1H, Ind), 7.69 (d, 1H, J = 7.5 Hz, Ind), 8.14 (d, 1H, J = 7.5 Hz, Ind); 
13
C NMR 
(100 MHz, (CD3)2CO). (R)-4b δ (ppm): 23.6 [Cγ (Lys)], 27.3 (C3), 28.3, 28.7 [9CH3 (3Boc)], 
30.6 [Cδ (Lys)], 33.5 [Cβ (Lys)], 40.8 [Cε (Lys)], 52.1 (OMe), 53.3 (C2), 54.5 (C1), 59.9 [Cα 
(Lys)], 78.3, 79.3, 84.1 [3C (3Boc)], 115.9 [CH (Ind)], 117.6 [C (Ind)], 119.6 (CN), 119.9, 
123.3, 124.8, 125.1 [4CH (Ind)], 131.7, 136.4 [2C (Ind)], 150.3, 156.5 [3CO (3Boc)], 174.5 
[CO2]. (S)-4b δ (ppm): 23.6 [Cγ (Lys)], 27.0 (C3), 28.3, 28.5 [9CH3 (3Boc)], 30.6 [Cδ (Lys)], 
33.7 [Cβ (Lys)], 40.9 [Cε (Lys)], 52.0 [OMe], 53.7 (C2), 54.0 (C1), 61.5 [Cα (Lys)], 78.3, 79.3, 
84.1 [3C (3Boc)], 115.9 [CH (Ind)], 117.7 [C (Ind)], 119.7 (CN), 119.9, 123.4, 124.8, 125.1 
[4CH (Ind)], 131.5, 136.3 [2C (Ind)], 150.3, 156.5 [3CO (3Boc)], 175.0 (CO2); ES-MS m/z 
658.8 [M+1]
+
; Anal. calcd. for C34H51N5O8: C, 62.08; H, 7.81; N, 10.65. Found: C, 62.29; H, 
7.67; N, 10.78. 
4.2.3. Boc-Phe[CH(CN)NH]Arg(Pbf)-OMe [(RS)-5a] 
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Foam [5.30 g, 95%, (R:S) = (1:1)]; HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 60-100% 
gradient of solvent A in 30 min] tR  10.05 min [(R)-5a] and 10.25 min [(S)-5a]; 
1
H NMR [400 
MHz, (CD3)2CO]. (R)-5a δ (ppm): 1.32 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 (Pbf)], 1.66 [m, 2H, 
-H (Arg)], 1.78 [m, 2H, -H (Arg)], 2.05 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.59 [s, 
3H, CH3 (Pbf)], 2.63 (m, 1H, 3-H), 2.73 (m, 1H, 3-H), 2.85 (m, 1H, NH), 2.98 [s, 2H, CH2 
(Pbf)], 3.24 [m, 2H, -H (Arg)], 3.53 [m, 1H, α-H (Arg)], 3.66 (s, 3H, OMe), 3.90 (t, 1H, J = 
7 Hz, 1-H), 4.08 (m, 1H, 2-H), 6.29 (d, 1H, J = 7.5 Hz, NHBoc), 6.49 [m, 3H, 
NHC(NH2)=N], 7.21 (m, 1H, Ph), 7.24-7.32 (m, 4H, Ph). (S)-5a δ (ppm): 1.32 (s, 9H, Boc), 
1.44 [s, 6H, 2CH3 (Pbf)], 1.66 [m, 2H, -H (Arg)], 1.78 [m, 2H, -H (Arg)], 2.05 [s, 3H, CH3 
(Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.59 [s, 3H, CH3 (Pbf)], 2.63 (m, 1H, 3-H), 2.73 (m, 1H, 3-H), 
2.81 (m, 1H, NH), 2.98 [s, 2H, CH2 (Pbf)], 3.24 [m, 2H, -H (Arg)], 3.36 [m, 1H, α-H (Arg)], 
3.69 (s, 3H, OMe), 3.84 (dd, 1H, J = 4.5 and 11 Hz, 1-H), 4.08 (m, 1H, 2-H), 6.38 (d, 1H, J = 
9 Hz, NHBoc), 6.49 [m, 3H, NHC(NH2)=N], 7.21 (m, 1H, Ph), 7.24-7.32 (m, 4H, Ph); 
13
C 
NMR (100 MHz, (CD3)2CO). (R)-5a δ (ppm): 12.5, 18.1, 19.4 [3CH3 (Pbf)], 26.6 [Cγ (Arg)], 
28.5 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 31.0 [Cβ (Arg)], 37.3 (C3), 41.3 [Cδ (Arg)], 43.6 [CH2 
(Pbf)], 52.1 (Ome), 53.8 (C2), 54.7 (C1), 59.5 [Cα (Arg)], 79.3 [C (Boc)], 86.6, 117.5 [2C 
(Pbf)], 119.3 (CN), 125.3 [C (Pbf)], 127.1, 129.1, 130.8 [5CH (Ph)], 132.8, 135.5, 138.7 [3C 
(Pbf)], 139.4 [C (Ph)], 156.3 [CO (Boc)], 157.9 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 174.4 
[CO2]. (S)-5a δ (ppm): 12.5, 18.1, 19.4 [3CH3 (Pbf)], 26.0 [Cγ (Arg)], 28.5 [2CH3 (Pbf)], 28.7 
[3CH3 (Boc)], 31.1 [Cβ (Arg)], 37.1 (C3), 41.3 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 52.0 (Ome), 54.5 
(C2), 54.5 (C1), 60.9 [Cα (Arg)], 79.3 [C (Boc)], 86.6, 117.5 [2C (Pbf)], 119.4 (CN), 125.3 [C 
(Pbf)], 127.2, 129.2, 130.8 [5CH (Ph)], 132.8, 135.5, 138.7 [3C (Pbf)], 139.4 [C (Ph)], 156.3 
[CO (Boc)], 157.9 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 174.7 (CO2).; ES-MS m/z 699.6 
[M+1]
+
; Anal. calcd. for C35H50N6O7S: C, 60.15; H, 7.21; N, 12.03. Found: C, 60.21; H, 7.39; 
N, 11.91. 
4.3. General procedure for the synthesis of the 2-oxopiperazine derivatives (R)- and (S)-6a,b 
and -7a 
Raney-Ni (1.50 g) was added to a solution of the corresponding epimeric mixture of 
pseudodipeptides (RS)-4a,b and -5a (2.88 mmol) in MeOH (15 mL) and the mixture was 
hydrogenated at 1 atm of H2 at room temperature for 12 h. Afterward, the reaction mixture 
was filtered over celite and the solvent was evaporated under reduced pressure. The residue 
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was purified by flash chromatography, by using MeOH in CH2Cl2 gradient as mobile phase to 
obtain the desired resolved 2-oxopiperazines (R)- and (S)-6a,b and -7a. 
4.3.1. (5R,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-yl) 
ethyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)-
propyl)-2-oxopiperazine [(R)-6a]
1
 
White solid (933 mg, 40%); [α]D
20
  -5.1 (c 1.0, CH2Cl2); Mp: 118-120 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), isocratic 50% of solvent A] tR  8.70 min;
 1
H 
NMR (400 MHz, (CD3)2CO) δ (ppm): 1.30 (s, 9H, Boc), 1.42 [s, 6H, 2CH3 (Pbf)], 1.66 [s, 
3H, Boc (Ind)], 1.69 [m, 1H, -H (Arg)], 1.73 [m, 1H, -H (Arg)], 1.82 [m, 1H, -H (Arg)], 
1.89 [m, 1H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.59 [s, 3H, CH3 
(Pbf)], 2.87 (m, 1H, CH2-Ind), 2.95 [s, 2H, CH2 (Pbf)], 3.19 (m, 1H, 5-H), 3.27 (m, 1H, 6-H), 
3.28 [m, 2H, -H (Arg)], 3.35 [m, 1H, 3-H], 3.40 (m, 1H, CH2-Ind), 3.48 (dt, 1H, J = 4 and 
11.5 Hz, 6-H), 3.90 (m, 1H, 5-CH), 6.06 (d, 1H, J = 9.5 Hz, NHBoc), 6.58 [m, 3H, 
NHC(NH2)=N], 6.90 (s, 1H, 1-H), 7.22 (t, 1H, J = 7.5 Hz, Ind), 7.30 (t, 1H, J = 7.5 Hz, Ind), 
7.51 (m, 1H, Ind), 7.61 (d, 1H, J = 7.5 Hz, Ind), 8.12 (d, 1H, J = 7.5 Hz, Ind). 
13
C NMR (100 
MHz, (CD3)2CO) δ (ppm): 12.5, 18.2, 19.5 [3CH3 (Pbf)], 27.7 [Cγ (Arg) and CH2-Ind], 28.3 
[3CH3 (Boc)], 28.6 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 29.6 [Cβ (Arg)], 41.5 [Cδ (Arg)], 43.6 
[CH2 (Pbf)], 46.1 (C6), 51.8 (C5), 53.6 (C5-CH), 56.7 (C3), 79.4, 83.9 [2C (2Boc)], 86.9 [C 
(Pbf)], 115.6 [CH (Ind)], 117.4 [C (Pbf)], 118.9 [C (Ind)], 120.1, 123.2, 124.3, 124.9 [4CH 
(Ind)], 125.3 [C (Pbf)], 132.0 [C (Ind)], 132.8, 135.7 [2C (Pbf)], 136.4 [C (Ind)], 138.7 [C 
(Pbf)], 150.3, 156.8 [2CO (2Boc)], 157.3 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 173.0 (C2); 
ES-MS m/z 810.9 [M+1]
+
; Anal. calcd. for C41H59N7O8S: C, 60.79; H, 7.34; N, 12.10. Found: 
C, 60.52; H, 7.51; N, 12.27. 
4.3.2. (5S,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-yl) 
ethyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)-
propyl)-2-oxopiperazine [(S)-6a] 
White solid (467 mg, 20%); [α]D
20
  -15 (c 1.1, CH2Cl2); Mp: 118-120 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), isocratic 50% of solvent A] tR  9.05 min;
 1
H 
                                                          
1
 As the 2-oxopiperazine ring is the common structure of the compounds, we have preferred to give preference 
to this ring in the nomenclature of the compounds with respect to other senior groups or skeletons in the 
IUPAC nomenclature system. 
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NMR (400 MHz, (CD3)2CO) δ (ppm): 1.33 (s, 9H, Boc), 1.42 [s, 6H, 2CH3 (Pbf)], 1.66 [s, 
3H, Boc (Ind)], 1.68 [m, 2H, -H (Arg)], 1.70 [m, 1H, -H (Arg)], 1.92 [m, 1H, -H (Arg)], 
2.05 [s, 3H, CH3 (Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.59 [s, 3H, CH3 (Pbf)], 2.96 (m, 1H, CH2-
Ind), 2.97 [s, 2H, CH2 (Pbf)], 3.07 (m, 1H, CH2-Ind), 3.12 (m, 1H, 5-H), 3.24 [m, 2H, -H 
(Arg)], 3.27 (m, 2H, 6-H), 3.32 [m, 1H, 3-H], 4.00 (m, 1H, 5-CH), 6.09 (d, 1H, J = 9.5 Hz, 
NHBoc), 6.53 [m, 3H, NHC(NH2)=N], 6.85 (s, 1H, 1-H), 7.23 (t, 1H, J = 7.5 Hz, Ind), 7.31 (t, 
1H, J = 7.5 Hz, Ind), 7.54 (m, 1H, Ind), 7.68 (d, 1H, J = 7.5 Hz, Ind), 8.12 (d, 1H, J = 7.5 Hz, 
Ind). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.5 [Cγ (Arg) 
and CH2-Ph], 27.9 [CH2-Ind], 28.3 [3CH3 (Boc)], 28.6 [2CH3 (Pbf)], 28.8 [3CH3 (Boc)], 29.6 
[Cβ (Arg)], 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 46.1 (C6), 53.0 (C5-CH), 55.7 (C5), 59.2 (C3), 
78.9, 84.0 [2C (2Boc)], 86.9 [C (Pbf)], 115.8 [CH (Ind)], 117.4 [C (Pbf)], 118.5 [C (Ind)], 
120.1, 123.2, 124.5, 125.0 [4CH (Ind)], 125.4 [C (Pbf)], 131.8 [C (Ind)], 132.8, 135.6 [2C 
(Pbf)], 136.4 [C (Ind)], 138.7 [C (Pbf)], 150.3, 156.8 [2CO (2Boc)], 157.3 [C 
(NHC(NH2)=N)], 158.9 [C (Pbf)], 171.8 (C2]; ES-MS m/z 810.9 [M+1]
+
; Anal. calcd. for 
C41H59N7O8S: C, 60.79; H, 7.34; N, 12.10. Found: C, 60.97; H, 7.15; N, 12.32. 
4.3.3. (5R,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-yl)-
ethyl-3-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxopiperazine [(R)-6b] 
White solid (726 mg, 40%); [α]D
20
  -12 (c 1.6, CH2Cl2); Mp: 84-86 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 30-100% gradient of solvent A in B, 30 min] tR  
13.89 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.31 (s, 9H, Boc), 1.37 [s, 9H, Boc 
(Lys)], 1.52 [m, 2H, -H (Lys)], 1.54 [m, 2H, -H (Lys)], 1.66 [s, 9H, Boc (Ind)], 1.69 [m, 
1H, -H (Lys)], 1.84 [m, 1H, -H (Lys)], 2.40 (m, 1H, 4-H), 2.89 (m, 1H, CH2-Ind), 3.10 [m, 
2H, ε-H (Lys)], 3.17 (m, 1H, 5-H), 3.26 (m, 1H, 6-H), 3.31 (m, 1H, 3-H), 3.43 (m, 1H, CH2-
Ind), 3.47 (m, 1H, 6-H), 3.87 (ddd, 1H, J = 3, 9.5 and 18.5 Hz, 5-CH), 5.95 [m, 1H, NHBoc 
(Lys)], 6.01 (d, 1H, J = 9.5 Hz, NHBoc), 6.78 (s, 1H, 1-H), 7.23 (t, 1H, J = 7.5 Hz, Ind), 7.30 
(t, 1H, J = 7.5 Hz, Ind), 7.51 (m, 1H, Ind), 7.63 (d, 1H, J = 7.5 Hz, Ind), 8.12 (d, 1H, J = 7.5 
Hz, Ind). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 24.6 [Cγ (Lys)], 27.7 [CH2-Ind], 28.3, 
28.6, 28.7 [9CH3 (3Boc)], 30.7 [Cδ (Lys)], 31.2 [Cβ (Lys)], 41.2 [Cε (Lys)], 46.4 (C6), 52.0 
(C5), 53.6 (C5-CH), 57.7 (C3), 78.3, 78.7, 83.9 [3C (3Boc)], 115.8 [CH (Ind)], 118.9 [C (Ind)], 
120.1, 123.1, 124.3, 124.9 [4CH (Ind)], 132.1, 136.3 [2C (Ind)], 150.3, 156.6 [3CO (3Boc)], 
173.0 (C2); ES-MS m/z 630.8 [M+1]
+
; Anal. calcd. for C33H51N5O7: C, 62.93; H, 8.16; N, 
11.12. Found: C, 62.66; H, 8.37; N, 10.95. 
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4.3.4. (5S,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-yl)-
ethyl-3-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxopiperazine [(S)-6b] 
White solid (363 mg, 20%); [α]D
20
  -10 (c 1.4, CH2Cl2); Mp: 76-78 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 30-100% gradient of solvent A in 30 min] tR 
13.56 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.35 (s, 9H, Boc), 1.39 [s, 9H, Boc 
(Lys)], 1.48 [m, 2H, -H (Lys)], 1.50 [m, 2H, -H (Lys)], 1.59 [m, 1H, -H (Lys)], 1.67 [s, 
9H, Boc (Ind)], 1.94 [m, 1H, -H (Lys)], 2.99 (dd, 1H, J = 8 and 14.5 Hz, CH2-Ind), 3.08 [m, 
2H, ε-H (Lys)], 3.10 (m, 1H, CH2-Ind), 3.12 (m, 1H, 5-H), 3.26 (m, 2H, 6-H), 3.27 (m, 1H, 3-
H), 4.00 (m, 1H, 5-CH), 5.94 [m, 1H, NHBoc (Lys)], 6.06 (d, 1H, J = 9 Hz, NHBoc), 6.73 (s, 
1H, 1-H), 7.25 (t, 1H, J = 7.5 Hz, Ind), 7.31 (t, 1H, J = 7.5 Hz, Ind), 7.55 (m, 1H, Ind), 7.70 
(d, 1H, J = 7.5 Hz, Ind), 8.13 (d, 1H, J = 7.5 Hz, Ind). 
13
C NMR (100 MHz, (CD3)2CO) δ 
(ppm): 23.9 [Cγ (Lys)], 28.0 [CH2-Ind], 28.3, 28.6, 28.8 [9CH3 (3Boc)], 31.0 [Cδ (Lys)], 32.6 
[Cβ (Lys)], 41.1 [Cε (Lys)], 46.2 (C6), 53.0 (C5-CH), 55.5 (C5), 59.7 (C3), 78.3, 78.9, 84.0 [3C 
(3Boc)], 115.6 [CH (Ind)], 118.5 [C (Ind)], 120.1, 123.3, 124.6, 125.0 [4CH (Ind)], 131.8, 
136.4 [2C (Ind)], 150.3, 156.7 [3CO (3Boc)], 171.7 (C2); ES-MS m/z 630.8 [M+1]
+
; Anal. 
calcd. for C33H51N5O7: C, 62.93; H, 8.16; N, 11.12. Found: C, 62.83; H, 8.02; N, 10.90. 
4.3.5. (5R,3S)-5-((S)-1-(tert-Butoxycarbonyl)amino-2-phenylethyl)-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-oxopiperazine 
[(R)-7a] 
White solid (754 mg, 39%); [α]D
20
  -6 (c 1.0, CH2Cl2); Mp: 136-138 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 10-100% gradient of solvent A in B, 30 min] tR  
18.05 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.31 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 
(Pbf)], 1.60 [m, 2H, -H (Arg)], 1.70 [m, 1H, -H (Arg)], 1.80 [m, 1H, -H (Arg)], 2.06 [s, 
3H, CH3 (Pbf)], 2.35 (m, 1H, 4-H), 2.51 [s, 3H, CH3 (Pbf)], 2.59 [s, 3H, CH3 (Pbf)], 2.75 (dd, 
1H, J = 10 and 14 Hz, CH2-Ph), 2.98 [s, 2H, CH2 (Pbf)], 3.07 (m, 1H, 5-H), 3.18 [m, 1H, -H 
(Arg)], 3.23 (m, 1H, CH2-Ph), 3.24 (m, 1H, 6-H), 3.30 [m, 2H, -H (Arg) and 3-H], 3.43 (dt, 
1H, J = 4 and 12 Hz, 6-H), 3.83 (ddd, 1H, J = 4, 9.5 and 18 Hz, 5-CH), 5.96 (d, 1H, J = 9.5 
Hz, NHBoc), 6.58 [m, 3H, NHC(NH2)=N], 6.85 (s, 1H, 1-H), 7.16 (m, 1H, Ph), 7.20-7.28 (m, 
4H, Ph). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 13.2, 18.9, 20.2 [3CH3 (Pbf)], 28.0 [Cγ 
(Arg)], 29.2 [3CH3 (Boc)], 29.4 [2CH3 (Pbf)], 29.5 [Cβ (Arg)], 38.8 [CH2-Ph], 42.2 [Cδ 
(Arg)], 44.3 [CH2 (Pbf)], 46.6 (C6), 52.4 (C5), 55.8 (C5-CH), 57.4 (C3), 79.4 [C (Boc)], 87.6, 
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118.1 [2C (Pbf)], 125.9 [C (Pbf)], 127.4, 129.6, 130.9 [5CH (Ph)], 133.5, 136.6, 139.4 [3C 
(Pbf)], 140.9 [C (Ph)], 158.0 [CO (Boc)], 157.3 [C (NHC(NH2)=N)], 159.5 [C (Pbf)], 173.6 
[C2]; ES-MS m/z 671.6 [M+1]
+
; Anal. calcd. for C34H50N6O6S: C, 60.87; H, 7.51; N, 12.53. 
Found: C, 60.98; H; 7.73; N, 12.29. 
4.3.6. (5S,3S)-5-((S)-1-(tert-Butoxycarbonyl)amino-2-phenylethyl)-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-oxopiperazine 
[(S)-7a] 
White solid (792 mg, 41%); [α]D
20
  -27 (c 1.0, CH2Cl2); Mp: 138-140 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 10-100% gradient of solvent A in B,30 min] tR  
18.05 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.31 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 
(Pbf)], 1.60 [m, 2H, -H (Arg)], 1.80 [m, 1H, -H (Arg)], 1.90 [m, 1H, -H (Arg)], 2.06 [s, 
3H, CH3 (Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.59 [s, 3H, CH3 (Pbf)], 2.82 (m, 1H, CH2-Ph), 2.96 
(m, 1H, CH2-Ph), 3.00 [s, 2H, CH2 (Pbf)], 3.02 (m, 1H, 5-H), 3.22 [m, 2H, -H (Arg)], 3.24 
(m, 2H, 6-H), 3.28 [m, 1H, 3-H], 3.87 (m, 1H, 5-CH), 5.98 (d, 1H, J = 9 Hz, NHBoc), 6.52 
[m, 3H, NHC(NH2)=N], 6.82 (s, 1H, 1-H), 7.18 (m, 1H, Ph), 7.23-7.33 (m, 4H, Ph). 
13
C NMR 
(100 MHz, (CD3)2CO) δ (ppm): 13.2, 18.9, 20.2 [3CH3 (Pbf)], 27.1 [Cγ (Arg)], 29.2 [2CH3 
(Pbf)], 29.4 [3CH3 (Boc)], 29.6 [Cβ (Arg)], 39.1 [CH2-Ph], 41.2 [Cδ (Arg)], 44.3 [CH2 (Pbf)], 
46.8 (C6), 55.2 [C5-CH], 56.2 (C5), 59.9 (C3), 79.5 [C (Boc)], 87.6, 118.1 [2C (Pbf)], 125.9 [C 
(Pbf)], 127.6, 129.7, 130.8 [5CH (Ph)], 133.5, 136.6, 139.4 [3C (Pbf)], 140.5 [C (Ph)], 157.3 
[CO (Boc)], 158.0 [C (NHC(NH2)=N)], 159.6 [C (Pbf)], 172.5 (C2); ES-MS m/z 671.2 
[M+1]
+
; Anal. calcd. for C34H50N6O6S: C, 60.87; H, 7.51; N, 12.53. Found: C, 60.69; H, 7.69; 
N, 12.68. 
4.4. General procedure for the synthesis of the 3,6-dioxooctahydroimidazo[1,5-a]pyrazines 
(R)- and (S)-8a and -9a 
The corresponding 2-oxopiperazine (R)- and (S)-6a and -7a (0.31 mmol) was dissolved in 
3.4 N solution of HCl in EtOAc (5 mL) and the mixture was stirred at room temperature for 
30 min. Afterward, the solvent was evaporated to dryness, the residue was dissolved in 
CH3CN/H2O (1:3, 2 mL) and the solution was lyophilized. Then, TEA (87 µL, 0.62 mmol) 
was added to a solution of the lyophilized powder in CH2Cl2 (10 mL). After 15 min of stirring 
at 0 ºC, TEA (101 µL, 0.73 mmol) and triphosgene (36 mg, 0.12 mmol) were successively 
added. The mixture was stirred at 0 ºC for 2 h and the reaction was diluted CH2Cl2 (10 mL). 
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The solution was successively washed with H2O (25 mL) and brine (5 mL), dried over 
Na2SO4 and evaporated to dryness. The residue was purified by flash chromatography, using 
MeOH in CH2Cl2 gradient as mobile phase to obtain the respective 3,6-
dioxooctahydroimidazo[1,5-a]pyrazine (R)- and (S)-8a and -9a. 
4.4.1. (1S,5S,8aR)-1-(Indol-3-yl)methyl-5-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydro-
benzofuran-5-yl)sulfonyl)guanidino) propyl)-3,6-dioxooctahydroimidazo[1,5-a]pyrazine 
[(R)-8a] 
Foam (118 mg, 60%); [α]D
20
  -4.4 (c 0.8, CH2Cl2); HPLC [Sunfire C18 (4.6  150 mm, 3.5 
μm), 10-60% gradient of solvent A in B, 30 min] tR  27.20 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.42 [s, 6H, 2CH3 (Pbf)], 1.58 [m, 2H, -H (Arg)], 1.70 [m, 1H, -H 
(Arg)], 1.90 [m, 1H, -H (Arg)], 2.03 [s, 3H, CH3 (Pbf)], 2.48 [s, 3H, CH3 (Pbf)], 2.56 [s, 3H, 
CH3 (Pbf)], 2.97 [s, 2H, CH2 (Pbf)], 3.04 (d, 2H, J = 8.5 Hz, 1-CH2), 3.21 [m, 2H, -H (Arg)], 
3.30 (dt, 1H, J = 4.5 and 11.5 Hz, 8-H), 3.68 (t, 1H, J = 11.5 Hz, 8-H), 4.00 (ddd, 1H, J = 4.5, 
7.5 and 11.5 Hz, 8a-H), 4.14 (dd, 1H, J = 4 and 9.5 Hz, 5-H), 4.41 (q, 1H, J = 7.5 Hz, 1-H), 
5.94 (bs, 1H, 2-H), 6.50 [m, 3H, NHC(NH2)=N], 7.03 (dd, 1H, J = 4 and 11 Hz, Ind), 7.10 (m, 
2H, 1-H and Ind), 7.31 (d, 1H, J = 2.5 Hz, Ind), 7.41 (d, 1H, J = 8 Hz, Ind), 7.61 (d, 1H, J = 
7.5 Hz, Ind), 10.18 [m, 1H, NH (Ind)]; 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.5, 18.2, 
19.5 [3CH3 (Pbf)], 25.7 [1-CH2], 26.3 [Cγ (Arg)], 28.7 [2CH3 (Pbf)], 30.5 [Cβ (Arg)], 40.6 
(C8), 41.2 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 52.1 (C8a), 53.7 (C5 and C1), 86.9 [C (Pbf)], 111.5 [C 
(Ind)], 112.3 [CH (Ind)], 117.4 [C (Pbf)], 119.2, 119.6, 122.4, 123.8 [4CH (Ind)], 125.3 [C 
(Pbf)], 128.2 [C (Ind)], 132.8, 135.8 [2C (Pbf)], 137.7 [C (Ind)], 138.7 [C (Pbf)], 157.3 [C 
(NHC(NH2)=N)], 158.8 [C (Pbf)], 161.8 (C3), 170.0 (C6); ES-MS m/z 636.6 [M+1]
+
; Anal. 
calcd. for C32H41N7O5S: C, 60.45; H, 6.50; N, 15.42. Found: C, 60.64; H, 6.75; N, 15.20. 
4.4.2. (1S,5S,8aS)-1-(Indol-3-yl)methyl-5-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydro-
benzofuran-5-yl)sulfonyl)guanidino) propyl)-3,6-dioxooctahydroimidazo[1,5-a]pyrazine 
[(S)-8a] 
Foam (118 mg, 60%); [α]D
20
  -4.6 (c 0.6, CH2Cl2); HPLC [Sunfire C18 (4.6  150 mm, 3.5 
μm), 10-60% gradient of solvent A in B, 30 min] tR  27.39 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.42 [s, 6H, 2CH3 (Pbf)], 1.40 [m, 2H, -H (Arg)], 1.65 [m, 1H, -H 
(Arg)], 1.96 [m, 1H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.42 [ddd, 1H, J = 5, 10.5 and 18.5 
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Hz, -H (Arg)], 2.48 [s, 3H, CH3 (Pbf)], 2.56 [s, 3H, CH3 (Pbf)], 2.78 (ddd, 1H, J = 3.5, 5.5 
and 11.5 Hz, 8-H), 2.97 [s, 2H, CH2 (Pbf)], 3.02 (m, 1H, 1-CH2), 3.06 (m, 1H, 8-H), 3.16 [m, 
1H, -H (Arg)], 3.17 (m, 1H, 1-CH2), 3.52 (dt, 1H, J = 3.5 and 10 Hz, 8a-H), 3.85 (m, 1H, 1-
H), 3.86 (m, 1H, 5-H), 6.00 (m, 1H, 2-H), 6.27 [m, 1H, NHC(NH2)=N], 6.50 [m, 2H, 
NHC(NH2)=N], 7.02 (ddd, 1H, J = 1, 7 and 8 Hz, Ind), 7.03 (m, 1H, 1-H), 7.11 (ddd, 1H, J = 
1, 7 and 8 Hz, Ind), 7.29 (d, 1H, J = 2.5 Hz, Ind), 7.40 (dt, 1H, J = 1 and 8 Hz, Ind), 7.61 (dd, 
1H, J = 1 and 8 Hz, Ind), 10.18 [m, 1H, NH (Ind)]; 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 
12.5, 18.2, 19.5 [3CH3 (Pbf)], 24.8 [Cγ (Arg)], 28.3 [Cβ (Arg)], 28.7 [2CH3 (Pbf)], 30.7 [1-
CH2], 41.4 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 44.9 (C8), 55.9 (C8a), 57.9 (C5), 59.7 (C1), 86.9 [C 
(Pbf)], 110.9 [C (Ind)], 112.3 [CH (Ind)], 117.4 [C (Pbf)], 119.2, 119.7, 122.3, 124.3 [4CH 
(Ind)], 125.2 [C (Pbf)], 128.4 [C (Ind)], 132.8, 135.6 [2C (Pbf)], 137.6 [C (Ind)], 138.7 [C 
(Pbf)], 157.2 [C (NHC(NH2)=N)], 158.8 [C (Pbf)], 161.0 (C3), 170.2 (C6); ES-MS m/z 636.6 
[M+1]
+
; Anal. calcd. for C32H41N7O5S: C, 60.45; H, 6.50; N, 15.42. Found: C, 60.59; H, 6.24; 
N, 15.63. 
4.4.3. (1S,5S,8aR)-5-(3-(2-((2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-
guanidino)propyl)-1-phenylmethyl-3,6-dioxooctahydroimidazo[1,5-a]pyrazine [(R)-9a] 
Foam (94 mg, 51%); [α]D
20
  +4.1 (c 1.0, CH2Cl2); HPLC [Sunfire C18 (4.6  150 mm, 3.5 
μm), 10-100% gradient of solvent A in 30 min] tR 20.41 min;
 1
H NMR (400 MHz, (CD3)2CO) 
δ (ppm): 1.44 [s, 6H, 2CH3 (Pbf)], 1.64 [m, 2H, -H (Arg)], 1.90 [m, 2H, -H (Arg)], 2.04 [s, 
3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.57 [s, 3H, CH3 (Pbf)], 2.87 (m, 2H, 1-CH2), 2.98 
[s, 2H, CH2 (Pbf)], 3.19 [m, 2H, -H (Arg)], 3.27 (ddd, 1H, J = 4, 5 and 11.5 Hz, 8-H), 3.65 
(t, 1H, J = 11.5 Hz, 8-H), 3.97 (ddd, 1H, J = 4, 7 and 11.5 Hz, 8a-H), 4.13 (dd, 1H, J = 4 and 
9.5 Hz, 5-H), 4.29 (q, 1H, J = 7 Hz, 1-H), 5.86 (m, 1H, 2-H), 6.50 [m, 3H, NHC(NH2)=N], 
7.13 (m, 1H, Ph), 7.14 (d, 1H, J = 5 Hz, 1-H), 7.28-7.35 (m, 4H, Ph); 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm): 13.2, 18.8, 20.3 [3CH3 (Pbf)], 26.9 [Cγ (Arg)], 29.4 [2CH3 (Pbf)], 30.6 
[Cβ (Arg)], 36.4 [1-CH2], 41.7 (C8), 41.8 [Cδ (Arg)], 44.0 [CH2 (Pbf)], 52.8 (C8a), 54.4 (C5), 
55.4 (C1), 87.8, 118.1, 126.0 [3C (Pbf)], 128.1, 130.2, 130.4 [5CH (Ph)], 133.5, 136.6 [2C 
(Pbf)], 139.4 [C (Pbf) and C (Ph)], 158.0 [C (NHC(NH2)=N)], 159.5 [C (Pbf)], 162.3 (C3), 
170.6 (C6); ES-MS m/z 597.5 [M+1]
+
; Anal. calcd. for C30H40N6O5S: C, 60.38; H, 6.76; N, 
14.08. Found: C, 60.12; H, 6.47; N, 14.20. 
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4.4.4. (1S,5S,8aS)-5-(3-(2-((2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-
guanidino)propyl)-1-phenylmethyl-3,6-dioxooctahydroimidazo[1,5-a]pyrazine [(S)-9a] 
Foam (111 mg, 60%); [α]D
20
  -9.9 (c 1.2, CH2Cl2); HPLC [Sunfire C18 (4.6  150 mm, 3.5 
μm), 10-100% gradient of solvent A in 30 min] tR 21.31 min;
 1
H NMR (400 MHz, (CD3)2CO) 
δ (ppm): 1.44 [s, 6H, 2CH3 (Pbf)], 1.45 [m, 2H, -H (Arg)], 1.66 [m, 1H, -H (Arg)], 1.97 [m, 
1H, -H (Arg)], 2.05 [s, 3H, CH3 (Pbf)], 2.42 [m, 1H, -H (Arg)], 2.50 [s, 3H, CH3 (Pbf)], 
2.57 [s, 3H, CH3 (Pbf)], 2.74 (ddd, 1H, J = 3.5, 5.5 and 12 Hz, 8-H), 2.87 (m, 1H, 1-CH2), 
2.99 [s, 2H, CH2 (Pbf)], 3.07 (m, 2H, 8-H and 1-CH2), 3.17 [m, 1H, -H (Arg)], 3.51 (dt, 1H, 
J = 3.5 and 10 Hz, 8a-H), 3.77 (ddd, 1H, J = 6, 7.5 and 10 Hz, 1-H), 3.86 (dd, 1H, J = 3 and 6 
Hz, 5-H), 6.01 (m, 1H, 2-H), 6.30 [m, 1H, NHC(NH2)=N], 6.60 [m, 2H, NHC(NH2)=N], 7.13 
(d, 1H, J = 5.5 Hz, 1-H), 7.21-7.38 (m, 5H, Ph); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 
11.9, 17.5, 18.9 [3CH3 (Pbf)], 24.2 [Cγ (Arg)], 27.7 [Cβ (Arg)], 28.8 [2CH3 (Pbf)], 40.2 [1-
CH2], 40.8 [Cδ (Arg)], 43.0 [CH2 (Pbf)], 44.0 (C8), 57.2 (C5), 56.0 (C1), 58.7 (C8a), 86.3, 
116.7, 124.6 [3C (Pbf)], 126.9, 128.8, 129.5 [5CH (Ph)], 132.1, 134.9 [2C (Pbf)], 137.4 [C 
(Ph)], 138.0 [C (Pbf)], 156.6 [C (NHC(NH2)=N)], 158.2 [C (Pbf)], 160.3 (C3), 169.6 (C6); ES-
MS m/z 597.6 [M+1]
+
; Anal. calcd. for C30H40N6O5S: C, 60.38; H, 6.76; N, 14.08. Found: C, 
60.45; H, 6.50; N, 13.93. 
4.5 General procedure for the N4-alkylation of 2-oxopiperazines 6a,b and 7a. Synthesis of 
the 4-alkyl-2-oxopiperazines (R)- and (S)-(10a,b-13a) 
DIEA (456 µL, 2.71 mmol) and benzyl bromide (541 µL, 2.71 mmol) or tert-butyl 
bromoacetate (540 µL, 2.71 mmol) were added under argon in four equal portions over 72 h 
to a solution of the corresponding 2-oxopiperazine (R)- and (S)-6a,b and -7a (0.66 mmol) in 
anhydrous CH3CN (10 mL) at 60 ºC. After 4 days of stirring, the solvent was removed under 
reduced pressure and the residue was dissolved in CH2Cl2 (100 mL). The solution was 
successively washed with H2O (225 mL) and brine (25 mL), dried over Na2SO4 and 
evaporated to dryness. The residue was purified by flash chromatography, using MeOH in 
CH2Cl2 gradient as mobile phase to obtain the respective 4-benzyl-2-oxopiperazines (R)- and 
(S)-10a,b-13a. 
4.5.1. (5R,3S)-4-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(R)-10a] 
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Reddish solid (446 mg, 75%); [α]D
20
 -48 (c 1.5, CH2Cl2); Mp: 106-108 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 80-100% gradient of solvent A 
in B, 30 min] tR 7.35 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.29 (s, 9H, Boc), 1.42 [s, 
6H, 2CH3 (Pbf)], 1.65 [s, 3H, Boc (Ind)], 1.82 [m, 4H, -H and -H (Arg)], 2.02 [s, 3H, CH3 
(Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.57 [s, 3H, CH3 (Pbf)], 2.88 (m, 1H, CH2-Ind), 2.92 [s, 2H, 
CH2 (Pbf)], 3.03 [m, 1H, 3-H], 3.06 [m, 2H, -H (Arg)], 3.49 (m, 1H, 5-H), 3.50 (m, 1H, 6-
H), 3.61 [m, 3H, CH2-Ind, 4-CH2 (Bn) and 6-H], 4.20 [m, 2H, 5-CH and 4-CH2 (Bn)], 6.10 
(d, 1H, J = 9.5 Hz, NHBoc), 6.47 [m, 3H, NHC(NH2)=N], 6.97 (s, 1H, 1-H), 7.15 (t, 1H, J = 
7.5 Hz, Ar), 7.28 (m, 4H, Ar), 7.51 (m, 2H, Ar), 7.53 (m, 2H, Ar), 8.12 (d, 1H, J = 7.5 Hz, 
Ind). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.5, 18.2, 19.5 [3CH3 (Pbf)], 27.1 [Cγ 
(Arg)], 28.2 [CH2-Ind and 2CH3 (Pbf)], 28.3 [3CH3 (Boc)], 28.5 [Cβ (Arg)], 28.7 [3CH3 
(Boc)], 41.3 [Cδ (Arg)], 41.5 (C6), 43.6 [CH2 (Pbf)], 51.4 [C5-CH], 51.8 [4-CH2 (Bn)], 55.4 
(C5), 61.9 (C3), 78.8, 83.9 [2C (2Boc)], 86.9 [C (Pbf)], 115.8 [CH (Ar)], 117.4 [C (Pbf)], 
118.8 [C (Ar)], 119.9, 123.2, 124.4, 124.9 [4CH (Ar)], 125.3 [C (Pbf)], 128.1, 129.3, 129.8 
[5CH (Ar)], 132.0 [C (Ar)], 132.8, 135.6 [2C (Pbf)], 136.4 [C (Ar)], 138.7 [C (Pbf)], 139.6 [C 
(Ar)], 150.3, 156.6 [2CO (2Boc)], 157.4 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 172.1 (C2); 
ES-MS m/z 901.1 [M+1]
+
; Anal. calcd. for C48H65N7O8S: C, 64.05; H, 7.28; N, 10.89. Found: 
C, 64.23; H, 7.05; N, 11.13. 
4.5.2. (5S,3S)-4-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-
guanidino)propyl)-2-oxopiperazine [(S)-10a] 
Reddish solid (357 mg, 60%); [α]D
20
 -14 (c 1.1, CH2Cl2); Mp: 112-114 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 80-100% gradient of solvent A 
in B, 30 min] tR 7.32 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.33 (s, 9H, Boc), 1.43 [s, 
6H, 2CH3 (Pbf)], 1.44 [m, 2H, -H (Arg)], 1.55 [m, 3H, -H (Arg)], 1.66 [s, 3H, Boc (Ind)], 
2.03 [s, 3H, CH3 (Pbf)], 2.47 [s, 3H, CH3 (Pbf)], 2.55 [s, 3H, CH3 (Pbf)], 2.86 (m, 1H, CH2-
Ind), 2.94 [s, 2H, CH2 (Pbf)], 2.97 [m, 1H, -H (Arg)], 3.06 [m, 2H, -H (Arg) and 3-H], 3.14 
(m, 1H, 5-H), 3.16 [m, 3H, CH2-Ind], 3.47 (m, 1H, 6-H), 3.60 (m, 1H, 6-H), 3.76 [d, 1H, J = 
14 Hz, 4-CH2 (Bn)], 4.05 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.14 [m, 2H, 5-CH], 6.18 (d, 1H, J 
= 9 Hz, NHBoc), 6.40 [m, 3H, NHC(NH2)=N], 7.17 (s, 1H, 1-H), 7.24-7.55 (m, 8H, Ar), 7.64 
(d, 1H, J = 7.5 Hz, Ar), 8.13 (d, 1H, J = 7.5 Hz, Ind); 
13
C NMR (100 MHz, (CD3)2CO) δ 
(ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.6 [CH2-Ind], 27.6 [Cγ (Arg)], 28.3 [3CH3 (Boc)], 
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28.6 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 31.4 [Cβ (Arg)], 40.3 (C6), 41.3 [Cδ (Arg)], 43.6 [CH2 
(Pbf)], 53.5 [C5-CH], 62.3 [4-CH2 (Bn)], 63.4 (C5), 63.5 (C3), 78.9, 84.0 [2C (2Boc)], 86.9 [C 
(Pbf)], 115.9 [CH (Ar)], 117.4 [C (Pbf)], 118.9 [C (Ar)], 120.0, 123.2, 124.1, 125.0 [4CH 
(Ar)], 125.2 [C (Pbf)], 128.1, 129.1, 130.3 [5CH (Ar)], 131.9 [C (Ar)], 132.8, 135.7 [2C 
(Pbf)], 136.3 [C (Ar)], 138.7 [C (Pbf)], 140.0 [C (Ar)], 150.3, 156.7 [2CO (2Boc)], 157.3 [C 
(NHC(NH2)=N)], 158.9 [C (Pbf)], 173.4 (C2); ES-MS m/z 901.1 [M+1]
+
; Anal. calcd. for 
C48H65N7O8S: C, 64.05; H, 7.28; N, 10.89. Found: C, 63.87; H, 7.03; N, 11.24. 
4.5.3. (5R,3S)-4-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-3-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxopiperazine [(R)-10b] 
Reddish solid (333 mg, 70%); [α]D
20
 +0.9 (c 1.1, CH2Cl2); Mp: 76-78 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 70-100% gradient of solvent A in B, 30 min] tR 
11.27 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.29 [m, 2H, -H (Lys)], 1.30 (s, 9H, 
Boc), 1.34 [m, 2H, -H (Lys)], 1.36 [s, 9H, Boc (Lys)], 1.61 [m, 1H, -H (Lys)], 1.66 [s, 9H, 
Boc (Ind)], 1.72 [m, 1H, -H (Lys)], 1.83 [m, 1H, ε-H (Lys)], 2.88 (dd, 1H, J = 11 and 15 Hz, 
CH2-Ind), 3.00 [m, 1H, ε-H (Lys)], 3.04 (m, 1H, 3-H), 3.49 (m, 1H, 5-H), 3.50 (m, 1H, 6-H), 
3.60 [m, 2H, 4-CH2 (Bn) and 6-H], 3.63 (m, 1H, CH2-Ind), 4.22 [m, 1H, 4-CH2 (Bn)], 4.23 
(m, 1H, 5-CH), 5.80 [m, 1H, NHBoc (Lys)], 6.08 (d, 1H, J = 9.5 Hz, NHBoc), 6.82 (s, 1H, 1-
H), 7.18 (t, 1H, J = 7.5 Hz, Ar), 7.29 (m, 2H, Ar), 7.52 (m, 2H, Ar), 7.53 (m, 4H, Ar), 8.12 (d, 
1H, J = 7.5 Hz, Ar). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 24.5 [Cγ (Lys)], 28.2 [CH2-
Ind], 28.3, 28.5, 28.7 [9CH3 (3Boc)], 30.3 [Cδ (Lys)], 31.1 [Cβ (Lys)], 41.1 [Cε (Lys)], 41.5 
(C6), 51.3 [C5-CH], 51.9 [4-CH2 (Bn)], 55.4 (C5), 62.2 (C3), 78.8, 83.9 [3C (3Boc)], 115.8 
[CH (Ar)], 118.8 [C (Ar)], 119.9, 123.2, 124.3, 124.9, 128.0, 129.3, 129.9 [9CH (Ar)], 132.0, 
136.4, 139.7 [3C (Ar)], 150.3, 156.6 [3CO (3Boc)], 172.0 (C2); ES-MS m/z 720.9 [M+1]
+
; 
Anal. calcd. for C40H57N5O7: C, 66.73; H, 7.98; N, 9.73. Found: C, 66.51; H, 8.15; N, 9.95. 
4.5.4. (5S,3S)-4-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-3-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxopiperazine [(S)-10b] 
Reddish solid (381 mg, 80%); [α]D
20
 +13.6 (c 1.2, CH2Cl2); Mp: 84-86 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 70-100% gradient of solvent A 
in B 30 min] tR 11.86 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.21 [m, 2H, -H (Lys)], 
1.31 [m, 2H, -H (Lys)], 1.36 [m, 19H, Boc, Boc (Lys) and -H (Lys)], 1.67 [s, 9H, Boc 
(Ind)], 1.68 [m, 1H, -H (Lys)], 2.92 (m, 1H, CH2-Ind), 2.94 [m, 2H, ε-H (Lys)], 3.07 (t, 1H, 
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J = 7 Hz, 3-H), 3.14 (m, 1H, 5-H), 3.24 (dd, 1H, J = 2.5 and 15 Hz, CH2-Ind), 3.53 (m, 2H, 6-
H), 3.80 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.08 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.17 (m, 1H, 5-
CH), 5.82 [m, 1H, NHBoc (Lys)], 6.13 (d, 1H, J = 8.5 Hz, NHBoc), 7.03 (s, 1H, 1-H), 7.26 
(m, 2H, Ar), 7.34 (m, 3H, Ar), 7.51 (m, 3H, Ar), 7.66 (d, 1H, J = 7.5 Hz, Ar), 8.14 (d, 1H, J = 
7.5 Hz, Ar). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 24.1 [Cγ (Lys)], 26.6 [CH2-Ind], 28.3, 
28.7 [9CH3 (3Boc)], 30.0 [Cδ (Lys)], 34.4 [Cβ (Lys)], 40.2 (C6), 40.9 [Cε (Lys)], 52.9 [C5-
CH], 62.4 [4-CH2 (Bn)], 63.9 (C5), 64.0 (C3), 78.2, 78.8, 84.0 [3C (3Boc)], 115.9 [CH (Ar)], 
119.0 [C (Ar)], 120.0, 123.2, 124.0, 125.0, 128.0, 129.1, 130.2 [9CH (Ar)], 131.9, 136.4, 
140.2 [3C (Ar)], 150.3, 156.6 [3CO (3Boc)], 173.2 (C2); ES-MS m/z 720.9 [M+1]
+
; Anal. 
calcd. for C40H57N5O7: C, 66.73; H, 7.98; N, 9.73. Found: C, 66.49; H, 8.21; N, 9.51. 
4.5.5. (5R,3S)-4-Benzyl-5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-
oxopiperazine [(R)-11a] 
Reddish solid (401 mg, 80%); [α]D
20
 -25 (c 1.0, CH2Cl2); Mp: 102-104 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 60-100% gradient of solvent A 
in B, 30 min] tR 16.05 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.28 (s, 9H, Boc), 1.45 
[s, 6H, 2CH3 (Pbf)], 1.73 [m, 4H, -H and -H (Arg)], 2.05 [s, 3H, CH3 (Pbf)], 2.51 [s, 3H, 
CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.78 (dd, 1H, J = 11 and 14 Hz, CH2-Ph), 2.98 [s, 2H, 
CH2 (Pbf)], 3.00 [m, 2H, -H (Arg)], 3.06 [m, 1H, 3-H], 3.40 (m, 1H, 5-H), 3.44 (m, 1H, 6-
H), 3.50 (m, 1H, CH2-Ph), 3.54 [m, 1H, 4-CH2 (Bn)], 3.60 (m, 1H, 6-H), 4.10 (m, 1H, 5-CH), 
4.21 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 6.01 (d, 1H, J = 9.5 Hz, NHBoc), 6.48 [m, 3H, 
NHC(NH2)=N], 6.94 (s, 1H, 1-H), 7.14-7.52 (m, 10H, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ 
(ppm): 12.5, 18.2, 19.5 [3CH3 (Pbf)], 27.1 [Cγ (Arg)], 28.3 [Cβ (Arg)], 28.5 [3CH3 (Boc)], 
28.7 [2CH3 (Pbf)], 38.6 [CH2-Ph], 41.2 (C6), 41.4 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 51.7 [4-CH2 
(Bn)], 53.1 [C5-CH], 55.4 (C5), 61.9 (C3), 78.7 [C (Boc)], 86.9, 117.5, 125.3 [3C (Pbf)], 
126.7, 128.1, 128.9, 129.3, 129.9, 130.2 [10CH (Ar)], 132.8, 135.6, 138.7 [3C (Pbf)], 139.7 
[C (Ar)], 140.3 [C (Ar)], 156.5 [CO (Boc)], 157.3 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 172.0 
(C2); ES-MS m/z 761.6 [M+1]
+
; Anal. calcd. for C41H56N6O6S: C, 64.71; H, 7.42; N, 11.04. 
Found: C, 64.48; H, 7.65; N, 11.25. 
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4.5.6. (5S,3S)-4-Benzyl-5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-
oxopiperazine [(S)-11a] 
Reddish solid (351 mg, 70%); [α]D
20
 +21 (c 1.0, CH2Cl2); Mp: 100-102 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 60-100% gradient of solvent A 
in B, 30 min] tR 16.01 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.27 [m, 2H, -H (Arg)], 
1.30 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.59 [m, 2H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 
2.48 [s, 3H, CH3 (Pbf)], 2.54 [s, 3H, CH3 (Pbf)], 2.68 (dd, 1H, J = 11 and 13.5 Hz, CH2-Ph), 
2.93 [m, 1H, -H (Arg)], 2.97 [s, 2H, CH2 (Pbf)], 3.00 (m, 1H, 5-H), 3.01 [m, 1H, -H (Arg)], 
3.06 [m, 1H, 3-H], 3.10 (m, 1H, CH2-Ph), 3.38 (t, 1H, J = 13 Hz, 6-H), 3.53 (dt, 1H, J = 6 and 
13 Hz, 6-H), 3.72 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 3.99 (m, 1H, 5-CH), 4.06 [m, 1H, 4-CH2 
(Bn)], 6.17 (d, 1H, J = 9 Hz, NHBoc), 6.44 [m, 3H, NHC(NH2)=N], 7.12-7.48 (m, 11H, 1-H 
and Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 11.9, 17.5, 18.8 [3CH3 (Pbf)], 25.9 [Cγ 
(Arg)], 28.0 [3CH3 (Boc)], 28.2 [2CH3 (Pbf)], 30.9 [Cβ (Arg)], 36.1 [CH2-Ph], 39.5 (C6), 40.5 
[Cδ (Arg)], 42.9 [CH2 (Pbf)], 54.8 (C5-CH), 61.6 [4-CH2 (Bn)], 62.7 (C5), 63.1 (C3), 78.2 [C 
(Boc)], 86.2, 116.7, 124.6 [3C (Pbf)], 126.1, 127.4, 128.3, 128.4, 129.3, 129.6 [10CH (Ar)], 
132.1, 134.9, 138.0 [3C (Pbf)], 139.5 [C (Ar)], 139.7 [C (Ar)], 155.9 [CO (Boc)], 156.6 [C 
(NHC(NH2)=N)], 158.2 [C (Pbf)], 172.6 (C2); ES-MS m/z 761.6 [M+1]
+
; Anal. calcd. for 
C41H56N6O6S: C, 64.71; H, 7.42; N, 11.04. Found: C, 64.53; H, 7.21; N, 11.31. 
4.5.7. (5R,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-
yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(R)-12a] 
Reddish solid (397 mg, 65%); [α]D
20
 +19 (c 1.4, CH2Cl2); Mp: 102-104 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 80-100% gradient of solvent A 
in B, 30 min] tR 7.48 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.28 (s, 9H, Boc), 1.42 [s, 
6H, 2CH3 (Pbf)], 1.47 (s, 9H, 
t
Bu), 1.66 [s, 3H, Boc (Ind)], 1.80 [m, 4H, -H and -H (Arg)], 
2.03 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.80 (m, 1H, CH2-
Ind), 2.93 [s, 2H, CH2 (Pbf)], 3.20 [m, 1H, 3-H], 3.21 (m, 1H, 4-CH2), 3.33 [m, 2H, -H 
(Arg)], 3.40 (m, 1H, 5-H), 3.49 (m, 2H, 6-H), 3.60 (m, 1H, CH2-Ind), 3.64 (m, 1H, 4-CH2), 
3.92 (m, 1H, 5-CH), 6.07 (d, 1H, J = 9.5 Hz, NHBoc), 6.53 [m, 3H, NHC(NH2)=N], 6.92 (s, 
1H, 1-H), 7.24 (t, 1H, J = 7.5 Hz, Ind), 7.30 (t, 1H, J = 7.5 Hz, Ind), 7.51 (s, 1H, Ind), 7.64 (d, 
32 
 
1H, J = 7.5 Hz, Ind), 8.12 (d, 1H, J = 7.5 Hz, Ind); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 
12.5, 18.2, 19.5 [3CH3 (Pbf)], 27.4 (CH2-Ind), 27.8 [Cγ (Arg)], 28.3 [3CH3 (Boc)], 28.5 [Cβ 
(Arg) and 3CH3 (
t
Bu)], 28.7 [3CH3 (Boc) and 2CH3 (Pbf)], 41.6 [Cδ (Arg)], 41.8 (C6), 43.6 
[CH2 (Pbf)], 51.7 (C5-CH), 51.9 (4-CH2), 55.6 (C5), 64.9 (C3), 78.8 [C (Boc)], 81.6 [C (
t
Bu)], 
83.9 [C (Boc)], 86.9 [C (Pbf)], 115.8 [CH (Ind)], 117.4 [C (Pbf)], 118.9 [C (Ind)], 120.0, 
123.1, 124.5, 124.9 [4CH (Ind)], 125.3 [C (Pbf)], 131.9 [C (Ind)], 132.8, 135.6 [2C (Pbf)], 
136.4 [C (Ind)], 138.7 [C (Pbf)], 150.3, 156.6 [2CO (2Boc)], 157.4 [C (NHC(NH2)=N)], 
158.9 [C (Pbf)], 171.0 (CO2), 171.8 (C2); ES-MS m/z 925.2 [M+1]
+
; Anal. calcd. for 
C47H69N7O10S: C, 61.08; H, 7.53; N, 10.61. Found: C, 61.35; H, 7.29; N, 10.48. 
4.5.8. (5S,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-
yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(S)-12a] 
Reddish solid (305 mg, 50%); [α]D
20
 +9.0 (c 1.2, CH2Cl2); Mp: 120-122 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 80-100% gradient of solvent A 
in B, 30 min] tR 7.19 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.32 (s, 9H, Boc), 1.43 [s, 
6H, 2CH3 (Pbf)], 1.44 (s, 9H, 
t
Bu), 1.66 [s, 3H, Boc (Ind)], 1.77 [m, 4H, -H and -H (Arg)], 
2.03 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.57 [s, 3H, CH3 (Pbf)], 2.79 (dd, 1H, J = 10 
and 14 Hz, CH2-Ind), 2.96 [s, 2H, CH2 (Pbf)], 3.20 (m, 1H, CH2-Ind), 3.21 (m, 1H, 5-H), 3.24 
[m, 2H, -H (Arg)], 3.32 [m, 1H, 3-H], 3.46 (m, 1H, 6-H), 3.55 (m, 2H, 4-CH2 and 6-H), 3.66 
(d, 1H, J = 18 Hz, 4-CH2), 4.05 (m, 1H, 5-CH), 6.24 (d, 1H, J = 8.5 Hz, NHBoc), 6.50 [m, 
3H, NHC(NH2)=N], 7.15 (s, 1H, 1-H), 7.24 (t, 1H, J = 7.5 Hz, Ind), 7.31 (t, 1H, J = 7.5 Hz, 
Ind), 7.51 (s, 1H, Ind), 7.64 (d, 1H, J = 7.5 Hz, Ind), 8.12 (d, 1H, J = 7.5 Hz, Ind); 
13
C NMR 
(100 MHz, (CD3)2CO) δ (ppm): 12.5, 18.2, 19.5 [3CH3 (Pbf)], 25.5 (CH2-Ind), 26.4 [Cγ 
(Arg)], 28.3 [6CH3 (Boc and 
t
Bu)], 28.6 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 31.6 [Cβ (Arg)], 
39.9 [C6], 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 52.1 (C5-CH), 56.9 (4-CH2), 60.9 (C5), 64.6 (C3), 
78.8 [C (Boc)], 81.7 [C (
t
Bu)], 84.0 [C (Boc)], 86.9 [C (Pbf)], 115.9 [CH (Ind)], 117.4 [C 
(Pbf)], 119.1 [C (Ind)], 120.0, 123.1, 124.1, 125.0 [4CH (Ind)], 125.6 [C (Pbf)], 131.8 [C 
(Ind)], 132.8, 135.7 [2C (Pbf)], 136.4 [C (Ind)], 138.7 [C (Pbf)], 150.3, 156.5 [2CO (2Boc)], 
157.3 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 171.3 (CO2 and C2); ES-MS m/z 925.1 [M+1]
+
; 
Anal. calcd. for C47H69N7O10S: C, 61.08; H, 7.53; N, 10.61. Found: C, 61.29; H, 7.75; N, 
10.40. 
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4.5.9. (5R,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-
yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(4-((tert-butoxycarbonyl)amino)butyl)-2-
oxopiperazine [(R)-12b] 
Reddish solid (368 mg, 75%); [α]D
20
 +3 (c 1.7, CH2Cl2); Mp: 78-80 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 70-100% gradient of solvent A in b, 30 min] tR 
11.54 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.29 (s, 9H, Boc), 1.36 [s, 9H, Boc 
(Lys)], 1.49 (s, 9H, 
t
Bu), 1.59 [m, 2H, -H (Lys)], 1.60 [m, 2H, -H (Lys)], 1.67 [s, 9H, Boc 
(Ind)], 1.79 [m, 1H, -H (Lys)], 1.80 [m, 1H, -H (Lys)], 2.78 (dd, 1H, J = 11 and 15 Hz, 
CH2-Ind), 3.12 [m, 2H, ε-H (Lys)], 3.19 (m, 2H, 3-H and 4-CH2), 3.39 (m, 1H, 5-H), 3.41 (m, 
2H, 6-H), 3.64 (d, 1H, J = 16 Hz, 4-CH2), 3.66 (dd, 1H, J = 2 and 15 Hz, CH2-Ind), 3.94 (m, 
1H, 5-CH), 5.93 [m, 1H, NHBoc (Lys)], 6.07 (d, 1H, J = 9.5 Hz, NHBoc), 6.84 (s, 1H, 1-H), 
7.23 (t, 1H, J = 7.5 Hz, Ind), 7.30 (t, 1H, J = 7.5 Hz, Ind), 7.51 (s, 1H, Ind), 7.64 (d, 1H, J = 
7.5 Hz, Ind), 8.13 (d, 1H, J = 7.5 Hz, Ind). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 24.7 [Cγ 
(Lys)], 27.8 (CH2-Ind), 28.3 [6CH3 (Boc and 
t
Bu)], 28.5, 28.7 [6CH3 (2Boc)], 30.4 [Cδ (Lys)], 
31.1 [Cβ (Lys)], 41.2 [Cε (Lys)], 41.8 (C6), 51.9 (C5-CH), 52.1 (4-CH2), 55.8 (C5), 65.2 (C3), 
78.2, 78.8 [2C (2Boc)], 81.5[C (
t
Bu)], 83.9 [C (Boc)], 115.8 [CH (Ind)], 118.9 [C (Ind)], 
120.0, 123.1, 124.3, 124.9 [4CH (Ind)], 132.0, 136.4 [2C (Ind)], 150.3, 156.6 [3CO (3Boc)], 
171.0 (CO2), 171.8 (C2); ES-MS m/z 744.9 [M+1]
+
; Anal. calcd. for C39H61N5O9: C, 62.97; H, 
8.26; N, 9.41. Found: C, 63.21; H, 8.15; N, 9.24. 
4.5.10. (5S,3S)-5-((S)-1-((tert-Butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-indol-3-
yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(4-((tert-butoxycarbonyl)amino)butyl)-2-
oxopiperazine [(S)-12b] 
Reddish solid (295 mg, 60%); [α]D
20
 +10 (c 1.2, CH2Cl2); Mp: 80-82 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 70-100% gradient of solvent A in B, 30 min] tR 
12.04 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.34 (s, 9H, Boc), 1.37 [s, 9H, Boc 
(Lys)], 1.45 (s, 9H, 
t
Bu), 1.53 [m, 2H, -H (Lys)], 1.56 [m, 2H, -H (Lys)], 1.66 [s, 9H, Boc 
(Ind)], 1.77 [m, 2H, -H (Lys)], 2.80 (m, 1H, CH2-Ind), 3.07 [m, 2H, ε-H (Lys)], 3.23 (m, 1H, 
CH2-Ind), 3.27 (m, 1H, 5-H), 3.30 (m, 1H, 3-H), 3.50 (m, 2H, 6-H), 3.57 (d, 1H, J = 18 Hz, 4-
CH2), 3.68 (d, 1H, J = 18 Hz, 4-CH2), 4.07 (m, 1H, 5-CH), 5.93 [m, 1H, NHBoc (Lys)], 6.21 
(d, 1H, J = 8.5 Hz, NHBoc), 7.00 (s, 1H, 1-H), 7.26 (t, 1H, J = 7.5 Hz, Ind), 7.31 (t, 1H, J = 
7.5 Hz, Ind), 7.52 (s, 1H, Ind), 7.67 (d, 1H, J = 7.5 Hz, Ind), 8.13 (d, 1H, J = 7.5 Hz, Ind). 
13
C 
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NMR (100 MHz, (CD3)2CO) δ (ppm): 23.8 [Cγ (Lys)], 25.6 (CH2-Ind), 28.3 [6CH3 (Boc and 
t
Bu)], 28.6 [6CH3 (2Boc)], 30.4 [Cδ (Lys)], 34.5 [Cβ (Lys)], 39.9 (C6), 41.1 [Cε (Lys)], 52.0 
(C5-CH), 57.0 (4-CH2), 60.1 (C5), 65.3 (C3), 78.2, 78.8 [2C (2Boc)], 81.7 [C (
t
Bu)], 84.0 [C 
(Boc)], 115.9 [CH (Ind)], 119.1 [C (Ind)], 119.6, 123.3, 124.1, 125.0 [4CH (Ind)], 131.8, 
136.4 [2C (Ind)], 150.3, 156.4 [3CO (3Boc)], 171.3 (CO2), 172.6 (C2); ES-MS m/z 744.9 
[M+1]
+
; Anal. calcd. for C39H61N5O9: C, 62.97; H, 8.26; N, 9.41. Found: C, 62.71; H, 8.05; N, 
9.63. 
4.5.11. (5R,3S)-5-((S)-1-(tert-Butoxycarbonyl)amino-2-phenylethyl)- 4-(tert-butoxycarbonyl)-
methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) 
propyl)-2-oxopiperazine [(R)-13a] 
Reddish solid (363 mg, 70%); [α]D
20
 -19 (c 1.0, CH2Cl2); Mp: 100-102 ºC 
(EtOAc/hexane); HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 60-100% gradient of solvent A 
in B, 30 min] tR 15.95 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.26 (s, 9H, Boc), 1.44 
[s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.72 [m, 2H, -H (Arg)], 1.95 [m, 2H, β-H (Arg)], 2.04 
[s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.67 (dd, 1H, J = 11 and 
14 Hz, CH2-Ph), 2.97 [s, 2H, CH2 (Pbf)], 3.15 (m, 2H, 3-H and 4-CH2), 3.30 [m, 2H, -H 
(Arg)], 3.32 (m, 1H, 5-H), 3.39 (m, 2H, 6-H), 3.50 (dd, 1H, J = 3 and 14 Hz, CH2-Ph), 3.61 
(d, 1H, J = 16 Hz, 4-CH2), 3.85 (m, 1H, 5-CH), 5.97 (d, 1H, J = 9.5 Hz, NHBoc), 6.55 [m, 
3H, NHC(NH2)=N], 6.90 (s, 1H, 1-H), 7.13-7.19 (m, 5H, Ph); 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm): 12.5, 18.2, 19.5 [3CH3 (Pbf)], 27.3 [Cγ (Arg)], 28.3 [3CH3 (
t
Bu)], 28.5 
[3CH3 (Boc)], 28.7 [Cβ (Arg) and 2CH3 (Pbf)], 38.2 (CH2-Ph), 41.6 [Cδ (Arg)], 41.8 [C6], 43.6 
[CH2 (Pbf)], 51.7 (4-CH2), 54.0 (C5-CH), 55.5 (C5), 64.9 (C3), 78.7 [C (Boc)], 81.4 [C (
t
Bu)], 
86.9, 117.4, 125.3 [3C (Pbf)], 126.7, 128.8, 130.3 [5CH (Ph)], 132.8, 135.6, 138.7 [3C (Pbf)], 
140.5 [C (Ph)], 156.4 [CO (Boc)], 157.4 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 171.0 (CO2), 
171.8 (C2); ES-MS m/z 785.7 [M+1]
+
; Anal. calcd. for C40H60N6O8S: C, 61.20; H, 7.70; N, 
10.71. Found: C, 61.48; H, 7.40; N, 11.00. 
4.5.12. (5S,3S)-5-((S)-1-(tert-Butoxycarbonyl)amino-2-phenylethyl)- 4-(tert-butoxycarbonyl)-
methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) 
propyl)-2-oxopiperazine [(S)-13a] 
Reddish solid (363 mg, 70%); [α]D
20
 +11 (c 1.2, CH2Cl2); Mp: 98-100 ºC (EtOAc/hexane); 
HPLC [Sunfire C18 (4.6  150 mm, 3.5 μm), 60-100% gradient of solvent A in B, 30 min] tR 
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14.98 min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm): 1.29 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 
(Pbf)], 1.45 (s, 9H, 
t
Bu), 1.70 [m, 2H, -H (Arg)], 1.72 [m, 2H, β-H (Arg)], 2.05 [s, 3H, CH3 
(Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.63 (dd, 1H, J = 11 and 14 Hz, CH2-
Ph), 2.98 [s, 2H, CH2 (Pbf)], 3.10 (dd, 1H, J = 3 and 14 Hz, CH2-Ph), 3.19 (m, 1H, 5-H), 3.24 
[m, 2H, -H (Arg)], 3.31 [m, 1H, 3-H], 3.38 (m, 1H, 6-H), 3.50 (m, 1H, 6-H), 3.51 (m, 1H, 4-
CH2), 3.65 (d, 1H, J = 18 Hz, 4-CH2), 3.92 (m, 1H, 5-CH), 6.16 (d, 1H, J = 8.5 Hz, NHBoc), 
6.55 [m, 3H, NHC(NH2)=N], 7.10-7.21 (m, 2H, 1-H and Ph), 7.22-7.31 (m, 4H, Ph); 
13
C 
NMR (100 MHz, (CD3)2CO) δ (ppm): 13.2, 18.9, 20.1 [3CH3 (Pbf)], 27.0 [Cγ (Arg)], 28.9 
[3CH3 (
t
Bu)], 29.0 [3CH3 (Boc)], 29.2 [2CH3 (Pbf)], 32.3 [Cβ (Arg)], 36.4 (CH2-Ph), 40.6 
(C6), 42.3 [Cδ (Arg)], 44.3 [CH2 (Pbf)], 54.8 (C5-CH), 57.4 (4-CH2), 61.4 (C5), 65.3 (C3), 79.4 
[C (Boc)], 82.4 [C (
t
Bu)], 87.6, 118.1, 125.9 [3C (Pbf)], 127.5, 129.7, 130.6 [5CH (Ph)], 
133.5, 136.3, 139.4 [3C (Pbf)], 141.3 [C (Ph)], 156.9 [CO (Boc)], 158.0 [C (NHC(NH2)=N)], 
159.5 [C (Pbf)], 171.2 (CO2), 173.5 (C2); ES-MS m/z 785.7 [M+1]
+
; Anal. calcd. for 
C40H60N6O8S: C, 61.20; H, 7.70; N, 10.71. Found: C, 61.01; H, 7.62; N, 10.94. 
4.6. General procedure for the benzylation of the 4-alkyl-2-oxopiperazines 10a-13a. 
Synthesis of the 4-alkyl-1-benzyl-2-oxopiperazines (R)- and (S)-(14a, 17a, 20a and 23a), 
and (R)- and (S)-(16a, 19a, 22a and 25a) 
NaH (60% suspension in mineral oil, 24 mg, 1.02 mmol) and benzyl bromide (152 µL, 
0.51 mmol) were added in three equal portions over 2 h to a solution of the corresponding 2-
oxopiperazine 10a-13a (0.34 mmol) in anhydrous mixture THF/DMF (9:1, 10 mL) under 
argon at 0 ºC. After 1h of stirring, the crude reaction mixture was diluted with EtOAc (100 
mL) and the excess of NaH was hydrolysed by addition of H2O (20 mL). The aqueous layer 
was extracted with EtOAc (250 mL) and the organic extracts were dried over Na2SO4 and 
evaporated to dryness. The residue was purified by flash chromatography, using MeOH in 
CH2Cl2 gradient as mobile phase to give the respective 4-alkyl-1-benzyl-2-oxopiperazines 
14a, 17a, 20a and 23a in 40-57 % and the respective derivative benzylated at the guanidino 
group 16a, 19a, 22a and 25a as (Z/E)-isomeric mixtures in 11-20 % yield. The compounds 
were dissolved in CH3CN/H2O (1:2, 2 mL) and the solutions were lyophilized to obtain 
amorphous solids. 
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4.6.1. (5R,3S)-1,4-Dibenzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxy-
carbonyl)-indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(R)-14a] 
Amorphous solid (135 mg, 40%); [α]D
20
 -12 (c 1.2, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 13.05 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.24 (s, 9H, Boc), 1.42 [s, 6H, 2CH3 (Pbf)], 1.64 [s, 3H, Boc (Ind)], 1.85 
[m, 4H, -H and -H (Arg)], 2.03 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.56 [s, 3H, 
CH3 (Pbf)], 2.83 (m, 1H, CH2-Ind), 2.92 [s, 2H, CH2 (Pbf)], 3.09 [m, 2H, -H (Arg)], 3.16 [m, 
1H, 3-H], 3.39 (m, 1H, 6-H), 3.53 [m, 1H, CH2-Ind], 3.54 [m, 1H, 4-CH2 (Bn)], 3.58 (m, 2H, 
5-H and 6-H), 4.14 [m, 1H, 5-CH], 4.17 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 4.51 [d, 1H, J = 
14.5 Hz, 1-CH2 (Bn)], 4.79 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.98 (d, 1H, J = 9.5 Hz, 
NHBoc), 6.47 [m, 3H, NHC(NH2)=N], 7.07-7.55 (m, 14H, Ar), 8.10 (d, 1H, J = 8 Hz, Ar). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 27.2 (CH2-Ind), 27.9 
[Cγ (Arg)], 28.3 [3CH3 (Boc)], 28.5 [2CH3 (Pbf)], 28.6 [3CH3 (Boc)], 28.8 [Cβ (Arg)], 41.3 
[Cδ (Arg)], 43.6 [CH2 (Pbf)], 45.6 (C6), 50.2 [1-CH2 (Bn)], 51.3 (C5-CH), 51.9 [4-CH2 (Bn)], 
55.7 (C5), 62.2 (C3), 78.9, 83.9 [2C (2Boc)], 86.9 [C (Pbf)], 115.8 [CH (Ar)], 117.4 [C (Pbf)], 
118.7 [C (Ar)], 119.9, 123.2, 124.4, 124.9 [4CH (Ar)], 125.3 [C (Pbf)], 128.2, 128.8, 129.3, 
129.5, 129.8 [10CH (Ar)], 131.9 [C (Ar)], 132.8, 135.6 [2C (Pbf)], 136.3 [C (Ar)], 138.7 [2C 
(Pbf and Ar)], 139.4 [C (Ar)], 150.3, 156.5 [2CO (2Boc)], 157.3 [C (NHC(NH2)=N)], 158.9 
[C (Pbf)], 170.8 (C2); ES-MS m/z 991.1 [M+1]
+
; Anal. calcd. for C55H71N7O8S: C, 66.71; H, 
7.23; N, 9.90. Found: C, 66.98; H, 7.41; N, 9.54. 
4.6.2. (5S,3S)-1,4-Dibenzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxy-
carbonyl)-indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(S)-14a] 
Amorphous solid (175 mg, 52%); [α]D
20
 +22 (c 1.1, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 13.87 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.29 (s, 9H, Boc), 1.42 [s, 6H, 2CH3 (Pbf)], 1.66 [s, 3H, Boc 
(Ind)], 1.73 [m, 4H, -H and -H (Arg)], 2.03 [s, 3H, CH3 (Pbf)], 2.48 [s, 3H, CH3 (Pbf)], 
2.56 [s, 3H, CH3 (Pbf)], 2.78 (m, 1H, CH2-Ind), 2.94 [s, 2H, CH2 (Pbf)], 3.00 [m, 1H, -H 
(Arg)], 3.07 [m, 1H, -H (Arg)], 3.13 (m, 1H, CH2-Ind), 3.15 (m, 1H, 5-H), 3.26 [m, 1H, 3-
H], 3.53 (m, 2H, 6-H), 3.81 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.04 [d, 1H, J = 14 Hz, 4-CH2 
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(Bn)], 4.10 (m, 1H, 5-CH), 4.53 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 4.69 [d, 1H, J = 15 Hz, 1-
CH2 (Bn)], 6.13 (d, 1H, J = 9 Hz, NHBoc), 6.39 [m, 3H, NHC(NH2)=N], 7.14-7.36 (m, 11H, 
Ar), 7.39-7.50 (m, 2H, Ar), 7.58 (d, 1H, J = 7.5 Hz, Ar), 8.12 (d, 1H, J = 7.5 Hz, Ar). 
13
C 
NMR (100 MHz, (CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.3 (CH2-Ind), 26.8 [Cγ 
(Arg)], 28.3 [3CH3 (Boc)], 28.6 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 31.9 [Cβ (Arg)], 41.3 [Cδ 
(Arg)], 43.6 [CH2 (Pbf)], 45.2 (C6), 49.9 [1-CH2 (Bn)], 53.2 (C5-CH), 62.0 [4-CH2 (Bn)], 63.2 
(C5), 63.7 (C3), 79.0, 84.0 [2C (2Boc)], 86.9 [C (Pbf)], 115.9 [CH (Ar)], 117.4 [C (Pbf)], 
118.8 [C (Ar)], 120.0, 123.2, 124.1, 125.0 [4CH (Ar)], 125.2 [C (Pbf)], 128.2, 128.7, 129.1, 
129.5, 130.4 [10CH (Ar)], 131.9 [C (Ar)], 132.8, 135.7 [2C (Pbf)], 136.3 [C (Ar)], 138.6 [C 
(Ar)], 138.7 [C (Pbf)], 139.7 [C (Ar)], 150.3, 156.7 [2CO (2Boc)], 157.2 [C (NHC(NH2)=N)], 
158.9 [C (Pbf)], 171.8 (C2); ES-MS m/z 991.2 [M+1]
+
; Anal. calcd. for C55H71N7O8S: C, 
66.71; H, 7.23; N, 9.90. Found: C, 66.85; H, 7.52; N, 9.61. 
4.6.3. (5R,3S)-1,4-Dibenzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxy-
carbonyl)-indol-3-yl)ethyl-3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(R)-16a] 
Amorphous solid (2:1 isomeric mixture, 55 mg, 15%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 20.20 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm) Major isomer: 1.25 (s, 9H, Boc), 1.40 [s, 3H, CH3 (Pbf)], 1.45 [s, 3H, 
CH3 (Pbf)], 1.63 [s, 3H, Boc (Ind)], 1.83 [m, 2H, -H (Arg)], 1.92 [m, 2H, -H (Arg)], 2.00 
[s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.81 [s, 2H, CH2 (Pbf)], 
2.90 (m, 1H, CH2-Ind), 3.07 [m, 2H, -H (Arg)], 3.14 [m, 1H, 3-H], 3.38 (m, 1H, 6-H), 3.55 
[m, 2H, 5-H and 4-CH2 (Bn)], 3.57 (m, 1H, 6-H), 3.58 [m, 1H, CH2-Ind], 4.20 [m, 1H, 4-CH2 
(Bn)], 4.22 [m, 1H, 5-CH], 4.43 [t, 2H, J = 5.5 Hz, CH2 (NHC(NHBn)=N)], 4.54 [d, 1H, J = 
15 Hz, 1-CH2 (Bn)], 4.78 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 5.99 (d, 1H, J = 9.5 Hz, NHBoc), 
7.02-7.57 [m, 21H, Ar and NHC(NHBn)=N], 8.11 (d, 1H, J = 8 Hz, Ar). Minor isomer: 1.22 
(s, 9H, Boc), 1.38 [s, 3H, CH3 (Pbf)], 1.45 [s, 3H, CH3 (Pbf)], 1.63 [s, 3H, Boc (Ind)], 1.83 
[m, 2H, -H (Arg)], 1.92 [m, 2H, -H (Arg)], 1.99 [s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 (Pbf)], 
2.50 [s, 3H, CH3 (Pbf)], 2.83 (m, 1H, CH2-Ind), 2.93 [s, 2H, CH2 (Pbf)], 3.07 [m, 2H, -H 
(Arg)], 3.14 [m, 1H, 3-H], 3.38 (m, 1H, 6-H), 3.47 [m, 1H, CH2-Ind], 3.55 [m, 2H, 5-H and 4-
CH2 (Bn)], 3.57 (m, 1H, 6-H), 4.20 [m, 1H, 4-CH2 (Bn)], 4.22 [m, 1H, 5-CH], 4.48 [d, 1H, J 
= 15 Hz, 1-CH2 (Bn)], 4.64 [m, 2H, CH2 (NHC(NHBn)=N)], 4.81 [d, 1H, J = 15 Hz, 1-CH2 
(Bn)], 5.94 (d, 1H, J = 9.5 Hz, NHBoc), 7.02-7.57 [m, 21H, Ar and NHC(NHBn)=N], 8.11 (d, 
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1H, J = 8 Hz, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm) Major isomer: 12.5, 18.3, 19.6 
[3CH3 (Pbf)], 25.6 (CH2-Ind), 27.0 [Cγ (Arg)], 28.0 [Cβ (Arg)], 28.3 [3CH3 (Boc) and 2CH3 
(Pbf)], 28.6 [3CH3 (Boc)], 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 45.3 [CH2 (NHC(NHBn)=N)], 
45.9 (C6), 50.3 [1-CH2 (Bn)], 51.4 (C5-CH), 51.8 [4-CH2 (Bn)], 55.7 (C5), 61.9 (C3), 78.8, 
83.9 [2C (2Boc)], 86.9 [C (Pbf)], 115.8 [CH (Ar)], 117.6 [C (Pbf)], 118.7 [C (Ar)], 120.0, 
123.2, 124.5, 124.9 [4CH (Ar)], 125.3 [C (Pbf)], 128.2, 128.8, 129.4, 129.5, 129.8 [15CH 
(Ar)], 131.9 [C (Ar)], 132.8, 135.4 [2C (Pbf)], 136.3 [C (Ar)], 138.7 [2C (Pbf and Ar)], 138.8 
[C (Ar)], 139.3 [C (Ar)], 150.3, 156.0 [2CO (2Boc)], 156.5 [C (NHC(NHBn)=N)], 158.9 [C 
(Pbf)], 170.7 (C2). Minor isomer: 12.5, 18.3, 19.5 [3CH3 (Pbf)], 25.6 [CH2-Ind], 27.0 [Cγ 
(Arg)], 28.0 [Cβ (Arg)], 28.3 [3CH3 (Boc) and 2CH3 (Pbf)], 28.6 [3CH3 (Boc)], 41.6 [Cδ 
(Arg)], 43.6 [CH2 (Pbf)], 45.9 (C6), 50.3 [1-CH2 (Bn)], 51.5 (C5-CH), 51.8 [4-CH2 (Bn) and 
CH2 (NHC(NHBn)=N)], 55.6 (C5), 62.0 (C3), 78.8, 83.9 [2C (2Boc)], 86.9 [C (Pbf)], 115.8 
[CH (Ar)], 117.5 [C (Pbf)], 118.6 [C (Ar)], 119.9, 123.2, 124.5, 124.9 [4CH (Ar)], 125.3 [C 
(Pbf)], 128.2, 128.9, 129.2, 129.4, 129.5 [15CH (Ar)], 131.9 [C (Ar)], 132.8, 135.4 [2C 
(Pbf)], 136.3 [C (Ar)], 138.7 [2C (Pbf and Ar)], 138.8 [C (Ar)], 139.3 [C (Ar)], 150.3, 156.0 
[2CO (2Boc)], 156.5 [C (NHC(NHBn)=N)], 158.9 [C (Pbf)], 170.7 (C2); ES-MS m/z 1081.2 
[M+1]
+
; Anal. calcd. for C62H77N7O8S: C, 68.93; H, 7.18; N, 9.08. Found: C, 69.24; H, 7.32; 
N, 8.91. 
4.6.4. (5S,3S)-1,4-Dibenzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxy-
carbonyl)-indol-3-yl)ethyl-3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(S)-16a] 
Amorphous solid (3:1 isomeric mixture, 55 mg, 15%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 20.78 min (major isomer) and 21.64 
min (minor isomer);
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm) Major isomer: 1.29 (s, 9H, 
Boc), 1.42 [s, 3H, CH3 (Pbf)], 1.50 [s, 3H, CH3 (Pbf)], 1.64 [m, 2H, -H (Arg)], 1.66 [s, 3H, 
Boc (Ind)], 1.71 [m, 2H, -H (Arg)], 2.01 [s, 3H, CH3 (Pbf)], 2.42 [s, 3H, CH3 (Pbf)], 2.49 [s, 
3H, CH3 (Pbf)], 2.79 (m, 1H, CH2-Ind), 2.88 [s, 2H, CH2 (Pbf)], 3.11 [m, 2H, -H (Arg)], 
3.14 [m, 2H, 5-H], 3.15 [m, 1H, CH2-Ind], 3.30 [m, 1H, 3-H], 3.53 (m, 2H, 6-H), 3.82 [d, 1H, 
J = 14 Hz, 4-CH2 (Bn)], 4.07 [m, 1H, 4-CH2 (Bn)], 4.13 [m, 1H, 5-CH], 4.38 [d, 2H, J = 5 
Hz, CH2 (NHC(NHBn)=N)], 4.53 [m, 1H, 1-CH2 (Bn)], 4.69 [m, 1H, 1-CH2 (Bn)], 6.12 (d, 
1H, J = 8.5 Hz, NHBoc), 7.02-7.37 [m, 16H, Ar and NHC(NHBn)=N], 7.44 (m, 4H, Ar), 7.60 
(m, 1H, Ar), 8.12 (d, 1H, J = 8 Hz, Ar). Minor isomer: 1.29 (s, 9H, Boc), 1.43 [s, 3H, CH3 
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(Pbf)], 1.45 [s, 3H, CH3 (Pbf)], 1.64 [m, 5H, -H (Arg) and Boc (Ind)], 1.71 [m, 2H, -H 
(Arg)], 2.02 [s, 3H, CH3 (Pbf)], 2.46 [s, 3H, CH3 (Pbf)], 2.54 [s, 3H, CH3 (Pbf)], 2.79 (m, 1H, 
CH2-Ind), 2.97 [s, 2H, CH2 (Pbf)], 3.11 [m, 2H, -H (Arg)], 3.14 [m, 2H, 5-H], 3.15 [m, 1H, 
CH2-Ind], 3.27 [m, 1H, 3-H], 3.53 (m, 2H, 6-H), 3.81 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.04 
[m, 1H, 4-CH2 (Bn)], 4.13 [m, 1H, 5-CH], 4.59 [m, 1H, CH2 (NHC(NHBn)=N)], 4.50 [m, 1H, 
1-CH2 (Bn)], 4.60 [m, 1H, CH2 (NHC(NHBn)=N)], 4.63 [m, 1H, 1-CH2 (Bn)], 6.07 (d, 1H, J 
= 8.5 Hz, NHBoc), 7.02-7.37 [m, 16H, Ar and NHC(NHBn)=N], 7.43 (m, 4H, Ar), 7.56 (m, 
1H, Ar), 8.12 (d, 1H, J = 8 Hz, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm) Major isomer: 
12.6, 18.3, 19.6 [3CH3 (Pbf)], 26.2 (CH2-Ind), 26.4 [Cγ (Arg)], 28.3 [3CH3 (Boc)], 28.6 [2CH3 
(Pbf)], 28.7 [3CH3 (Boc)], 30.1 [Cβ (Arg)], 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 44.9 (C6), 45.3 
[CH2 (NHC(NHBn)=N)], 49.9 [1-CH2 (Bn)], 52.7 (C5-CH), 61.9 [4-CH2 (Bn)], 63.5 (C3 and 
C5), 78.9, 84.0 [2C (2Boc)], 86.9 [C (Pbf)], 115.9 [CH (Ar)], 117.5 [C (Pbf)], 118.9 [C (Ar)], 
120.0, 123.2, 124.0, 125.0 [4CH (Ar)], 125.3 [C (Pbf)], 128.1, 128.7, 129.1, 129.5, 130.3 
[15CH (Ar)], 131.8 [C (Ar)], 132.8, 135.9 [2C (Pbf)], 136.3 [C (Ar)], 138.4 [C (Ar)], 138.7 
[C (Pbf], 139.6 [2C (Ar)], 150.3, 155.9 [2CO (2Boc)], 156.5 [C (NHC(NHBn)=N)], 158.9 [C 
(Pbf)], 171.7 (C2). Minor isomer: 12.6, 18.2, 19.4 [3CH3 (Pbf)], 26.2 (CH2-Ind), 26.4 [Cγ 
(Arg)], 28.1 [3CH3 (Boc)], 28.6 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 30.2 [Cβ (Arg)], 41.6 [Cδ 
(Arg)], 43.6 [CH2 (Pbf)], 44.9 (C6), 49.9 [1-CH2 (Bn)], 51.0 [CH2 (NHC(NHBn)=N)], 52.7 
(C5-CH), 61.9 [4-CH2 (Bn)], 63.5 (C5), 64.0 (C3), 78.9, 84.0 [2C (2Boc)], 87.3 [C (Pbf)], 
115.9 [CH (Ar)], 117.5 [C (Pbf)], 118.9 [C (Ar)], 120.0, 123.2, 124.0, 125.0 [4CH (Ar)], 
125.3 [C (Pbf)], 128.1, 128.7, 129.2, 129.4, 130.3 [15CH (Ar)], 131.8 [C (Ar)], 132.8, 136.1 
[2C (Pbf)], 136.3 [C (Ar)], 138.4 [C (Ar)], 138.7 [C (Pbf], 139.6 [2C (Ar)], 150.3, 155.9 
[2CO (2Boc)], 156.5 [C (NHC(NHBn)=N)], 158.9 [C (Pbf)], 171.7 (C2); ES-MS m/z 1081.2 
[M+1]
+
; Anal. calcd. for C62H77N7O8S: C, 68.93; H, 7.18; N, 9.08. Found: C, 69.14; H, 7.02; 
N, 9.27. 
4.6.5. (5R,3S)-1,4-Dibenzyl-5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-
oxopiperazine [(R)-17a] 
Amorphous solid (139 mg, 48%); [α]D
20
 -12 (c 1.0, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 7.14 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.22 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.81 [m, 4H, -H and -H 
(Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.48 [s, 3H, CH3 (Pbf)], 2.57 [s, 3H, CH3 (Pbf)], 2.71 (dd, 1H, 
40 
 
J = 11 and 14 Hz, CH2-Ph), 2.96 [s, 2H, CH2 (Pbf)], 3.05 [m, 2H, -H (Arg)], 3.12 [m, 1H, 3-
H], 3.32 (dd, 1H, J = 4 and 12 Hz, 6-H), 3.48 (m, 2H, 5-H and CH2-Ph), 3.50 [m, 1H, 4-CH2 
(Bn)], 3.57 (m, 1H, 6-H), 4.06 (ddd, 1H, J = 3.5, 10 and 13 Hz, 5-CH), 4.17 [d, 1H, J = 14.5 
Hz, 4-CH2 (Bn)], 4.47 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.78 [d, 1H, J = 14.5 Hz, 1-CH2 
(Bn)], 5.90 (d, 1H, J = 9.5 Hz, NHBoc), 6.50 [m, 3H, NHC(NH2)=N], 7.09-7.45 (m, 15H, 
Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 11.9, 17.6, 18.8 [3CH3 (Pbf)], 26.5 [Cγ (Arg)], 
27.6 [Cβ (Arg)], 27.8 [3CH3 (Boc)], 28.1 [2CH3 (Pbf)], 37.6 (CH2-Ph), 40.6 [Cδ (Arg)], 42.9 
[CH2 (Pbf)], 45.0 (C6), 49.5 [1-CH2 (Bn)], 51.0 [4-CH2 (Bn)], 52.4 (C5-CH), 55.0 (C5), 61.5 
(C3), 78.1 [C (Boc)], 86.3, 116.8, 124.6 [3C (Pbf)], 126.1, 127.5, 128.1, 128.2, 128.6, 128.8, 
129.3, 129.5 [15CH (Ar)], 132.2, 134.9 [2C (Pbf)], 138.0 [C (Ar)], 138.1 [2C (Pbf and Ar)], 
139.5 [C (Ar)], 155.7 [CO (Boc)], 156.6 [C (NHC(NH2)=N)], 158.2 [C (Pbf)], 170.2 (C2); 
ES-MS m/z 852.0 [M+1]
+
; Anal. calcd. for C48H62N6O6S: C, 67.74; H, 7.34; N, 9.87. Found: 
C, 67.51; H, 7.65; N, 9.63. 
4.6.6. (5S,3S)-1,4-Dibenzyl-5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-
oxopiperazine [(S)-17a] 
Amorphous solid (130 mg, 45%); [α]D
20
 +21 (c 1.1, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 6.96 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.26 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.56 [m, 2H, -H 
(Arg)], 1.67 [m, 2H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.56 [s, 3H, 
CH3 (Pbf)], 2.60 (m, 1H, CH2-Ph), 2.96 [s, 2H, CH2 (Pbf)], 2.99 [m, 1H, -H (Arg)], 3.04 (m, 
1H, CH2-Ph), 3.05 [m, 1H, -H (Arg)], 3.07 (m, 2H, 5-H), 3.23 [m, 1H, 3-H], 3.45 (m, 2H, 6-
H), 3.77 [m, 1H, J = 14 Hz, 4-CH2 (Bn)], 3.97 (m, 1H, 5-CH), 4.03 [d, 1H, J = 14 Hz, 4-CH2 
(Bn)], 4.49 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 4.69 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 6.09 (d, 1H, 
J = 9 Hz, NHBoc), 6.41 [m, 3H, NHC(NH2)=N], 7.11-7.29 (m, 15H, Ar); 
13
C NMR (100 
MHz, (CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.6 [Cγ (Arg)], 28.6 [3CH3 (Boc)], 
28.7 [2CH3 (Pbf)], 31.9 [Cβ (Arg)], 36.5 (CH2-Ph), 41.2 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 45.1 
(C6), 49.8 [1-CH2 (Bn)], 55.5 (C5-CH), 62.0 [4-CH2 (Bn)], 63.4 (C5), 63.8 (C3), 78.9 [C 
(Boc)], 86.9, 117.4, 125.3 [3C (Pbf)], 126.8, 128.2, 128.7, 128.9, 129.2, 129.5, 130.0, 130.4 
[15CH (Ar)], 132.8, 135.7 [2C (Pbf)], 138.5 [C (Ar)], 138.7 [C (Pbf)], 139.9 [C (Ar)], 140.3 
[C (Ar)], 156.5 [CO (Boc)], 157.2 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 171.8 (C2); ES-MS 
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m/z 852.0 [M+1]
+
; Anal. calcd. for C48H62N6O6S: C, 67.74; H, 7.34; N, 9.87. Found: C, 67.86; 
H, 7.61; N, 10.12. 
4.6.7. (5R,3S)-1,4-Dibenzyl-5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)-3-(3-(3-
benzyl-2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) 
propyl)-2-oxopiperazine [(R)-19a] 
Amorphous solid (2.5:1 isomeric mixture, 45 mg, 15%); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 13.14 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm) Major isomer: 1.21 (s, 9H, Boc), 1.41 [s, 3H, CH3 (Pbf)], 1.45 [s, 3H, 
CH3 (Pbf)], 1.80 [m, 4H, -H and -H (Arg)], 2.01 [s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 
(Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.74 (dd, 1H, J = 11 and 14 Hz, CH2-Ph), 2.89 [s, 2H, CH2 
(Pbf)], 3.05 [m, 2H, -H (Arg)], 3.15 [m, 1H, 3-H], 3.33 (dd, 1H, J = 4 and 12 Hz, 6-H), 3.50 
(m, 1H, 5-H), 3.52 [m, 1H, 4-CH2 (Bn)], 3.56 (m, 1H, CH2-Ph), 3.57 (m, 1H, 6-H), 4.12 (m, 
1H, 5-CH), 4.18 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 4.42 [m, 2H, CH2 (NHC(NHBn)=N)], 4.49 
[d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.79 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.89 (d, 1H, J = 9.5 
Hz, NHBoc), 7.04-7.57 [m, 22H, Ar and NHC(NHBn)=N]. Minor isomer: 1.22 (s, 9H, Boc), 
1.43 [s, 3H, CH3 (Pbf)], 1.44 [s, 3H, CH3 (Pbf)], 1.80 [m, 4H, -H and -H (Arg)], 2.01 [s, 
3H, CH3 (Pbf)], 2.46 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.66 (m, 1H, CH2-Ph), 2.96 
[s, 2H, CH2 (Pbf)], 3.05 [m, 2H, -H (Arg)], 3.15 [m, 1H, 3-H], 3.30 (m, 1H, 6-H), 3.41 (dd, 
1H, J = 3 and 14 Hz, CH2-Ph), 3.50 (m, 1H, 5-H), 3.51 [m, 1H, 4-CH2 (Bn)], 3.59 (m, 1H, 6-
H), 4.10 [m, 1H, 4-CH2 (Bn)], 4.12 (m, 1H, 5-CH), 4.49 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 
4.60 [m, 2H, CH2 (NHC(NHBn)=N)], 4.81 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.86 (d, 1H, J = 
10 Hz, NHBoc), 7.04-7.57 [m, 22H, Ar and NHC(NHBn)=N]; 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm) Major isomer: 11.9, 17.6, 18.9 [3CH3 (Pbf)], 26.2 [Cγ (Arg)], 27.6 [Cβ 
(Arg) and 3CH3 (Boc)], 27.8 [2CH3 (Pbf)], 37.6 (CH2-Ph), 40.5 [Cδ (Arg)], 42.9 [CH2 (Pbf)], 
45.1 [C6 and CH2 (NHC(NHBn)=N)], 49.6 [1-CH2 (Bn)], 51.0 [4-CH2 (Bn)], 52.6 (C5-CH), 
55.0 (C5), 61.4 (C3), 78.0 [C (Boc)], 86.3, 116.9, 124.6 [3C (Pbf)], 127.5, 128.1, 128.3, 128.7, 
128.8, 129.2, 129.6 [20CH (Ar)], 132.2, 134.9 [2C (Pbf)], 138.0 [C (Ar)], 138.1 [C (Ar)], 
138.7 [C (Pbf)], 138.9 [C (Ar)], 139.5 [C (Ar)], 155.3 [C (NHC(NHBn)=N)], 155.6 [CO 
(Boc)], 158.3 [C (Pbf)], 170.1 (C2). Minor isomer: 11.9, 17.6, 18.9 [3CH3 (Pbf)], 26.2 [Cγ 
(Arg)], 27.6 [Cβ (Arg) and 3CH3 (Boc)], 27.8 [2CH3 (Pbf)], 37.7 (CH2-Ph), 40.5 [Cδ (Arg)], 
42.9 [CH2 (Pbf)], 44.7 (C6), 49.6 [1-CH2 (Bn)], 50.8 [CH2 (NHC(NHBn)=N)], 51.0 [4-CH2 
(Bn)], 52.4 (C5-CH), 55.0 (C5), 61.1 (C3), 78.0 [C (Boc)], 86.3, 116.9, 124.6 [3C (Pbf)], 
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127.5, 128.2, 128.3, 128.5, 129.2, 129.5 [20CH (Ar)], 132.2, 134.9 [2C (Pbf)], 138.0 [C (Ar)], 
138.1 [C (Ar)], 138.7 [C (Pbf)], 138.9 [C (Ar)], 139.5 [C (Ar)], 155.3 [C (NHC(NHBn)=N)], 
155.7 [CO (Boc)], 158.3 [C (Pbf)], 170.1 (C2); ES-MS m/z 942.2 [M+1]
+
; Anal. calcd. for 
C55H68N6O6S: C, 70.18; H, 7.28; N, 8.93. Found: C, 69.92; H, 7.47; N, 8.67. 
4.6.8. (5S,3S)-1,4-Dibenzyl-5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)-3-(3-(3-
benzyl-2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) 
propyl)-2-oxopiperazine [(S)-19a] 
Amorphous solid (5:3 isomeric mixture, 35 mg, 11%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.49 (major isomer) and 13.19 
(minor isomer) min;
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm) Major isomer: 1.26 (s, 9H, 
Boc), 1.44 [s, 6H, 2CH3 (Pbf)], 1.64 [m, 4H, -H and -H (Arg)], 2.01 [s, 3H, CH3 (Pbf)], 
2.43 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.62 (m, 1H, CH2-Ph), 2.94 [s, 2H, CH2 
(Pbf)], 3.08 [m, 3H, 5-H and -H (Arg)], 3.09 (m, 1H, CH2-Ph), 3.26 [m, 1H, 3-H], 3.46 (m, 
2H, 6-H), 3.78 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.06 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.08 (m, 
1H, 5-CH), 4.40 [d, 2H, J = 5.5 Hz, CH2 (NHC(NHBn)=N)], 4.49 [d, 1H, J = 15 Hz, 1-CH2 
(Bn)], 4.68 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 6.05 (d, 1H, J = 8.5 Hz, NHBoc), 7.02-7.52 [m, 
22H, Ar and NHC(NHBn)=N]. Minor isomer: 1.25 (s, 9H, Boc), 1.45 [s, 6H, 2CH3 (Pbf)], 
1.64 [m, 4H, -H and -H (Arg)], 2.01 [s, 3H, CH3 (Pbf)], 2.47 [s, 3H, CH3 (Pbf)], 2.50 [s, 
3H, CH3 (Pbf)], 2.62 (m, 1H, CH2-Ph), 2.97 [s, 2H, CH2 (Pbf)], 3.08 [m, 3H, 5-H and -H 
(Arg)], 3.09 (m, 1H, CH2-Ph), 3.26 [m, 1H, 3-H], 3.46 (m, 2H, 6-H), 3.77 [d, 1H, J = 14 Hz, 
4-CH2 (Bn)], 4.06 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.08 (m, 1H, 5-CH), 4.49 [d, 1H, J = 15 
Hz, 1-CH2 (Bn)], 4.58 [m, 2H, CH2 (NHC(NHBn)=N)], 4.64 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 
6.05 (d, 1H, J = 8.5 Hz, NHBoc), 7.02-7.52 [m, 22H, Ar and NHC(NHBn)=N]; 
13
C NMR 
(100 MHz, (CD3)2CO) δ (ppm) Major isomer: 12.5, 18.7, 19.6 [3CH3 (Pbf)], 26.4 [Cγ (Arg)], 
28.6 [3CH3 (Boc)], 29.3 [2CH3 (Pbf)], 32.1 [Cβ (Arg)], 36.3 (CH2-Ph), 41.6 [Cδ (Arg)], 43.6 
[CH2 (Pbf)], 44.9 [C6 and CH2 (NHC(NHBn)=N)], 49.8 [1-CH2 (Bn)], 54.7 (C5-CH), 61.7 [4-
CH2 (Bn)], 63.6 (C3 and C5), 78.9 [C (Boc)], 86.9, 117.4, 125.3 [3C (Pbf)], 126.8, 128.2, 
128.7, 129.0, 129.1, 129.2, 129.5, 129.9, 130.3 [20CH (Ar)], 132.8, 135.6 [2C (Pbf)], 138.4 
[C (Ar)], 138.7 [C (Pbf)], 139.5 [C (Ar)], 139.8 [C (Ar)], 139.9 [C (Ar)], 155.9 [C 
(NHC(NHBn)=N)], 156.3 [CO (Boc)], 158.9 [C (Pbf)], 171.8 (C2). Minor isomer: 12.5, 18.7, 
19.6 [3CH3 (Pbf)], 26.4 [Cγ (Arg)], 28.6 [3CH3 (Boc)], 29.3 [2CH3 (Pbf)], 32.1 [Cβ (Arg)], 
36.3 (CH2-Ph), 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 44.9 (C6), 49.9 [1-CH2 (Bn)], 51.0 [CH2 
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(NHC(NHBn)=N)], 54.7 (C5-CH), 61.7 [4-CH2 (Bn)], 63.6 (C3 and C5), 78.9 [C (Boc)], 86.9, 
117.4, 125.3 [3C (Pbf)], 126.8, 127.9, 128.2, 128.5, 128.8, 129.4, 129.9, 130.2 [20CH (Ar)], 
132.8, 135.6 [2C (Pbf)], 138.4 [C (Ar)], 138.7 [C (Pbf)], 139.5 [C (Ar)], 139.8 [C (Ar)], 139.9 
[C (Ar)], 156.5 [C (NHC(NHBn)=N)], 156.3 [CO (Boc)], 158.9 [C (Pbf)], 171.8 (C2); ES-MS 
m/z 942.2 [M+1]
+
; Anal. calcd. for C55H68N6O6S: C, 70.18; H, 7.28; N, 8.93. Found: C, 70.35; 
H, 7.03; N, 9.22. 
4.6.9. (5R,3S)-1-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(R)-20a] 
Amorphous solid (172 mg, 50%); [α]D
20
 +3.1 (c 1.1, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.48 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.22 (s, 9H, Boc), 1.42 [s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.65 
[s, 3H, Boc (Ind)], 1.90 [m, 4H, -H and -H (Arg)], 2.03 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 
(Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.78 (m, 1H, CH2-Ind), 2.93 [s, 2H, CH2 (Pbf)], 3.19 (d, 1H, J 
= 16 Hz, 4-CH2), 3.29 (m, 1H, 6-H), 3.32 [m, 1H, 3-H], 3.34 [m, 2H, -H (Arg)], 3.41 (m, 
1H, 6-H), 3.50 (m, 1H, 5-H), 3.56 (m, 1H, CH2-Ind), 3.64 (d, 1H, J = 16 Hz, 4-CH2), 3.90 (m, 
1H, 5-CH), 4.37 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.84 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 
5.97 (d, 1H, J = 9.5 Hz, NHBoc), 6.52 [m, 3H, NHC(NH2)=N], 7.20 (t, 1H, J = 7.5 Hz, Ar), 
7.25-7.38 (m, 6H, Ar), 7.49 (s, 1H, Ar), 7.58 (d, 1H, J = 7.5 Hz, Ar), 8.11 (d, 1H, J = 7.5 Hz, 
Ar). 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 27.5 [CH2-Ind 
and Cγ (Arg)], 28.2 [3CH3 (
t
Bu)], 28.3 [3CH3 (Boc)], 28.5 [Cβ (Arg) and 2CH3 (Pbf)], 28.7 
[3CH3 (Boc)], 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 46.1 (C6), 50.2 [1-CH2 (Bn)], 51.7 (4-CH2), 
51.9 (C5-CH), 55.8 (C5), 65.2 (C3), 78.8 [C (Boc)], 81.7 [C (
t
Bu)], 83.9 [C (Boc)], 86.9 [C 
(Pbf)], 115.8 [CH (Ar)], 117.4 [C (Pbf)], 118.9 [C (Ar)], 120.0, 123.1, 124.5, 124.9 [4CH 
(Ar)], 125.3 [C (Pbf)], 127.1, 128.7, 129.4 [5CH (Ar)], 131.9 [C (Ar)], 132.8, 135.6 [2C 
(Pbf)], 136.3 [C (Ar)], 138.6 [C (Pbf)], 138.7 [C (Ar)], 150.3, 156.5 [2CO (2Boc)], 157.4 [C 
(NHC(NH2)=N)], 158.9 [C (Pbf)], 170.6 (C2), 170.9 (CO2); ES-MS m/z 1015.2 [M+1]
+
; Anal. 
calcd. for C54H75N7O10S: C, 63.94; H, 7.45; N, 9.67. Found: C, 64.22; H, 7.63; N, 9.36. 
4.6.10. (5S,3S)-1-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(S)-20a] 
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Amorphous solid (197 mg, 57%); [α]D
20
 +20 (c 1.1, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 13.67 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.27 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.45 (s, 9H, 
t
Bu), 1.65 
[s, 3H, Boc (Ind)], 1.76 [m, 2H, -H (Arg)], 1.80 [m, 2H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 
2.49 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.68 (dd, 1H, J = 11 and 15 Hz, CH2-Ind), 
2.95 [s, 2H, CH2 (Pbf)], 3.13 (m, 1H, CH2-Ind), 3.26 [m, 2H, -H (Arg)], 3.28 (m, 1H, 5-H), 
3.49 (m, 3H, 3-H and 6-H), 3.58 (d, 1H, J = 18 Hz, 4-CH2), 3.68 (d, 1H, J = 18 Hz, 4-CH2), 
4.01 (m, 1H, 5-CH), 4.59 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.69 [d, 1H, J = 14.5 Hz, 1-CH2 
(Bn)], 6.15 (d, 1H, J = 8 Hz, NHBoc), 6.49 [m, 3H, NHC(NH2)=N], 7.18-7.38 (m, 7H, Ar), 
7.47 (s, 1H, Ar), 7.58 (d, 1H, J = 7.5 Hz, Ar), 8.11 (d, 1H, J = 7.5 Hz, Ar). 
13
C NMR (100 
MHz, (CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 25.3 (CH2-Ind), 26.5 [Cγ (Arg)], 
28.3 [3CH3 (
t
Bu) and 3CH3 (Boc)], 28.6 [2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 32.2 [Cβ (Arg)], 
41.7 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 44.9 (C6), 50.0 [1-CH2 (Bn)], 52.0 (C5-CH), 56.6 (4-CH2), 
60.9 (C5), 65.0 (C3), 78.9 [C (Boc)], 81.7 [C (
t
Bu)], 84.0 [C (Boc)], 86.9 [C (Pbf)], 115.9 [CH 
(Ar)], 117.4 [C (Pbf)], 119.0 [C (Ar)], 119.9, 123.3, 124.1, 125.0 [4CH (Ar)], 125.3 [C (Pbf)], 
128.1, 128.8, 129.4 [5CH (Ar)], 131.7 [C (Ar)], 132.8, 135.7 [2C (Pbf)], 136.3, 138.5 [2C 
(Ar)], 138.7 [C (Pbf)], 150.3, 156.4 [2CO (2Boc)], 157.3 [C (NHC(NH2)=N)], 158.9 [C 
(Pbf)], 171.0 (C2), 171.3 (CO2); ES-MS m/z 1015.2 [M+1]
+
; Anal. calcd. for C54H75N7O10S: 
C, 63.94; H, 7.45; N, 9.67. Found: C, 63.76; H, 7.69; N, 9.92. 
4.6.11. (5R,3S)-1-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-
2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(R)-22a] 
Amorphous solid (5:1 isomeric mixture, 60 mg, 16%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 20.05 min (major isomer) and 19.34 
min (minor isomer);
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm) Major isomer: 1.20 (s, 9H, 
Boc), 1.42 [s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.64 [s, 3H, Boc (Ind)], 1.90 [m, 4H, -H 
and -H (Arg)], 2.00 [s, 3H, CH3 (Pbf)], 2.44 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.79 
(m, 1H, CH2-Ind), 2.93 [s, 2H, CH2 (Pbf)], 3.20 (d, 1H, J = 16 Hz, 4-CH2), 3.30 (m, 1H, 6-H), 
3.34 [m, 1H, 3-H], 3.38 [m, 1H, -H (Arg)], 3.41 (m, 1H, 6-H), 3.47 [m, 1H, -H (Arg)], 3.49 
(m, 1H, 5-H), 3.57 (m, 1H, CH2-Ind), 3.65 (d, 1H, J = 16 Hz, 4-CH2), 3.90 (m, 1H, 5-CH), 
4.38 [dd, 1H, J = 6 and 15 Hz, CH2 (NHC(NHBn)=N)], 4.40 [d, 1H, J = 14.5 Hz, 1-CH2 
(Bn)], 4.46 [dd, 1H, J = 6 and 15 Hz, CH2 (NHC(NHBn)=N)], 4.83 [d, 1H, J = 14.5 Hz, 1-
45 
 
CH2 (Bn)], 5.96 (d, 1H, J = 9.5 Hz, NHBoc), 7.09-7.40 [m, 14H, Ar and NHC(NHBn)=N], 
7.50 (s, 1H, Ar), 7.61 (d, 1H, J = 7.5 Hz, Ar), 8.11 (d, 1H, J = 7.5 Hz, Ar). Minor isomer: 
1.23 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.44 (s, 9H, 
t
Bu), 1.66 [s, 3H, Boc (Ind)], 1.90 
[m, 4H, -H and -H (Arg)], 2.00 [s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, 
CH3 (Pbf)], 2.79 (m, 1H, CH2-Ind), 2.95 [s, 2H, CH2 (Pbf)], 3.22 (d, 1H, J = 16 Hz, 4-CH2), 
3.30 (m, 1H, 6-H), 3.34 [m, 1H, 3-H], 3.38 [m, 1H, -H (Arg)], 3.41 (m, 1H, 6-H), 3.47 [m, 
1H, -H (Arg)], 3.49 (m, 1H, 5-H), 3.57 (m, 1H, CH2-Ind), 3.65 (d, 1H, J = 16 Hz, 4-CH2), 
3.90 (m, 1H, 5-CH), 4.35 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.68 [d, 1H, J = 16 Hz, CH2 
(NHC(NHBn)=N)], 4.77 [d, 1H, J = 16 Hz, CH2 (NHC(NHBn)=N)], 4.85 [d, 1H, J = 14.5 Hz, 
1-CH2 (Bn)], 5.94 (d, 1H, J = 9.5 Hz, NHBoc), 7.09-7.40 [m, 14H, Ar and NHC(NHBn)=N], 
7.47 (s, 1H, Ar), 7.55 (d, 1H, J = 7.5 Hz, Ar), 8.11 (d, 1H, J = 7.5 Hz, Ar); 
13
C NMR (100 
MHz, (CD3)2CO) δ (ppm) Major isomer: 12.5, 18.3, 19.6 [3CH3 (Pbf)], 27.2 (CH2-Ind), 27.6 
[Cγ (Arg)], 28.3 [3CH3 (
t
Bu)], 28.7 [3CH3 (Boc)], 28.4 [Cβ (Arg) and 2CH3 (Pbf)], 28.7 [3CH3 
(Boc)], 41.8 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 45.4 [CH2 (NHC(NHBn)=N)], 46.2 (C6), 50.3 [1-
CH2 (Bn)], 51.6 (4-CH2), 52.0 (C5-CH), 55.5 (C5), 65.0 (C3), 78.8 [C (Boc)], 81.7 [C (
t
Bu)], 
83.9 [C (Boc)], 86.9 [C (Pbf)], 115.8 [CH (Ar)], 117.5 [C (Pbf)], 118.6 [C (Ar)], 120.0, 123.1, 
124.7, 124.9 [4CH (Ar)], 125.3 [C (Pbf)], 128.1, 128.7, 129.5 [10CH (Ar)], 131.9 [C (Ar)], 
132.8, 135.6 [2C (Pbf)], 136.4 [C (Ar)], 138.6 [C (Pbf)], 138.8 [2C (Ar)], 150.3, 156.1 [2CO 
(2Boc)], 156.5 [C (NHC(NHBn)=N)], 158.9 [C (Pbf)], 170.5 (C2), 171.0 (CO2). Minor 
isomer: 12.5, 18.3, 19.6 [3CH3 (Pbf)], 27.2 (CH2-Ind), 27.6 [Cγ (Arg)], 28.3 [3CH3 (
t
Bu)], 
28.7 [3CH3 (Boc)], 28.4 [Cβ (Arg) and 2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 41.8 [Cδ (Arg)], 43.6 
[CH2 (Pbf)], 46.2 (C6), 50.3 [1-CH2 (Bn)], 51.6 [4-CH2 and CH2 (NHC(NHBn)=N)], 52.0 (C5-
CH), 55.5 (C5), 65.0 (C3), 78.8 [C (Boc)], 81.7 [C (
t
Bu)], 83.9 [C (Boc)], 86.9 [C (Pbf)], 115.8 
[CH (Ar)], 117.5 [C (Pbf)], 118.8 [C (Ar)], 120.0, 123.1, 124.5, 124.9 [4CH (Ar)], 125.3 [C 
(Pbf)], 128.1, 128.8, 129.2 [10CH (Ar)], 131.9 [C (Ar)], 132.7, 135.4 [2C (Pbf)], 136.4 [C 
(Ar)], 138.5 [C (Pbf)], 138.8 [2C (Ar)], 150.3, 156.1 [2CO (2Boc)], 156.5 [C 
(NHC(NHBn)=N)], 158.9 [C (Pbf)], 170.4 (C2), 171.0 (CO2); ES-MS m/z 1105.3 [M+1]
+
; 
Anal. calcd. for C61H81N7O10S: C, 66.34; H, 7.39; N, 8.88. Found: C, 66.58; H, 7.67; N, 8.61. 
4.6.12. (5S,3S)-1-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-
2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine [(S)-22a] 
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Amorphous solid (3:1 isomeric mixture, 75 mg, 20%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 21.04 min (major isomer) and 21.82 
min (minor isomer);
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm) Major isomer: 1.27 (s, 9H, 
Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.65 [s, 3H, Boc (Ind)], 1.79 [m, 2H, -H 
(Arg)], 1.81 [m, 2H, -H (Arg)], 2.01 [s, 3H, CH3 (Pbf)], 2.43 [s, 3H, CH3 (Pbf)], 2.51 [s, 3H, 
CH3 (Pbf)], 2.70 (m, 1H, CH2-Ind), 2.91 [s, 2H, CH2 (Pbf)], 3.15 (m, 1H, CH2-Ind), 3.28 (m, 
1H, 5-H), 3.31 [m, 2H, -H (Arg)], 3.48 (m, 2H, 6-H), 3.54 [m, 1H, 3-H], 3.60 (m, 1H, 4-
CH2), 3.70 (m, 1H, 4-CH2), 4.02 (m, 1H, 5-CH), 4.42 [d, 2H, J = 5.5 Hz, CH2 
(NHC(NHBn)=N)], 4.58 [m, 1H, 1-CH2 (Bn)], 4.70 [m, 1H, 1-CH2 (Bn)], 6.14 (d, 1H, J = 8 
Hz, NHBoc), 7.10-7.41 [m, 14H, Ar and NHC(NHBn)=N], 7.50 (s, 1H, Ar), 7.59 (d, 1H, J = 
7.5 Hz, Ar), 8.11 (d, 1H, J = 7.5 Hz, Ar). Minor isomer: 1.27 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 
(Pbf)], 1.45 (s, 9H, 
t
Bu), 1.65 [s, 3H, Boc (Ind)], 1.79 [m, 2H, -H (Arg)], 1.81 [m, 2H, -H 
(Arg)], 2.01 [s, 3H, CH3 (Pbf)], 2.43 [s, 3H, CH3 (Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.70 (m, 1H, 
CH2-Ind), 2.96 [s, 2H, CH2 (Pbf)], 3.15 (m, 1H, CH2-Ind), 3.28 (m, 1H, 5-H), 3.31 [m, 2H, -
H (Arg)], 3.48 (m, 2H, 6-H), 3.54 [m, 1H, 3-H], 3.60 (m, 1H, 4-CH2), 3.70 (m, 1H, 4-CH2), 
4.02 (m, 1H, 5-CH), 4.52 [m, 1H, 1-CH2 (Bn)], 4.60 [m, 1H, CH2 (NHC(NHBn)=N)], 4.66 
[m, 1H, CH2 (NHC(NHBn)=N)], 4.70 [m, 1H, 1-CH2 (Bn)], 6.14 (d, 1H, J = 8 Hz, NHBoc), 
7.10-7.41 [m, 14H, Ar and NHC(NHBn)=N], 7.50 (s, 1H, Ar), 7.59 (d, 1H, J = 7.5 Hz, Ar), 
8.11 (d, 1H, J = 7.5 Hz, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm) Major isomer: 11.8, 
17.5, 18.7 [3CH3 (Pbf)], 24.7 (CH2-Ind), 25.8 [Cγ (Arg)], 27.6 [3CH3 (
t
Bu) and 3CH3 (Boc)], 
27.9 [2CH3 (Pbf)], 28.0 [3CH3 (Boc)], 31.3 [Cβ (Arg)], 41.4 [Cδ (Arg)], 43.0 [CH2 (Pbf)], 44.4 
(C6), 44.9 [CH2 (NHC(NHBn)=N)], 49.6 [1-CH2 (Bn)], 51.5 (C5-CH), 56.1 (4-CH2), 60.4 
(C5), 64.1 (C3), 78.3 [C (Boc)], 81.2 [C (
t
Bu)], 83.4 [C (Boc)], 86.2 [C (Pbf)], 115.2 [CH 
(Ar)], 116.8 [C (Pbf)], 118.3 [C (Ar)], 119.3, 122.6, 123.6, 124.3 [4CH (Ar)], 124.6 [C (Pbf)], 
127.5, 128.1, 128.4, 128.7 [10CH (Ar)], 131.1 [C (Ar)], 132.2, 135.2 [2C (Pbf)], 135.8 [C 
(Ar)], 137.8 [2C (Ar)], 138.0 [C (Pbf)], 149.6, 155.3 [2CO (2Boc)], 155.8 [C 
(NHC(NHBn)=N)], 158.3 [C (Pbf)], 170.4 (C2), 170.6 (CO2). Minor isomer:  11.8, 17.5, 18.7 
[3CH3 (Pbf)], 24.7 (CH2-Ind), 25.8 [Cγ (Arg)], 27.6 [3CH3 (
t
Bu) and 3CH3 (Boc)], 27.9 [2CH3 
(Pbf)], 28.0 [3CH3 (Boc)], 31.3 [Cβ (Arg)], 41.4 [Cδ (Arg)], 43.0 [CH2 (Pbf)], 44.4 (C6), 49.6 
[1-CH2 (Bn) and CH2 (NHC(NHBn)=N)], 51.5 (C5-CH), 56.1 (4-CH2), 60.4 (C5), 64.1 (C3), 
78.3 [C (Boc)], 81.2 [C (
t
Bu)], 83.4 [C (Boc)], 86.2 [C (Pbf)], 115.2 [CH (Ar)], 116.8 [C 
(Pbf)], 118.3 [C (Ar)], 119.3, 122.6, 123.6, 124.3 [4CH (Ar)], 124.6 [C (Pbf)], 127.5, 128.1, 
128.4, 128.7 [10CH (Ar)], 131.1 [C (Ar)], 132.2, 135.2 [2C (Pbf)], 135.8 [C (Ar)], 137.8 [2C 
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(Ar)], 138.0 [C (Pbf)], 149.6, 155.3 [2CO (2Boc)], 155.8 [C (NHC(NHBn)=N)], 158.3 [C 
(Pbf)], 170.4 (C2), 170.6 (CO2); ES-MS m/z 1105.3 [M+1]
+
; Anal. calcd. for C61H81N7O10S: 
C, 66.34; H, 7.39; N, 8.88. Found: C, 66.07; H, 7.27; N, 9.14. 
4.6.13. (5R,3S)-1-Benzyl- 5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)- 4-(tert-
butoxycarbonyl)methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino) propyl)-2-oxopiperazine [(R)-23a] 
Amorphous solid (152 mg, 51%); [α]D
20
 -2.8 (c 1.0, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 6.90 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.21 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.88 
[m, 4H, β-H (Arg) and -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.58 [s, 
3H, CH3 (Pbf)], 2.62 (dd, 1H, J = 11 and 14 Hz, CH2-Ph), 2.97 [s, 2H, CH2 (Pbf)], 3.13 (d, 
1H, J = 16 Hz, 4-CH2), 3.22 (m, 1H, 6-H), 3.30 [m, 2H, -H (Arg)], 3.35 [m, 1H, 3-H], 3.37 
(m, 1H, 6-H), 3.39 (m, 1H, 5-H), 3.46 (dd, 1H, J = 3 and 14 Hz, CH2-Ph), 3.60 (d, 1H, J = 16 
Hz, 4-CH2), 3.82 (dt, 1H, J = 3.5 and 12 Hz, 5-CH), 4.35 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 
4.83 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.89 (d, 1H, J = 9.5 Hz, NHBoc), 6.55 [m, 3H, 
NHC(NH2)=N], 7.10-7.38 (m, 10H, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.7, 
18.2, 19.5 [3CH3 (Pbf)], 27.4 [Cγ (Arg)], 28.3 [3CH3 (
t
Bu)], 28.5 [2CH3 (Pbf)], 28.7 [3CH3 
(Boc)], 28.9 [Cβ (Arg)], 38.0 (CH2-Ph), 41.6 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 46.0 (C6), 50.2 [1-
CH2 (Bn)], 51.7 (4-CH2), 53.6 (C5-CH), 55.7 (C5), 65.3 (C3), 78.8 [C (Boc)], 81.5 [C (
t
Bu)], 
86.9, 117.4, 125.3 [3C (Pbf)], 126.7, 128.1, 128.7, 128.8, 129.4, 130.2 [10CH (Ar)], 132.8, 
135.6, 138.7 [3C (Pbf)], 138.6, 140.4 [C (Ar)], 156.3 [CO (Boc)], 157.4 [C (NHC(NH2)=N)], 
158.9 [C (Pbf)], 170.6 (C2), 170.9 (CO2); ES-MS m/z 876.1 [M+1]
+
; Anal. calcd. for 
C47H66N6O8S: C, 64.51; H, 7.60; N, 9.60. Found: C, 64.25; H, 7.38; N, 9.94. 
4.6.14. (5S,3S)-1-Benzyl- 5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)- 4-(tert-
butoxycarbonyl)methyl -3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino) propyl)-2-oxopiperazine [(S)-23a] 
Amorphous solid (149 mg, 50%); [α]D
20
 +16 (c 1.0, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 6.80 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.25 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.75 
[m, 4H, β-H (Arg) and -H (Arg)], 2.05 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.57 [s, 
3H, CH3 (Pbf)], 2.55 (m, 1H, CH2-Ph), 2.98 [s, 2H, CH2 (Pbf)], 3.03 (d, 1H, J = 13 Hz, CH2-
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Ph), 3.22 (m, 1H, 5-H), 3.24 [m, 2H, -H (Arg)], 3.40 (m, 2H, 6-H), 3.46 (m, 1H, 3-H), 3.53 
(d, 1H, J = 18 Hz, 4-CH2), 3.67 (d, 1H, J = 18 Hz, 4-CH2), 3.82 (m, 1H, 5-CH), 4.53 [d, 1H, J 
= 14.5 Hz, 1-CH2 (Bn)], 4.70 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 6.10 (d, 1H, J = 8 Hz, 
NHBoc), 6.50 [m, 3H, NHC(NH2)=N], 7.10-7.40 (m, 10H, Ar); 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm): 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.4 [Cγ (Arg)], 28.3 [3CH3 (
t
Bu)], 28.5 
[2CH3 (Pbf)], 28.7 [3CH3 (Boc)], 32.2 [Cβ (Arg)], 35.5 (CH2-Ph), 41.6 [Cδ (Arg)], 43.6 [CH2 
(Pbf)], 44.9 (C6), 49.9 [1-CH2 (Bn)], 54.0 (C5-CH), 56.4 (4-CH2), 60.7 (C5), 65.0 (C3), 78.8 
[C (Boc)], 81.7 [C (
t
Bu)], 86.9, 117.4, 125.3 [3C (Pbf)], 126.8, 128.1, 128.8, 129.0, 129.4, 
129.9 [10CH (Ar)], 132.8, 135.7, 138.7 [3C (Pbf)], 138.5, 140.6 [C (Ar)], 156.1 [CO (Boc)], 
157.3 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 171.1 (C2), 171.3 (CO2); ES-MS m/z 876.1 
[M+1]
+
; Anal. calcd. for C47H66N6O8S: C, 64.51; H, 7.60; N, 9.60. Found: C, 64.68; H, 7.42; 
N, 9.72. 
4.6.15. (5R,3S)-1-Benzyl- 5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)- 4-(tert-
butoxycarbonyl)methyl -3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-oxopiperazine [(R)-25a] 
Amorphous solid (5:1 isomeric mixture, 46 mg, 14%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.82 min (major isomer) and 12.53 
min (minor isomer);
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm) Major isomer: 1.20 (s, 9H, 
Boc), 1.44 [s, 6H, 2CH3 (Pbf)], 1.45 (s, 9H, 
t
Bu), 1.85 [m, 4H, β-H (Arg) and -H (Arg)], 2.01 
[s, 3H, CH3 (Pbf)], 2.44 [s, 3H, CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.64 (dd, 1H, J = 11 and 
14 Hz, CH2-Ph), 2.93 [s, 2H, CH2 (Pbf)], 3.14 (d, 1H, J = 16 Hz, 4-CH2), 3.26 (m, 1H, 6-H), 
3.36 [m, 2H, -H (Arg) and 3-H], 3.40 (m, 1H, 5-H), 3.42 (m, 1H, 6-H), 3.47 [m, 1H, -H 
(Arg)], 3.48 (dd, 1H, J = 3 and 14 Hz, CH2-Ph), 3.62 (d, 1H, J = 16 Hz, 4-CH2), 3.82 (m, 1H, 
5-CH), 4.36 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.43 [dd, 1H, J = 6 and 16 Hz, CH2 
(NHC(NHBn)=N)], 4.46 [dd, 1H, J = 6 and 16 Hz, CH2 (NHC(NHBn)=N)], 4.83 [d, 1H, J = 
14.5 Hz, 1-CH2 (Bn)], 5.86 (d, 1H, J = 9.5 Hz, NHBoc), 7.09-7.39 (m, 17H, Ar and 
NHC(NHBn)=N). Minor isomer: 1.22 (s, 9H, Boc), 1.43 [s, 6H, 2CH3 (Pbf)], 1.45 (s, 9H, 
t
Bu), 1.85 [m, 4H, β-H (Arg) and -H (Arg)], 2.01 [s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 (Pbf)], 
2.50 [s, 3H, CH3 (Pbf)], 2.58 (m, 1H, CH2-Ph), 2.95 [s, 2H, CH2 (Pbf)], 3.16 (d, 1H, J = 16 
Hz, 4-CH2), 3.26 (m, 1H, 6-H), 3.36 [m, 2H, -H (Arg) and 3-H], 3.42 (m, 1H, 6-H), 3.47 [m, 
1H, -H (Arg)], 3.46 (m, 1H, CH2-Ph), 3.63 (d, 1H, J = 16 Hz, 4-CH2), 3.82 (m, 1H, 5-CH), 
4.36 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.67 [d, 1H, J = 16 Hz, CH2 (NHC(NHBn)=N)], 4.75 
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[d, 1H, J = 16 Hz, CH2 (NHC(NHBn)=N)], 4.85 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.85 (d, 
1H, J = 9.5 Hz, NHBoc), 7.09-7.39 (m, 17H, Ar and NHC(NHBn)=N); 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm) Major isomer: 11.9, 17.6, 18.9 [3CH3 (Pbf)], 26.6 [Cγ (Arg)], 27.6 [3CH3 
(
t
Bu)], 27.8 [3CH3 (Boc)], 28.0 [2CH3 (Pbf) and Cβ (Arg)], 37.4 (CH2-Ph), 41.2 [Cδ (Arg)], 
42.9 [CH2 (Pbf)], 44.7 [CH2 (NHC(NHBn)=N)], 45.4 (C6), 49.6 [1-CH2 (Bn)], 50.9 (4-CH2), 
52.6 (C5-CH), 55.0 (C5), 64.4 (C3), 78.1 [C (Boc)], 80.9 [C (
t
Bu)], 86.3, 116.8, 124.6 [3C 
(Pbf)], 126.1, 127.5, 128.6, 128.2, 128.8, 129.6 [15CH (Ar)], 132.1, 134.8 [2C (Pbf)], 137.9 
[2C (Ar)], 138.0 [C (Pbf)], 139.7 [C (Ar)], 153.9 [C (NHC(NHBn)=N)], 155.9 [CO (Boc)], 
158.3 [C (Pbf)], 170.1 (C2), 170.4 (CO2). Minor isomer: 11.9, 17.6, 18.9 [3CH3 (Pbf)], 26.6 
[Cγ (Arg)], 27.6 [3CH3 (
t
Bu)], 27.8 [3CH3 (Boc)], 28.0 [2CH3 (Pbf) and Cβ (Arg)], 37.4 (CH2-
Ph), 41.2 [Cδ (Arg)], 42.9 [CH2 (Pbf)], 45.4 (C6), 49.6 [1-CH2 (Bn)], 50.7 (4-CH2), 50.9 [CH2 
(NHC(NHBn)=N)], 52.6 (C5-CH), 64.4 (C3), 78.1 [C (Boc)], 80.9 [C (
t
Bu)], 86.3, 116.8, 
124.6 [3C (Pbf)], 126.1, 127.5, 127.9, 128.2, 128.5, 129.5 [15CH (Ar)], 132.0, 134.8 [2C 
(Pbf)], 137.9 [2C (Ar)], 138.0 [C (Pbf)], 139.7 [C (Ar)], 153.9 [C (NHC(NHBn)=N)], 155.9 
[CO (Boc)], 158.2 [C (Pbf)], 169.9 (C2), 170.4 (CO2); ES-MS m/z 966.2 [M+1]
+
; Anal. calcd. 
for C54H72N6O8S: C, 67.19; H, 7.52; N, 8.71. Found: C, 67.45; H, 7.38; N, 9.02. 
4.6.16. (5S,3S)-1-Benzyl- 5-((S)-1-(tert-butoxycarbonyl)amino-2-phenylethyl)- 4-(tert-
butoxycarbonyl)methyl -3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-oxopiperazine [(S)-25a] 
Amorphous solid (3:1 isomeric mixture, 49 mg, 15%); HPLC [Sunfire C18 (4.6  150 mm, 
3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.28 min (major isomer) and 12.83 
min (minor isomer);
 1
H NMR (400 MHz, (CD3)2CO) δ (ppm) Major isomer: 1.25 (s, 9H, 
Boc), 1.45 [s, 6H, 2CH3 (Pbf)], 1.46 (s, 9H, 
t
Bu), 1.77 [m, 4H, β-H (Arg) and -H (Arg)], 2.02 
[s, 3H, CH3 (Pbf)], 2.44 [s, 3H, CH3 (Pbf)], 2.52 [s, 3H, CH3 (Pbf)], 2.54 (m, 1H, CH2-Ph), 
2.95 [s, 2H, CH2 (Pbf)], 3.03 (m, 1H, CH2-Ph), 3.24 (m, 1H, 5-H), 3.30 [m, 2H, -H (Arg)], 
3.40 (m, 2H, 6-H), 3.51 (m, 1H, 3-H), 3.54 (m, 1H, 4-CH2), 3.68 (m, 1H, 4-CH2), 3.88 (m, 
1H, 5-CH), 4.44 [d, 1H, J = 5.5 Hz, CH2 (NHC(NHBn)=N)], 4.52 [d, 1H, J = 15 Hz, 1-CH2 
(Bn)], 4.70 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 6.08 (d, 1H, J = 8.5 Hz, NHBoc), 7.10-7.37 (m, 
17H, Ar and NHC(NHBn)=N). Minor isomer: 1.24 (s, 9H, Boc), 1.44 [s, 6H, 2CH3 (Pbf)], 
1.45 (s, 9H, 
t
Bu), 1.77 [m, 4H, β-H (Arg) and -H (Arg)], 2.02 [s, 3H, CH3 (Pbf)], 2.47 [s, 3H, 
CH3 (Pbf)], 2.52 [s, 3H, CH3 (Pbf)], 2.54 (m, 1H, CH2-Ph), 2.97 [s, 2H, CH2 (Pbf)], 3.03 (m, 
1H, CH2-Ph), 3.24 (m, 1H, 5-H), 3.30 [m, 2H, -H (Arg)], 3.40 (m, 2H, 6-H), 3.51 (m, 1H, 3-
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H), 3.59 (m, 1H, 4-CH2), 3.63 (m, 1H, 4-CH2), 3.88 (m, 1H, 5-CH), 4.48 [m, 1H, CH2 
(NHC(NHBn)=N)], 4.58 [m, 1H, 1-CH2 (Bn)], 4.64 [m, 1H, 1-CH2 (Bn)], 6.08 (d, 1H, J = 8.5 
Hz, NHBoc), 7.10-7.37 [m, 17H, Ar and NHC(NHBn)=N]; 
13
C NMR (100 MHz, (CD3)2CO) δ 
(ppm) Major isomer: 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.3 [Cγ (Arg)], 28.4 [3CH3 (Boc)], 28.5 
[2CH3 (Pbf)], 28.8 [3CH3 (
t
Bu)], 32.1 [Cβ (Arg)], 35.3 (CH2-Ph), 42.0 [Cδ (Arg)], 43.7 [CH2 
(Pbf)], 44.9 [C6 and CH2 (NHC(NHBn)=N)], 50.0 [1-CH2 (Bn)], 53.9 (C5-CH), 56.2 (4-CH2), 
60.7 (C5), 64.8 (C3), 78.1 [C (Boc)], 81.7 [C (
t
Bu)], 86.9, 117.5, 125.3 [3C (Pbf)], 126.8, 
128.1, 128.7, 129.0, 129.4, 129.9 [15CH (Ar)], 132.8, 135.6 [2C (Pbf)], 138.4 [2C (Ar)], 
138.7 [C (Pbf)], 140.7 [C (Ar)], 156.0 [CO (Boc) and C (NHC(NHBn)=N)], 158.9 [C (Pbf)], 
171.1 (C2), 171.2 (CO2). Minor isomer: 12.6, 18.2, 19.5 [3CH3 (Pbf)], 26.3 [Cγ (Arg)], 28.4 
[3CH3 (Boc)], 28.5 [2CH3 (Pbf)], 28.8 [3CH3 (
t
Bu)], 32.1 [Cβ (Arg)], 35.3 (CH2-Ph), 42.0 [Cδ 
(Arg)], 43.7 [CH2 (Pbf)], 44.9 (C6), 50.0 [1-CH2 (Bn)], 52.6 [CH2 (NHC(NHBn)=N)], 53.9 
(C5-CH), 56.2 (4-CH2), 60.7 (C5), 64.8 (C3), 78.7 [C (Boc)], 81.7 [C (
t
Bu)], 86.9, 117.5, 125.3 
[3C (Pbf)], 126.8, 128.1, 128.9, 129.2, 129.4, 129.9 [15CH (Ar)], 132.7, 135.6 [2C (Pbf)], 
138.4 [2C (Ar)], 138.7 [C (Pbf)], 140.7 [C (Ar)], 156.0 [CO (Boc)], 156.1 [C 
(NHC(NHBn)=N)], 158.9 [C (Pbf)], 171.1 (C2), 171.2 (CO2); ES-MS m/z 966.2 [M+1]
+
; 
Anal. Calcd. for C54H72N6O8S: C, 67.19; H, 7.52; N, 8.71. Found: C, 67.37; H, 7.74; N, 8.84. 
4.7. General procedure for the benzylation of the 4-alkyl-2-oxopiperazines 10b and 12b. 
Synthesis of the 4-alkyl-1-benzyl-2-oxopiperazines (R)- and (S)-(26b and 27b) 
NaH (60% suspension in mineral oil, 9 mg, 0.38 mmol) and benzyl bromide (0.45 µL, 0.38 
mmol) were added to a solution of the corresponding 2-oxopiperazine 10b and 12b (0.34 
mmol) in anhydrous mixture THF/DMF (9:1, 10 mL) under argon at 0 ºC. After 1h of stirring, 
the crude reaction mixture was diluted with EtOAc (100 mL) and the excess of NaH was 
hydrolysed by addition of H2O (20 mL). The aqueous layer was extracted with EtOAc (250 
mL) and the organic extracts were dried over Na2SO4 and evaporated to dryness. The residue 
was purified by flash chromatography, using MeOH in CH2Cl2 gradient as mobile phase to 
obtain the respective 4-alkyl-1-benzyl-2-oxopiperazine derivatives (R)- and (S)-(26b and 
27b) in 70-80 %. The compounds were dissolved in CH3CN/H2O (1:2, 2 mL) and the 
solutions were lyophilized. 
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4.7.1. (5R,3S)-1,4-Dibenzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxy-
carbonyl)-indol-3-yl)ethyl-3-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxopiperazine 
[(R)-26b] 
Amorphous solid (220 mg, 80%); [α]D
20
 -15 (c 1.4, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.75 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.25 (s, 9H, Boc), 1.31 [m, 4H, -H (Lys) and -H (Lys)], 1.36 [s, 9H, 
Boc (Lys)], 1.61 [m, 1H, -H (Lys)], 1.64 [s, 9H, Boc (Ind)], 1.80 [m, 1H, -H (Lys)], 1.86 
[m, 1H, ε-H (Lys)], 2.80 (m, 1H, CH2-Ind), 3.03 [m, 1H, ε-H (Lys)], 3.17 (dd, 1H, J = 4.5 and 
10 Hz, 3-H), 3.37 (m, 1H, 6-H), 3.54 [m, 1H, 4-CH2 (Bn)], 3.59 (m, 3H, 5-H, 6-H and CH2-
Ind), 4.17 (m, 1H, 5-CH), 4.18 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 4.51 [d, 1H, J = 14.5 Hz, 1-
CH2 (Bn)], 4.79 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.84 [m, 1H, NHBoc (Lys)], 6.00 (d, 1H, J 
= 9.5 Hz, NHBoc), 7.16 (t, 1H, J = 7.5 Hz, Ar), 7.22-7.57 (m, 13H, Ar), 8.12 (d, 1H, J = 7.5 
Hz, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 24.5 [Cγ (Lys)], 27.9 (CH2-Ind), 28.3, 
28.5, 28.7 [9CH3 (3Boc)], 30.3 [Cδ (Lys)], 31.2 [Cβ (Lys)], 41.1 [Cε (Lys)], 45.8 (C6), 50.2 [1-
CH2 (Bn)], 51.3 (C5-CH), 51.9 [4-CH2 (Bn)], 55.6 (C5), 62.5 (C3), 78.2, 78.9, 83.9 [3C 
(3Boc)], 115.8 [CH (Ar)], 118.7 [C (Ar)], 119.9, 123.2, 124.3, 124.9, 128.1, 128.2, 128.9, 
129.3, 129.4, 129.9 [14CH (Ar)], 131.9, 136.3, 138.9, 139.5 [4C (Ar)], 150.3, 156.5 [3CO 
(3Boc)], 171.0 (C2); ES-MS m/z 811.2 [M+1]
+
; Anal. calcd. for C47H63N5O7: C, 69.69; H, 
7.84; N, 8.65. Found: C, 69.92; H, 8.06; N, 8.41. 
4.7.2. (5S,3S)-1,4-Dibenzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxy-
carbonyl)-indol-3-yl)ethyl-3-(4-((tert-butoxycarbonyl)amino)butyl)-2-oxopiperazine [(S)-
26b] 
Amorphous solid (220 mg, 80%); [α]D
20
 +11 (c 1.3, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.99 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.28 [m, 2H, -H (Lys)], 1.31 [m, 9H, Boc], 1.34 [m, 2H, -H 
(Lys)], 1.37 [m, 9H, Boc (Lys)], 1.43 [m, 1H, -H (Lys)], 1.66 [s, 9H, Boc (Ind)], 1.71 [m, 
1H, -H (Lys)], 2.85 (m, 1H, CH2-Ind), 2.95 [m, 2H, ε-H (Lys)], 3.16 (m, 1H, 5-H), 3.19 (m, 
1H, CH2-Ind), 3.27 (t, 1H, J = 7 Hz, 3-H), 3.46 (dd, 1H, J = 5 and 13.5 Hz, 6-H), 3.57 (m, 1H, 
6-H), 3.85 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.08 [d, 1H, J = 14 Hz, 4-CH2 (Bn)], 4.12 (m, 1H, 
5-CH), 4.57 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 4.66 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 5.80 [m, 
1H, NHBoc (Lys)], 6.09 (d, 1H, J = 9 Hz, NHBoc), 7.18-7.38 (m, 10H, Ar), 7.47 (m, 3H, Ar), 
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7.61 (d, 1H, J = 7.5 Hz, Ar), 8.12 (d, 1H, J = 7.5 Hz, Ar). 
13
C NMR (100 MHz, (CD3)2CO) δ 
(ppm): 24.2 [Cγ (Lys)], 26.4 (CH2-Ind), 28.3, 28.7 [9CH3 (3Boc)], 31.2 [Cδ (Lys)], 34.8 [Cβ 
(Lys)], 41.0 [Cε (Lys)], 45.0 [C6], 49.8 [1-CH2 (Bn)], 52.8 (C5-CH), 62.3 [4-CH2 (Bn)], 63.6 
(C5), 64.3 (C3), 78.2, 78.8, 84.0 [3C (3Boc)], 115.9 [CH (Ar)], 119.0 [C (Ar)], 119.9, 123.2, 
124.0, 125.0, 128.1, 128.7, 129.1, 129.4, 130.2 [14CH (Ar)], 131.8, 136.3, 138.7, 139.9 [4C 
(Ar)], 150.3, 156.5 [3CO (3Boc)], 171.7 (C2); ES-MS m/z 811.2 [M+1]
+
; Anal. calcd. for 
C47H63N5O7: C, 69.69; H, 7.84; N, 8.65. Found: C, 69.90; H, 7.96; N, 8.52. 
4.7.3. (5R,3S)-1-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(4-((tert-butoxycarbonyl)amino)-
butyl)-2-oxopiperazine [(R)-27b] 
Amorphous solid (227 mg, 80%); [α]D
20
 -4.2 (c 1.5, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 11.80 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.23 (s, 9H, Boc), 1.37 [s, 9H, Boc (Lys)], 1.48 (s, 9H, 
t
Bu), 1.61 
[m, 2H, -H (Lys)], 1.63 [m, 2H, -H (Lys)], 1.65 [s, 9H, Boc (Ind)], 1.79 [m, 1H, -H (Lys)], 
1.87 [m, 1H, -H (Lys)], 2.75 (dd, 1H, J = 10.5 and 15 Hz, CH2-Ind), 3.13 (m, 1H, 4-CH2), 
3.16 [m, 2H, ε-H (Lys)], 3.29 (m, 1H, 6-H), 3.33 (m, 1H, 3-H), 3.40 (m, 1H, 6-H), 3.46 (m, 
1H, 5-H), 3.61 (m, 1H, CH2-Ind), 3.62 (d, 1H, J = 16 Hz, 4-CH2), 3.91 (m, 1H, 5-CH), 4.38 
[d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 4.84 [d, 1H, J = 14.5 Hz, 1-CH2 (Bn)], 5.93 [m, 1H, NHBoc 
(Lys)], 5.98 (d, 1H, J = 9.5 Hz, NHBoc), 7.22 (t, 1H, J = 7.5 Hz, Ar), 7.25-7.37 (m, 6H, Ar), 
7.47 (s, 1H, Ind), 7.62 (d, 1H, J = 7.5 Hz, Ind), 8.11 (d, 1H, J = 7.5 Hz, Ind); 
13
C NMR (100 
MHz, (CD3)2CO) δ (ppm): 24.7 [Cγ (Lys)], 27.6 (CH2-Ind), 28.3 [6CH3 (Boc and 
t
Bu)], 28.5, 
28.7 [6CH3 (2Boc)], 30.4 [Cδ (Lys)], 31.3 [Cβ (Lys)], 41.2 [Cε (Lys)], 46.0 (C6), 50.2 [1-CH2 
(Bn)], 51.9 (C5-CH), 52.1 (4-CH2), 56.0 (C5), 65.6 (C3), 78.2, 78.9 [2C (2Boc)], 81.5 [C 
(
t
Bu)], 83.9 [C (Boc)], 115.8 [CH (Ar)], 118.9 [C (Ar)], 120.0, 123.1, 124.4, 124.9, 128.1, 
128.8, 129.4 [9CH (Ar)], 131.9, 136.3, 138.7 [3C (Ar)], 150.3, 156.4 [3CO (3Boc)], 170.7 
[CO2], 170.8 (C2); ES-MS m/z 835.1 [M+1]
+
; Anal. calcd. for C46H67N5O9: C, 66.24; H, 8.10; 
N, 8.40. Found: C, 66.03; H, 7.86; N, 8.35. 
4.7.4. (5S,3S)-1-Benzyl-5-((S)-1-((tert-butoxycarbonyl)amino-2-(1-(tert-butoxycarbonyl)-
indol-3-yl)ethyl-4-(tert-butoxycarbonyl)methyl -3-(4-((tert-butoxycarbonyl)amino)-
butyl)-2-oxopiperazine [(S)-27b] 
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Amorphous solid (198 mg, 70%); [α]D
20
 +7.0 (c 1.3, CH2Cl2); HPLC [Sunfire C18 (4.6  
150 mm, 3.5 μm), 80-100% gradient of solvent A in B, 30 min] tR 12.41 min;
 1
H NMR (400 
MHz, (CD3)2CO) δ (ppm): 1.29 (s, 9H, Boc), 1.37 [s, 9H, Boc (Lys)], 1.45 (s, 9H, 
t
Bu), 1.55 
[m, 2H, -H (Lys)], 1.57 [m, 2H, -H (Lys)], 1.65 [s, 9H, Boc (Ind)], 1.80 [m, 2H, -H (Lys)], 
2.71 (dd, 1H, J = 11 and 15 Hz, CH2-Ind), 3.17 (dd, 1H, J = 2 and 15 Hz, CH2-Ind), 3.09 [m, 
2H, ε-H (Lys)], 3.30 (m, 1H, 5-H), 3.44 (m, 1H, 3-H), 3.47 (m, 2H, 6-H), 3.58 (d, 1H, J = 18 
Hz, 4-CH2), 3.70 (d, 1H, J = 18 Hz, 4-CH2), 4.02 (m, 1H, 5-CH), 4.64 [m, 2H, 1-CH2 (Bn)], 
5.92 [m, 1H, NHBoc (Lys)], 6.14 (d, 1H, J = 8.5 Hz, NHBoc), 7.18-7.41 (m, 7H, Ar), 7.48 (s, 
1H, Ar), 7.61 (d, 1H, J = 7.5 Hz, Ar), 8.11 (d, 1H, J = 7.5 Hz, Ar). 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm): 23.9 [Cγ (Lys)], 25.3 (CH2-Ind), 28.3 [6CH3 (Boc and 
t
Bu)], 28.6, 28.7 
[6CH3 (2Boc)], 30.8 [Cδ (Lys)], 35.0 [Cβ (Lys)], 41.1 [Cε (Lys)], 44.8 [C6], 50.0 [1-CH2 (Bn)], 
51.9 (C5-CH), 56.9 (4-CH2), 60.9 (C5), 65.6 (C3), 78.2, 78.8 [2C (2Boc)], 81.7 [C (
t
Bu)], 84.0 
[C (Boc)], 115.9 [CH (Ar)], 119.1 [C (Ar)], 119.9, 123.3, 124.1, 125.0, 128.1, 128.8, 129.4 
[9CH (Ar)], 131.7, 136.4, 138.7 [3C (Ar)], 150.3, 156.6 [3CO (3Boc)], 171.2 (CO2), 171.3 
(C2); ES-MS m/z 835.1 [M+1]
+
; Anal. calcd. for C46H67N5O9: C, 66.24; H, 8.10; N, 8.40. 
Found: C, 65.98; H, 8.36; N, 8.61. 
4.8. General procedure for the synthesis of the 1,4-dibenzyl-2-oxopiperazine-derived benzyl 
ureas (R)- and (S)-(28a and 29a) 
The corresponding 1,4-dibenzyl-2-oxopiperazine 14a and 17a (0.10 mmol) was dissolved 
in 3.4 N solution of  HCl in EtOAc (5 mL) and the mixture was stirred at room temperature 
for 30 min. Afterward, the solvent was evaporated to dryness and the residue was dissolved in 
CH3CN/H2O (1:3, 2 mL) and the solution was lyophilized. The residue was dissolved in dry 
THF (10 mL) and TEA (56 µL, 0.40 mmol) and benzyl isocyanate (15 µL, 0.12 mmol) were 
successively added to the solution. After 1 h of stirring at room temperature, the solvent was 
removed under reduced pressure and the residue was dissolved in CH2Cl2 (40 mL). The 
solution was successively washed with H2O (10 mL) and brine (10 mL), dried over Na2SO4, 
and evaporated to dryness. The residue was purified by flash chromatography, using a MeOH 
in EtOAc gradient as mobile phase to obtain the resèctove 1,4-dibenzyl-2-oxopiperazine-
derived benzyl ureas 28a and 29a in 50-85 % yield. The purified compounds were dissolved 
in CH3CN/H2O (1:2, 2 mL) and the solutions were lyophilized. 
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4.8.1. (5R,3S)-1,4-Dibenzyl-5-((S)-1-(3-benzylureido)-2-(1H-indol-3-yl)ethyl-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-
oxopiperazine [(R)-28a] 
Amorphous solid (46 mg, 50%); [α]D
20
 -13 (c 1.2, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 50-100% gradient of solvent A in B, 30 min] tR 11.23 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.42 [s, 6H, 2CH3 (Pbf)], 1.79 [m, 4H, -H and -H (Arg)], 2.02 [s, 3H, 
CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.58 [s, 3H, CH3 (Pbf)], 2.92 [s, 2H, CH2 (Pbf)], 2.98 (m, 
1H, CH2-Ind), 3.06 [m, 2H, -H (Arg)], 3.11 [m, 1H, 3-H], 3.39 (dd, 1H, J = 4.5 and 12.5 Hz, 
6-H), 3.49 [m, 1H, 4-CH2 (Bn)], 3.53 [m, 2H, CH2-Ind and 5-H], 3.65 (t, 1H, J = 12.5 Hz, 6-
H), 4.20 [m, 2H, CH2 (Bn, Urea)], 4.23 [m, 1H, 4-CH2 (Bn)], 4.40 [m, 1H, 5-CH], 4.51 [d, 
1H, J = 15 Hz, 1-CH2 (Bn)], 4.69 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 5.55 (d, 1H, J = 9.5 Hz, 5-
CH-NH), 5.79 (m, 1H, CONH), 6.52 [br s, 3H, NHC(NH2)=N], 6.91 (t, 1H, J = 7.5 Hz, Ar), 
7.05 (t, 1H, J = 7.5 Hz, Ar), 7.11 (d, 1H, J = 7.5 Hz, Ar), 7.14-7.39 (m, 15H, Ar), 7.41 (d, 1H, 
J = 7.5 Hz, Ar), 7.49 (d, 1H, J = 7.5 Hz, Ar), 10.08 [s, 1H, NH (Ar)]; 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm): 12.6, 18.3, 19.5 [3CH3 (Pbf)], 27.2 (CH2-Ind), 28.1 [Cγ (Arg)], 28.7 
[2CH3 (Pbf)], 28.8 [Cβ (Arg)], 41.2 [Cδ (Arg)], 43.5 [CH2 (Pbf)], 44.1 [CH2 (Bn, Urea)], 46.2 
(C6), 50.4 [1-CH2 (Bn)], 51.4 (C5-CH), 51.9 [4-CH2 (Bn)], 55.5 (C5), 62.2 (C3), 87.0 [C 
(Pbf)], 112.1 [C (Ar)], 112.5 [CH (Ar)], 117.5 [C (Pbf)], 119.4, 121.9, 124.1 [4CH (Ar)], 
125.3 [C (Pbf)], 127.3, 127.7, 128.1, 128.6, 129.3, 129.4, 129.9 [15CH (Ar)], 129.0 [C (Ar)], 
132.8, 135.4 [2C (Pbf)], 137.5 [C (Ar)], 138.7 [C (Pbf)], 138.8, 139.6, 141.8 [C (Ar)], 157.4 
[C (NHC(NH2)=N)], 158.8 [C (Pbf)], 158.9 [CO (Urea)], 171.0 (C2); ES-MS m/z 924.1 
[M+1]
+
; Anal. calcd. for C53H62N8O5S: C, 68.95; H, 6.77; N, 12.14. Found: C, 68.61; H, 6.89; 
N, 12.06. 
4.8.2. (5S,3S)-1,4-Dibenzyl-5-((S)-1-(3-benzylureido)-2-(1H-indol-3-yl)ethyl-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-
oxopiperazine [(S)-28a] 
Amorphous solid (46 mg, 50%); [α]D
20
 +11 (c 1.1, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 50-100% gradient of solvent A in B, 30 min] tR 13.75 min;
 1
H NMR (500 MHz, 
(CD3)2CO) δ (ppm): 1.30 [m, 1H, -H (Arg)], 1.43 [s, 6H, 2CH3 (Pbf)], 1.54 [m, 2H, -H and 
-H (Arg)], 1.73 [m, 1H, -H (Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.57 [s, 
3H, CH3 (Pbf)], 2.77 (m, 1H, CH2-Ind), 2.88 [m, 1H, -H (Arg)], 2.96 [s, 2H, CH2 (Pbf)], 
55 
 
3.09 [m, 1H, -H (Arg)], 3.10 [m, 1H, 3-H], 3.12 (m, 2H, 5-H and CH2-Ind), 3.47 (m, 2H, 6-
H), 3.74 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 3.96 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 4.24 [m, 
1H, 5-CH], 4.26 [dd, 1H, J = 5.5 and 15 Hz, CH2 (Bn, Urea)], 4.30 [dd, 1H, J = 6 and 15 Hz, 
CH2 (Bn, Urea)], 4.46 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 4.71 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 
5.70 (d, 1H, J = 8.5 Hz, 5-CH-NH), 6.03 (m, 1H, CONH), 6.45 [br s, 3H, NHC(NH2)=N], 
6.96 (t, 1H, J = 7.5 Hz, Ar), 7.02 (m, 1H, Ar), 7.08 (t, 1H, J = 7.5 Hz, Ar), 7.15-7.39 (m, 15H, 
Ar), 7.40 (d, 1H, J = 7.5 Hz, Ar), 7.53 (d, 1H, J = 7.5 Hz, Ar), 10.00 [s, 1H, NH (Ar)]; 
13
C 
NMR (125 MHz, (CD3)2CO) δ (ppm): 12.6, 18.3, 19.5 [3CH3 (Pbf)], 27.0 [Cγ (Arg)], 28.3 
(CH2-Ind), 28.7 [2CH3 (Pbf)], 31.1 [Cβ (Arg)], 40.9 [Cδ (Arg)], 43.6 [CH2 (Pbf)], 44.3 [CH2 
(Bn, Urea)], 45.9 (C6), 49.7 [1-CH2 (Bn)], 54.1 (C5-CH), 62.9 [C5 and 4-CH2 (Bn)], 63.6 (C3), 
86.9 [C (Pbf)], 112.1 [C and CH (Ar)], 117.4 [C (Pbf)], 119.4, 122.0, 123.7 [4CH (Ar)], 125.4 
[C (Pbf)], 127.4, 127.9, 128.1, 128.2, 128.8, 129.5, 130.3 [15CH (Ar)], 129.1 [C (Ar)], 132.8, 
135.7 [2C (Pbf)], 137.5 [C (Ar)], 138.7 [C (Pbf) and C (Ar)], 140.0, 141.7 [2C (Ar)], 157.5 [C 
(NHC(NH2)=N)], 158.9 [C (Pbf)], 159.2 [CO (Urea)], 172.1 (C2); ES-MS m/z 924.2 [M+1]
+
; 
Anal. calcd. for C53H62N8O5S: C: 68.95, H: 6.77, N: 12.14. Found: C: 68.59, H: 6.98, N: 
12.02. 
4.8.3. (5R,3S)-1,4-Dibenzyl-5-((S)-1-(3-benzylureido)-2-phenylethyl)-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-oxopiperazine 
[(R)-29a] 
Amorphous solid (62 mg, 70%); [α]D
20
 -14 (c 1.3, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 60-100% gradient of solvent A in B, 30 min] tR 8.12 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.43 [s, 6H, 2CH3 (Pbf)], 1.79 [m, 4H, -H and -H (Arg)], 2.03 [s, 3H, 
CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.57 [s, 3H, CH3 (Pbf)], 2.76 (dd, 1H, J = 11 and 14 Hz, 
CH2-Ph), 2.96 [s, 2H, CH2 (Pbf)], 3.07 [m, 2H, -H (Arg)], 3.12 [m, 1H, 3-H], 3.38 (dd, 1H, J 
= 4.5 and 12.5 Hz, 6-H), 3.48 [m, 1H, 4-CH2 (Bn)], 3.49 (m, 1H, CH2-Ph), 3.50 (m, 1H, 5-H), 
3.63 (t, 1H, J = 12.5 Hz, 6-H), 4.18 [m, 2H, CH2 (Bn, Urea)], 4.20 [m, 1H, 4-CH2 (Bn)], 4.28 
(m, 1H, 5-CH), 4.53 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 4.68 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 
5.59 (d, 1H, J = 9 Hz, 5-CH-NH), 5.77 (t, 1H, J = 6 Hz, CONH), 6.50 [br s, 3H, 
NHC(NH2)=N], 7.04-7.43 (m, 20H, Ar); 
13
C NMR (100 MHz, (CD3)2CO) δ (ppm): 12.6, 
18.2, 19.5 [3CH3 (Pbf)], 27.1 [Cγ (Arg)], 28.7 [Cβ (Arg) and 2CH3 (Pbf)], 38.6 (CH2-Ph), 41.3 
[Cδ (Arg)], 43.6 [CH2 (Pbf)], 44.1 [CH2 (Bn, Urea)], 46.2 (C6), 50.4 [1-CH2 (Bn)], 51.8 [4-
CH2 (Bn)], 52.5 (C5-CH), 55.8 (C5), 62.1 (C3), 86.9, 117.5, 125.3 [3C (Pbf)], 126.8, 127.3, 
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128.1, 128.7, 128.9, 129.0, 129.3, 129.4, 129.9, 130.3 [20CH (Ar)], 132.8, 135.5 [2C (Pbf)], 
138.7 [C (Ar)], 138.8 [C (Pbf)], 139.6, 140.3, 141.8 [3C (Ar)], 157.4 [C (NHC(NH2)=N)], 
158.6 [CO (Urea)], 158.9 [C (Pbf)], 171.0 (C2); ES-MS m/z 885.0 [M+1]
+
; Anal. calcd. for 
C51H61N7O5S: C, 69.28; H, 6.95; N, 11.09. Found: C, 69.54; H, 7.12; N, 10.86. 
4.8.4. (5S,3S)-1,4-Dibenzyl-5-((S)-1-(3-benzylureido)-2-phenylethyl)-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino) propyl)-2-oxopiperazine 
[(S)-29a] 
Amorphous solid (75 mg, 85%); [α]D
20
 +9.9 (c 1.2, CH2Cl2); HPLC [Sunfire C18 (4.6  150 
mm, 3.5 μm), 60-100% gradient of solvent A in B, 30 min] tR 11.52 min;
 1
H NMR (400 MHz, 
(CD3)2CO) δ (ppm): 1.43 [s, 6H, 2CH3 (Pbf)], 1.54 [m, 2H, -H (Arg)], 1.70 [m, 2H, β-H 
(Arg)], 2.04 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.56 (m, 1H, CH2-Ph), 2.57 [s, 3H, 
CH3 (Pbf)], 2.98 (m, 1H, CH2-Ph), 2.99 [s, 2H, CH2 (Pbf)], 3.08 [m, 2H, -H (Arg)], 3.10 [m, 
1H, 3-H and 5-H], 3.45 (d, 2H, J = 8 Hz, 6-H), 3.75 [d, 1H, J = 13.5 Hz, 4-CH2 (Bn)], 3.99 [d, 
1H, J = 13.5 Hz, 4-CH2 (Bn)], 4.15 (m, 1H, 5-CH), 4.18 [dd, 1H, J = 5.5 and 15 Hz, CH2 (Bn, 
Urea)], 4.27 [dd, 1H, J = 6.5 and 15 Hz, CH2 (Bn, Urea)], 4.51 [d, 1H, J = 15 Hz, 1-CH2 
(Bn)], 4.68 [d, 1H, J = 15 Hz, 1-CH2 (Bn)], 5.75 (d, 1H, J = 9 Hz, 5-CH-NH), 5.97 (m, 1H, 
CONH), 6.40 [br s, 3H, NHC(NH2)=N], 7.07-7.45 (m, 20H, Ar); 
13
C NMR (100 MHz, 
(CD3)2CO) δ (ppm): 12.6, 18.3, 19.5 [3CH3 (Pbf)], 26.9 [Cγ (Arg)], 28.7 [2CH3 (Pbf)], 
31.4[Cβ (Arg)], 38.4 (CH2-Ph), 41.0 [Cδ (Arg)], 43.7 [CH2 (Pbf)], 44.2 [CH2 (Bn, Urea)], 45.8 
(C6), 49.8 [1-CH2 (Bn)], 54.9 (C5-CH), 63.1 [4-CH2 (Bn)], 63.6 (C5), 63.8 (C3), 87.0, 117.5, 
125.4 [3C (Pbf)], 126.9, 127.4, 127.8, 128.1, 128.2, 128.7, 129.0, 129.1, 129.2, 129.5, 130.1, 
130.3 [20CH (Ar)], 132.8, 135.7 [2C (Pbf)], 138.6 [C (Ar)], 138.7 [C (Pbf)], 140.0, 141.6 [3C 
(Ar)], 157.5 [C (NHC(NH2)=N)], 158.9 [C (Pbf)], 159.9 [CO (Urea)], 172.1 (C2); ES-MS m/z 
885.0 [M+1]
+
; Anal. calcd. for C51H61N7O5S: C, 69.28; H, 6.95; N, 11.09. Found: C, 69.03; 
H, 7.21; N, 10.97. 
4.9. General procedure for the synthesis of the Arg derived -amino nitriles (RS)-32a and -
33a 
TEA (279 L, 2 mmol mmol) was added to a solution of H-Arg(Pbf)-OMe·HCl (954 mg, 2 
mmol) in MeOH (25 mL). After 15 min of stirring at rt, ZnCl2 (272 mg, 2 mmol) was added, 
followed by the addition of the corresponding aldehyde 30 (295mg, 2.2 mmol) or 31 [57, 58] 
(601 mg, 2.2 mmol, freshly prepared as indicated in the Supplementary content) and the 
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mixture was stirred for 1 h. Then, TMSCN was added (375 μL, 3 mmol) and the mixture was 
stirred overnight at rt. The solvent was removed under reduced pressure and the residue was 
processed as above indicated in the general procedure for the synthesis of [CH(CN)NH] 
pseudodipeptides to give the -amino nitriles (RS)-32a and -33a. 
4.9.1. N-((RS)-1-Cyano-3-phenylpropyl)-Arg(Pbf)-OMe [(RS)-32a] 
White solid (992 mg, 85 %)); HPLC-MS [Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% 
gradient of solvent A in B, 5 min] tR 5.52 min;
 1
H NMR (300 MHz, CDCl3) δ (ppm): 1.45 [s, 
6H, 2CH3 (Pbf)], 1.49-1.85 [m, 4H, -H and -H (Arg)], 1.95-2.14 (m, 2H, 3-H), 2.03 [s, 3H, 
CH3 (Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.56 [s, 3H, CH3 (Pbf)], 2.68-2.89 (m, 2H, 4-H), 2.94 [s, 
2H, CH2 (Pbf)], 3.08-3.24 [m, 2H, -H (Arg)], 3.32 and 3.43 [2t, 1H, J = 6 Hz, -H (Arg)], 
3.46 and 3.55 (2t, 1 H, J = 6 Hz, 2-H), 3.71 and 3.74 (2s, 3H, OMe), 5.81 and 5.99 (br s, 3H, 
NHC(NH2)=N), 7.14-7.31 (m, 5H, Ph); 
13
C NMR (75 MHz, CDCl3) δ (ppm): 12.6, 18.1, 19.4 
[3CH3 (Pbf)], 25.7 and 25.9 [Cγ (Arg)], 28.7 [2CH3 (Pbf)], 30.5 and 30.8 [Cβ (Arg)], 31.7 
(C4), 35.5 and 35.8 (C3), 40.9 and 43.3 [CH2 (Pbf)], 48.7 and 48.9 (C2), 52.6 (OMe), 58.8 and 
59.7 [C (Arg)], 86.6, 117.7, 124.8 [3C (Pbf)], 120.1 (CN), 126.6, 128.5, 128.8 (5 CH, Ph), 
132.3, 132.9 (2C, Ph), 138.4, 139.9, 158.9 [3C (Pbf)], 156.3[C (NHC(NH2)=N)], 174.3, 174.5 
(CO2); ES-MS m/z 583.2828 [M+1]
+
; Anal. calcd. for C30H41N5O5S: C, 61.73; H, 7.08; N, 
12.00. Found: C, 62.03; H, 7.21; N, 11.87. 
4.9.2. N-((RS)-3-(1-(tert-Butoxycarbonyl)-indol-3-yl)-1-cyanopropyl)-Arg(Pbf)-OMe [(RS)-
33a] 
White solid (751 mg, 52 %)); HPLC-MS [Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% 
gradient of solvent A in B, 5 min] tR 6.29 min;
 1
H NMR (300 MHz, CDCl3) δ (ppm): 1.44  [s, 
6H, 2CH3 (Pbf)], 1.67 (s. 9H, Boc), 1.53-1.89 [m, 4H, -H and -H (Arg)], 2.08 [s, 3H, CH3 
(Pbf)], 2.17 (m, 2H, 3-H), 2.51 [s, 3H, CH3 (Pbf)], 2.57 [s, 3H, CH3 (Pbf)], 2.80-3.05 (m, 2H, 
4-H), 2.93 [s, 2H, CH2 (Pbf)], 3.07-3.27 [m, 2H, -H (Arg)], 3.32 and 3.48 [m, 1H, -H 
(Arg)], 3.47 and 3.64 (m, 1 H, 2-H), 3.69 and 3.74 (2s, 3H, OMe), 5.71 and 5.96 [br s, 3H, 
NHC(NH2)=N], 7.21-7.41 (m, 4H, Ind), 7.51 [d, 1H, J = 8 Hz, 4-H (Ind)]; 
13
C NMR (75 
MHz, CDCl3) δ (ppm): 12.6, 18.1, 19.4 [3CH3 (Pbf)], 20.09 and 21.1 (C4), 25.3 and 25.5 [Cγ 
(Arg)], 28.4 [3CH3 (Boc)], 28.7 [2CH3 (Pbf)], 30.0 and 30.3 [Cβ (Arg)], 33.1 and 33.2 (C3), 
41.1 [C (Arg)], 43.3 [CH2 (Pbf)], 48.5 and 48.9 (C2), 52.4 and 52.5 (OMe), 58.7 and 59.4 [C 
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(Arg)], 83.9 (C, Boc), 86.6, 115.5, 123.1 [3C (Pbf)], 115.5 (C3, Ind), 118.9 and 119.1 (CN), 
118.6, 118.7, 119.0, 119.1, 119.9, 120.2, 122.7, 122.9, 124.8, 124.9 (CH, Ind), 130.2, 130.3 
135.6 (C3a and C7a, Ind), 132.6, 138.7, 155.9 [3C (Pbf)], 159.0 [C (NHC(NH2)=N)], 174.2 
(CO2); ES-MS m/z 722.3476 [M+1]
+
; Anal. calcd. for C37H50N6O7S: C, 61.47; H, 6.97; N, 
11.63. Found: C, 61.63; H, 7.11; N, 11.47. 
4.10. General procedure for the synthesis of the 2-oxopiperazine derivatives (R)- and (S)-
34a and -35a 
Raney-Ni (2.4 g, previously washed with MeOH) and hydrazine monohydrate (1.26 mL, 
26 mmol) were added to a solution of the corresponding epimeric mixture of -amino nitrile 
(RS)-32a and -33a (2.06 mmol) in MeOH (50 mL) and the mixture was heated at 65ºC for 20 
min. Afterward, the reaction mixture was filtered over celite and the solvent was evaporated 
under reduced pressure. The residue was purified by flash chromatography, by using MeOH 
in CH2Cl2 gradient as mobile phase to obtain the desired resolved 2-oxopiperazines (R)- and 
(S)-34a and -35a. 
4.10.1. (5R,3S)-3-(3-(2-((2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-
guanidino)propyl)-5-phenethyl-2-oxopiperazine [(R)-34a] 
White solid (345 mg, 31 %)); [α]D
20
 -0.4 (c 2, CHCl3); Mp: 129-131 ºC; HPLC-MS 
[Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 3.80 min;
 
1
H NMR (400 MHz, CDCl3) δ (ppm): 1.37 [s, 6H, 2CH3 (Pbf)], 1.53-1.91 [m, 6H, 1-H 
(phenethyl), -H and -H (Arg)], 2.00 [s, 3H, CH3 (Pbf)], 2.09 (br s, 1H, 4-H), 2.43 [s, 3H, 
CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.57 and 2.64 [2m, 2H, 2-H (phenethyl)], 2.85 [s, 2H, 
CH2 (Pbf)], 2.88 (m, 1H, 5-H), 2.99-3.24 [m, 4H, 6-H and -H (Arg)], 3.31 (m, 1H, 3-H), 
6.32 (br s, 1H, 1-H), 6.43 and 6.89 [br s, 3H, NHC(NH2)=N], 7.07-7.12 and 7.17-7.20 (2 m, 
5H, Ph); 
13
C NMR (100 MHz, CDCl3) δ (ppm): 12.6, 18.1, 19.4 [3CH3 (Pbf)], 26.1 [Cγ 
(Arg)], 28.7 [2CH3 (Pbf)], 29.5 [Cβ (Arg)], 32.3 [C2 (phenethyl)], 35.0 [C1 (phenethyl)], 41.0  
[C (Arg)], 43.4 [CH2 (Pbf)], 46.6 (C5), 48.1 (C6), 53.3(C3), 86.5, 117.5, 124.7 [3C (Pbf)], 
126.2, 128.4, 128.6 (5 CH, Ph), 141.4 (C, Ph), 132.4, 133.2 , 138.4, 158.7 [4C (Pbf)], 156.7 
[C (NHC(NH2)=N)], 173.3 (C2); ES-MS m/z 556.2950 [M+1]
+
; Anal. calcd. for C29H41N5O4S: 
C, 62.68; H, 7.44; N, 12.60. Found: C, 62.83; H, 7.51; N, 12.47. 
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4.10.2. (5S,3S)-3-(3-(2-((2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-
guanidino)propyl)-5-phenethyl-2-oxopiperazine [(S)-34a] 
White solid (389 mg, 35 %)); [α]D
20
 -0.4 (c 2, CHCl3); Mp: 128-130 ºC; HPLC-MS 
[Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 3.83 min;
 
1
H NMR (400 MHz, CDCl3) δ (ppm): 1.44 [s, 6H, 2CH3 (Pbf)], 1.57-1.92 [m, 6H, 1-H 
(phenethyl), -H and -H (Arg)], 2.07 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.56 [s, 3H, 
CH3 (Pbf)], 2.67 [2m, 2H, 2-H (phenethyl)], 2.93 [s, 2H, CH2 (Pbf)], 3.00 (m, 1H, 5-H), 3.18 
[m, 4H, 6-H and -H (Arg)], 3.50 (m, 1H, 3-H), 6.28- 6.56 [br s, 3H, NHC(NH2)=N], 6.86 (br 
s, 1H, 1-H), 7.14-7.20 and 7.24-7.28 (2 m, 5H, Ph); 
13
C NMR (100 MHz, CDCl3) δ (ppm): 
12.6, 18.1, 19.5 [3CH3 (Pbf)], 25.4 [Cγ (Arg)], 28.7 [2CH3 (Pbf)], 29.9 [Cβ (Arg)], 32.3 [C2 
(phenethyl)], 35.0 [C1 (phenethyl)], 41.1  [C (Arg)], 43.4 [CH2 (Pbf)], 48.0 (C6), 52.2 (C5), 
58.3(C3), 86.5, 117.6, 124.7 [3C (Pbf)], 126.3, 128.4, 128.8 (5 CH, Ph), 141.2 (C, Ph), 132.4, 
133.2, 138.4, 158.8 [4C (Pbf)], 156.5 [C (NHC(NH2)=N)], 172.5 (C2); ES-MS m/z 556.2953 
[M+1]
+
; Anal. calcd. for C29H41N5O4S: C, 62.68; H, 7.44; N, 12.60. Found: C, 62.81; H, 7.53; 
N, 12.55. 
4.10.3. (5R,3S)-5-(2-(1-(tert-Butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine 
[(R)-35a] 
White solid (361 mg, 26 %)); [α]D
20
 -5.8 (c 2, CHCl3); Mp: 124-126 ºC; HPLC-MS 
[Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 4.10 min;
 
1
H NMR (400 MHz, CDCl3) δ (ppm): 1.36 [s, 6H, 2CH3 (Pbf)], 1.58 (s, 9H, Boc), 1.50-1.90 
[m, 6H, 1-H (phenethyl), -H and -H (Arg)], 1.99 [s, 3H, CH3 (Pbf)], 2.42 [s, 3H, CH3 
(Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.62-2.80 [2m, 2H, 2-H (phenethyl)], 2.83 [s, 2H, CH2 (Pbf)], 
2.97 (m, 1H, 5-H), 3.02-3.28 [m, 4H, 6-H and -H (Arg)], 3.37 (m, 1H, 3-H), 6.34 (br s, 1H, 
1-H), 6.45 [br s, 3H, NHC(NH2)=N], 7.14 [t, 1H, J = 7 Hz, 5-H (Ind)], 7.23 [t, 1H, J = 7 Hz, 
6-H (Ind)], 7.28 [s, 1H, 2-H, (Ind)], 7.42 [d, 1H, J = 7 Hz, 7-H, (Ind)], 8.02 [ br s, 1H, 4-H, 
(Ind)]; 
13
C NMR (100 MHz, CDCl3) δ (ppm): 12.6, 18.1, 19.4 [3CH3 (Pbf)], 21.5 [C2 
(phenethyl)], 26.1 [Cγ (Arg)], 28.4 [3CH3 (Boc)],  28.7 [2CH3 (Pbf)], 29.5 [Cβ (Arg)], 32.3[C1 
(phenethyl)], 40.9 [C (Arg)], 43.3 [CH2 (Pbf)], 46.6 (C5), 48.0 (C6), 55.4 (C3), 83.8 (C, Boc), 
86.5, 117.6, 120.2 [3C (Pbf)], 115.4, 119.1, 122.5, 124,6 (5 CH, Ind), 130.5, 133.2 (2C, Ind), 
132.4, 138.5, 158.8 [3C (Pbf)], 150.0 (CO, Boc), 156.7 [C (NHC(NH2)=N)], 173.3 (C2); ES-
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MS m/z 695.3601 [M+1]
+
; Anal. calcd. for C36H50N6O6S: C, 62.22; H, 7.25; N, 12.09. Found: 
C, 62.41; H, 7.33; N, 11.92. 
4.10.4. (5S,3S)-5-(2-(1-(tert-Butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine 
[(S)-35a] 
White solid (278 mg, 20 %)); [α]D
20
 -4.4 (c 2, CHCl3); Mp: 134-136 ºC; HPLC-MS 
[Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 4.12 min;
 
1
H NMR (400 MHz, CDCl3) δ (ppm): 1.36 [s, 6H, 2CH3 (Pbf)], 1.59 (s, 9H, Boc), 1.57-1.86 
[m, 6H, 1-H (phenethyl), -H and -H (Arg)], 2.00 [s, 3H, CH3 (Pbf)], 2.42 [s, 3H, CH3 
(Pbf)], 2.50 [s, 3H, CH3 (Pbf)], 2.70  [m, 2H, 2-H (phenethyl)], 2.84 [s, 2H, CH2 (Pbf)], 2.91-
3.22 [m, 5H, 5-H, 6-H and -H (Arg)], 3.41 (m, 1H, 3-H), 6.26 [br s, 3H, NHC(NH2)=N], 
6.67 (br s, 1H, 1-H), 7.14 [t, 1H, J = 7 Hz, 5-H (Ind)], 7.23 [t, 1H, J = 7 Hz, 6-H (Ind)], 7.31 
[s, 1H, 2-H, (Ind)], 7.43 [d, 1H, J = 7 Hz, 7-H, (Ind)], 8.03 [ br s, 1H, 4-H, (Ind)]; 
13
C NMR 
(100 MHz, CDCl3) δ (ppm): 12.6, 18.1, 19.4 [3CH3 (Pbf)], 21.4 [C2 (phenethyl)], 25.4 [Cγ 
(Arg)], 28.4 [3CH3 (Boc)],  28.7 [2CH3 (Pbf)], 29.0 [Cβ (Arg)], 32.9 [C1 (phenethyl)], 41.0 
[C (Arg)], 43.3 [CH2 (Pbf)], 48.0 (C6), 52.3 (C5), 58.3 (C3), 83.8 (C, Boc), 86.5, 117.6, 120.1 
[3C (Pbf)], 115.5, 119.0, 122.6, 124,6 (5 CH, Ind), 130.5, 133.1 (2C, Ind), 132.4, 138.5, 158.8 
[3C (Pbf)], 150.0 (CO, Boc), 156.5 [C (NHC(NH2)=N)], 172.3 (C2); ES-MS m/z 695.3593 
[M+1]
+
; Anal. calcd. for C36H50N6O6S: C, 62.22; H, 7.25; N, 12.09. Found: C, 62.45; H, 7.27; 
N, 11.87. 
4.11. General procedure for the removal of the Pbf protecting group in (R)- and (S)-34a. 
Synthesis of (R)- and (S)-36a 
The corresponding protected 2-oxopiperazine derivative (R)- and (S)-34a (93 mg, 0.17 
mmol) was dissolved in (95:2.5:2.5) TFA:H2O:TIPS mixture (1 mL). After 24 h of stirring at 
rt, the solvents were evaporated to dryness and the residue was lyophilized to give 
quantitatively the respective deprotected derivative (R)- and (S)-36a. 
4.11.1. (5R,3S)-3-(3-Guanidino)propyl)-5-phenethyl-2-oxopiperazine [(R)-36a] 
trifluoroacetate 
Amorphous solid (89 mg, 100 %)); [α]D
20
 -2.3 (c 1, DMSO); HPLC-MS [Sunfire C18 
(4.650 mm, 3.5 μm), 2-30 % gradient of solvent A in B, 5 min] tR 1.02 min;
 1
H NMR (400 
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MHz, D2O) δ (ppm): 1.54-2.08 [m, 6H, 1-H (phenethyl), -H (Arg) and -H (Arg)], 2.59 [m, 
2H, 2-H (phenethyl)], 3.05 [t, 2H, J = 6 Hz, -H (Arg)], 3.28 (t, 1H, J = 12 Hz, 6-H) 3.42 (m, 
1H, 5-H), 3.49 (dd, 1H, J = 4 and 12 Hz, 6-H) , 3.84 (t, 1H, J = 6 Hz, 3-H), 7.09-7.22 (m, 5H, 
Ph); 
13
C NMR (100 MHz, D2O) δ (ppm): 24.4 [Cγ (Arg)], 26.3 [Cβ (Arg)], 30.4[C2 
(phenethyl)], 31.3 [C1 (phenethyl)], 40.5 [C (Arg)], 42.3 (C6), 52.5 (C5), 56.3 (C3), 126.8, 
128.5, 129.0 (5CH, Ph), 140.2 (C, Ph), 156.9 [C (NHC(NH2)=N)], 167.8 (C2); ES-MS m/z 
304.43 [M+1]
+
. 
4.11.2. (5S,3S)-3-(3-Guanidino)propyl)-5-phenethyl-2-oxopiperazine [(S)-36a] 
Amorphous solid (90 mg, 100 %)); [α]D
20
 -5.4 (c 1, DMSO); HPLC-MS [Sunfire C18 
(4.650 mm, 3.5 μm), 2-30 % gradient of solvent A in B, 5 min] tR 1.01 min;
 1
H NMR (400 
MHz, D2O) δ (ppm): 1.53 [m, 2H, -H (Arg)], 1.68-1.9 [m, 2H, -H (Arg)], 1.80-2.01 [m, 2H, 
1-H (phenethyl)], 2.58 [m, 2H, 2-H (phenethyl)], 2.98 [m, 2H, -H (Arg)], 3.25 (dd, 1H, J = 9 
and 15 Hz, 6-H) 3.41-3.51 (m, 2H, 5-H and 6-H), 3.85 (t, 1H, J = 7 Hz, 3-H), 7.06-7.19 (m, 
5H, Ph); 
13
C NMR (100 MHz, D2O) δ (ppm): 24.7 [Cγ (Arg)], 26.8 [Cβ (Arg)], 30.1 [C2 
(phenethyl)], 30.6 [C1 (phenethyl)], 40.4 [C (Arg)], 41.7 (C6), 49.1 (C5), 53.9 (C3), 126.8, 
128.6, 129.0 (5CH, Ph), 140.1 (C, Ph), 156.8 [C (NHC(NH2)=N)], 167.9 (C2); ES-MS m/z 
304.36 [M+1]
+
. 
4.12. General procedure for the N4-benzylation of the 2-oxopiperazines 34a and 35a. 
Synthesis of the 4-benzyl-2-oxopiperazines (R)- and (S)-(37a and 38a) 
DIEA (190 µL, 1.1 mmol) and benzyl bromide (260 µL, 2.2 mmol) were added under 
argon a solution of the corresponding 2-oxopiperazine (R)- and (S)-6a,b and -7a (0.55 mmol) 
in anhydrous CH3CN (5 mL) at 60 ºC. After 3 h of stirring, the solvent was removed under 
reduced pressure. The residue was processed as indicated for the benzylation of analogues 6a 
and 7a. 
4.12.1. (5R,3S)-4-Benzyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)-guanidino)propyl)-5-phenethyl-2-oxopiperazine [(R)-37a] 
White solid (259 mg, 73 %)); [α]D
20
 +0 (c 2, CHCl3); Mp: 89-91 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 5.51 min;
 1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.32 [m, 1H, -H (Arg)], 1.37 [s, 6H, 2CH3 (Pbf)], 1.43-1.74 [m, 
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4H, 1-H (phenethyl), -H and -H (Arg)], 1.85 [m, 1H, 1-H (phenethyl)], 2.00 [s, 3H, CH3 
(Pbf)], 2.42 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 (Pbf)], 2.63 and 2.72 [2m, 2H, 2-H 
(phenethyl)], 2.82 [m, 2H, -H (Arg)], 2.85 [s, 2H, CH2 (Pbf)], 2.97 (m, 1H, 3-H), 3.11 (m, 
2H, 5-H and 6-H), 3.23 (t, 1H, J = 12 Hz, 6-H), 3.30 and 3.84 (2 d, 2H, J =13 Hz, 4-CH2), 
6.22 and 6.27 [2br s, 4H, 1-H  and NHC(NH2)=N], 7.09-7.23 (m, 10H, Ph); 
13
C NMR (100 
MHz, CDCl3) δ (ppm): 12.7, 18.0, 19.4 [3CH3 (Pbf)], 25.7 [Cγ (Arg)], 28.8 [Cβ (Arg)], 28.7 
[2CH3 (Pbf)], 30.3 [C1 (phenethyl)], 32.4 [C2 (phenethyl)], 40.7 [C (Arg)], 43.4 [CH2 (Pbf)], 
43.1 (C6), 49.7 (C5), 50.8 (4-CH2), 60.3 (C3), 86.4, 117.5, 124.7 [3C (Pbf)], 126.3, 128.5, 
128.6 (10CH, Ph), 141.4 (2C, Ph), 132.4, 133.2, 138.5, 158.7 [4C (Pbf)], 156.5 [C 
(NHC(NH2)=N)], 173.3 (C2); ES-MS m/z 646.72 [M+1]
+
; Anal. calcd. for C36H47N5O4S: C, 
66.95; H, 7.33; N, 10.84. Found: C, 67.06; H, 7.51; N, 10.70. 
4.12.2. (5S,3S)-4-Benzyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)-guanidino)propyl)-5-phenethyl-2-oxopiperazine [(S)-37a] 
White solid (255 mg, 72 %)); [α]D
20
 +0  (c 2, CHCl3); Mp: 73-75 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 5.54 min;
 1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.44 [s, 6H, 2CH3 (Pbf)], 1.54 [m, 1H, -H (Arg)], 1.70 [m, 3H, 
1-H (phenethyl) and -H], 1.92 [m, 1H, 1-H (phenethyl)], 2.08 [s, 3H, CH3 (Pbf)], 2.49 [s, 
3H, CH3 (Pbf)], 2.55 [s, 3H, CH3 (Pbf)], 2.55 and 2.65 [2m, 2H, 2-H (phenethyl)], 2.80 (m, 
1H, 5-H), 2.82 [m, 2H, -H (Arg)], 2.93 [s, 2H, CH2 (Pbf)], 3.03-3.23 [m, 4H, 3-H, 6-H  and 
-H (Arg)], 3.40 (m, 1H, 6-H), 3.62 and 3.81 (2 d, 2H, J =13 Hz, 4-CH2), 6.59 [2br s, 4H, 1-H  
and NHC(NH2)=N], 7.09-7.30 (m, 10H, Ph); 
13
C NMR (100 MHz, CDCl3) δ (ppm): 12.7, 
18.0, 19.4 [3CH3 (Pbf)], 25.7 [Cγ (Arg)], 28.7 [2CH3 (Pbf)], 30.6 [Cβ (Arg)], 32.1 [C2 
(phenethyl)], 35.2 [C1 (phenethyl)], 40.7 [C (Arg)], 42.7 (C6), 43.4 [CH2 (Pbf)], 57.6 (C5), 
59.4 (4-CH2), 62.1 (C3), 86.5, 117.6, 124.7 [3C (Pbf)], 126.3, 128.4, 128.6, 129.1 (10CH, Ph), 
139.2, 141.6 (2C, Ph), 132.5, 133.2, 138.5, 158.8 [4C (Pbf)], 156.7 [C (NHC(NH2)=N)], 
174.1 (C2); ES-MS m/z 646.66 [M+1]
+
; Anal. calcd. for C36H47N5O4S: C, 66.95; H, 7.33; N, 
10.84. Found: C, 66.86; H, 7.41; N, 10.68. 
4.12.3. (5R,3S)-4-Benzyl-5-(2-(1-(tert-butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine 
[(R)-38a] 
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White solid (341 mg, 79 %)); [α]D
20
 -1.4 (c 2, CHCl3); Mp: 105-107 ºC; HPLC-MS 
[Sunfire C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 6.19 min;
 
1
H NMR (400 MHz, CDCl3) δ (ppm): 1.43 [s, 6H, 2CH3 (Pbf)], 1.66 (s, 9H, Boc), 1.60-1.90 
[m, 6H, 1-H (phenethyl), -H and -H (Arg)], 2.07 [s, 3H, CH3 (Pbf)], 2.49 [s, 3H, CH3 
(Pbf)], 2.55 [s, 3H, CH3 (Pbf)], 2.82 [2m, 2H, 2-H (phenethyl)], 2.91 [s, 2H, CH2 (Pbf)], 2.96 
[m, 2H, -H (Arg)],3.11 (m, 1H, 3-H), 3.18-3.48 (m, 3H, 6-H and 4-CH2), 3.69 (m, 1H, 5-H), 
3.92 (d, 1H, J = 13 Hz, 4-CH2), 6.33 [br s, 3H, NHC(NH2)=N], 7.20-7.35 (m, 9H, 1-H and 
Ar), 7.49 [d, 1H, J = 8 Hz, 7-H, (Ind)], 8.09 [ d, 1H, J = 8 Hz, 4-H, (Ind)]; 
13
C NMR (100 
MHz, CDCl3) δ (ppm): 12.6, 18.0, 19.4 [3CH3 (Pbf)], 21.7 [C2 (phenethyl)], 25.7 [Cγ (Arg)], 
28.4 [3CH3 (Boc)], 28.7 [2CH3 (Pbf)], 29.4 [Cβ (Arg)], 31.9 [C1 (phenethyl)], 40.7 [C (Arg)], 
43.0 (C6), 43.3 [CH2 (Pbf)], 50.9 (4-CH2), 54.2 (C5), 60.6 (C3), 83.8 (C, Boc), 86.4, 117.5, 
120.1 [3C (Pbf)], 115.5, 119.0, 122.6, 124,5, 124.6, 127.4, 128.5, 128.8, (10 CH, Ar), 130.4, 
133.3 (2C, Ind), 135.6 (C, Ph), 132.3, 138.3, 158.6 [3C (Pbf)], 149.9 (CO, Boc), 156.5 [C 
(NHC(NH2)=N)], 173.3 (C2); ES-MS m/z 786.03 [M+1]
+
; Anal. calcd. for C43H56N6O6S: C, 
65.79; H, 7.19; N, 10.71. Found: C, 65.92; H, 7.23; N, 10.82. 
4.12.4. (5S,3S)-4-Benzyl-5-(2-(1-(tert-butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(2-((2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-oxopiperazine 
[(S)-38a] 
White solid (302 mg, 70 %)); [α]D
20
 +1.2 (c 2, CHCl3); Mp: 94-96 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 6.15 min;
 1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.36 [s, 6H, 2CH3 (Pbf)], 1.58 (s, 9H, Boc), 1.40-1.77 [m, 5H, 1-
H (phenethyl), -H and -H (Arg)], 1.92 [m, 1H, 1-H (phenethyl)], 2.00 [s, 3H, CH3 (Pbf)], 
2.41 [s, 3H, CH3 (Pbf)], 2.48 [s, 3H, CH3 (Pbf)], 2.63 [m, 2H, 2-H (phenethyl)], 2.83 [s, 2H, 
CH2 (Pbf)], 2.96-3.20 [m, 4H, 3-H, 6-H, -H (Arg)], 3.37 (m, 1H, 6-H), 3.59 (m, 2H, 5-H  
and 4-CH2), 3.77 (br s, 1H, 4-CH2), 6.26-6.91 [br s, 4H, 1-H, NHC(NH2)=N], 7.11-7.24 (m, 
8H, Ar), 7.35 [d, 1H, J = 8 Hz, 7-H, (Ind)], 8.02 [br s, 1H, J = 8 Hz, 4-H, (Ind)]; 
13
C NMR 
(100 MHz, CDCl3) δ (ppm): 12.6, 17.9, 19.4 [3CH3 (Pbf)], 21.2 [C2 (phenethyl)], 25.6 [Cγ 
(Arg)], 28.3 [2CH3 (Pbf)], 28.6 [3CH3 (Boc)], 30.2 [Cβ (Arg)], 32.8 [C1 (phenethyl)], 40.6 [C 
(Arg)], 42.6 (C6), 43.2 [CH2 (Pbf)], 53.9 (C5), 59.3 (4-CH2), 62.1 (C3), 83.5 (C, Boc), 86.4, 
117.4, 120.3 [3C (Pbf)], 115.3, 118.9, 122.5, 124,4, 124.6, 127.4, 128.4, 128.8, (10 CH, Ar), 
130.4, 133.2 (2C, Ind), 135.5 (C, Ph), 132.3, 138.4, 158.6 [3C (Pbf)], 149.8 (CO, Boc), 156.7 
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[C (NHC(NH2)=N)], 174.1 (C2); ES-MS m/z 785.95 [M+1]
+
; Anal. calcd. for C36H50N6O6S: 
C, 65.79; H, 7.19; N, 10.71. Found: C, 65.94; H, 7.13; N, 10.65. 
4.13. General procedure for the benzylation of the 4-benzyl-2-oxopiperazines 37a and 38a. 
Synthesis of the 4-benzyl-2-oxopiperazines (R)- and (S)-(39a, 41a, 42a and 44a) 
NaH (60% suspension in mineral oil, 9 mg, 0.21 mmol) and benzyl bromide (69 µL, 0.23 
mmol) were added to a solution of the corresponding 2-oxopiperazine 37a and 38a (0.21 
mmol) in anhydrous mixture THF/DMF (9:1, 5 mL) under argon at 0 ºC. After 24h of stirring, 
the crude reaction mixture was diluted with EtOAc (10 mL) and the excess of NaH was 
hydrolysed by addition of H2O (2 mL). The aqueous layer was extracted with EtOAc (35 
mL) and the organic extracts were dried over Na2SO4 and evaporated to dryness. The residue 
was purified by flash chromatography, using 30-100 EtOAc gradient in hexane as mobile 
phase to give the respective 1,4-dibenzyl-2-oxopiperazines 39a and 42a, as solids, in 20-42 % 
yield and the respective derivative benzylated at the guanidino group 41a and 44a as (Z/E)-
isomeric mixtures in 8-14 % yield. These tribenzylated derivatives were dissolved in 
CH3CN/H2O (1:2, 2 mL) and the solutions were lyophilized to obtain amorphous solids. 
4.13.1. (5R,3S)-1,4-Dibenzyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)-
sulfonyl)-guanidino)propyl)-5-phenethyl-2-oxopiperazine [(R)-39a] 
White solid (65 mg, 42 %)); [α]D
20
 -3.1 (c 1, CHCl3); Mp: 93-95 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 6.36 min;
 1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.42 [s, 6H, 2CH3 (Pbf)], 1.55 [m, 2H, -H (Arg)], 1.64 and 1.86 
[2m, 2H, 1-H (phenethyl)], 1.71 [m, 2H, -H (Arg)], 2.05 [s, 3H, CH3 (Pbf)], 2.48 and 2.54 
[2s, 6H, CH3 (Pbf)], 2.54 and 2.62 [2m, 2H, 2-H (phenethyl)], 2.89 [m, 4H, -H (Arg) and 
CH2 (Pbf)], 3.03-3.24 (m, 4H, 3-H, 5-H, 6-H), 3.34 and 3.83 (2d, 2H, J =12 Hz, 4-CH2), 4.42 
and 4.62 (2d, 2H, J =14 Hz, 1-CH2), 6.97 and 6.08 [2br s, 3H, NHC(NH2)=N], 7.02-7.34 (m, 
15H, Ph); 
13
C NMR (100 MHz, CDCl3) δ (ppm): 12.6, 18.0, 19.4 [3CH3 (Pbf)], 25.7 [Cγ 
(Arg)], 28.1 [Cβ (Arg)], 28.7 [2CH3 (Pbf)], 29.8 [C1 (phenethyl)], 32.3 [C2 (phenethyl)], 40.5 
[C (Arg)], 43.3 [CH2 (Pbf)], 47.4 (C6), 50.2 (C5 and 1-CH2), 51.3 (4-CH2), 61.0 (C3), 86.4, 
117.5, 124.6 [3C (Pbf)], 126.2 and 127.9-129.2 (15CH, Ph), 136.6 and 141.4 (3C, Ph), 132.4, 
133.2, 138.5, 158.7 [4C (Pbf)], 156.2 [C (NHC(NH2)=N)], 171.0 (C2); ES-MS m/z 736.70 
[M+1]
+
; Anal. calcd. for C43H53N5O4S: C, 70.17; H, 7.26; N, 9.52. Found: C, 70.29; H, 7.31; 
N, 9.36. 
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4.13.2. (5S,3S)-1,4-Dibenzyl-3-(3-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)-
sulfonyl)-guanidino)propyl)-5-phenethyl-2-oxopiperazine [(S)-39a] 
White solid (60 mg, 40 %)); [α]D
20
 +1.7 (c 1, CHCl3); Mp: 70-72 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 10-100% gradient of solvent A in B, 5 min] tR 6.20 min;
 1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.36 [s, 6H, 2CH3 (Pbf)], 1.39-1.65 [m, 5H, -H, -H (Arg), and 
1-H (phenethyl)], 1.75 [m, 1H, 1-H (phenethyl)], 1.98 [s, 3H, CH3 (Pbf)], 2.34 [2m, 2H, 2-H 
(phenethyl)], 2.43 and 2.49 [2s, 6H, CH3 (Pbf)], 2.67 (m, 1H, 5-H), 2.83 [s, 2H, CH2 (Pbf)], 
2.95 [m, 2H, -H (Arg)], 3.05 (dd, 1H, J = 8 and 13 Hz, 6-H), 3.22 (m, 2H, 3-H, 6-H), 3.57 
and  3.65 (2d, 2H, J =14 Hz, 4-CH2), 4.38 and 4.52 (2d, 2H, J =14.5 Hz, 1-CH2), 6.00 and 
6.09 [2br s, 3H, NHC(NH2)=N], 6.83 (d, 2H, J = 7 Hz, Ph), 7.06-7.24 (m, 13H, Ph); 
13
C NMR 
(100 MHz, CDCl3) δ (ppm): 12.6, 18.0, 19.4 [3CH3 (Pbf)], 25.6 [Cγ (Arg)], 28.7 [2CH3 
(Pbf)], 29.8 [Cβ (Arg)], 30.6 [C1 (phenethyl)], 32.1 [C2 (phenethyl)], 40.8 [C (Arg)], 43.3 
[CH2 (Pbf)], 47.4 (C6), 50.1 (1-CH2), 56.7 (C5), 58.7 (4-CH2), 61.5 (C3), 86.4, 117.5, 124.6 
[3C (Pbf)], 126.1 and 127.9-129.0 (15CH, Ph), 136.5 and 141.2 (3C, Ph), 132.4, 133.3, 138.4, 
158.6 [4C (Pbf)], 156.2 [C (NHC(NH2)=N)], 171.2 (C2); ES-MS m/z 736.74 [M+1]
+
; Anal. 
calcd. for C43H53N5O4S: C, 70.17; H, 7.26; N, 9.52. Found: C, 70.09; H, 7.27; N, 9.43. 
4.13.3. (5R,3S)-1,4-Dibenzyl-3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-2,3-dihydro-
benzofuran-5-yl)sulfonyl)-guanidino)propyl)-5-phenethyl-2-oxopiperazine [(R)-41a] 
Amorphous solid (22 mg, 13 %)); HPLC-MS [Sunfire C18 (4.6  50 mm, 3.5 μm), 10-
100% gradient of solvent A in B, 5 min] tR 5.66 (83%) and 5.85 (17%) min;
 1
H NMR [500 
MHz, (CD3)2CO] δ (ppm): 1.41 and 1.42 [2s, 6H, 2CH3 (Pbf)], 1.57-1.78 [m, 4H, -H and -
H (Arg)], 1.71 and 1.94 [2m, 2H 1-H (phenethyl)], 2.01 [s, 3H, CH3 (Pbf)], 2.46 [s, 3H, CH3 
(Pbf)], 2.52 [s, 3H, CH3 (Pbf)], 2.60 and 2.75 [2m, 2H, 2-H (phenethyl)], 2.93 [s, 2H, CH2 
(Pbf)], 3.07 [m, 3H, 3-H and -H (Arg)], 3.19 (bd, 1H, J = 10 Hz, 6-H), 3.26 (m, 1H, 3-H), 
3.36 (m, 1H, 6-H), 3.39 (d, 1H, J = 14 Hz, 4-CH2), 3.94 (m, 1H, 4-CH2), 4.43 [d, 2H, J = 5 
Hz, NHC(NH-CH2)=N], 4.53 and 4.63 (2 d, 2H, J = 14.5 Hz, 1-CH2), 7.10-7.37 (m, 20H, Ph); 
13
C NMR [125 MHz, (CD3)2CO] δ (ppm): 12.5, 18.3, 19.6 [3CH3 (Pbf)], 26.7 [Cγ (Arg)], 28.6 
[Cβ (Arg)], 28.7 [2CH3 (Pbf)], 30.3 [C1 (phenethyl)], 33.0 [C2 (phenethyl)], 41.6 [C (Arg)], 
43.6 [CH2 (Pbf)], 45.3 (NHC(NH-CH2)=N), 48.1 (C6), 50.2 (1-CH2), 51.0 (C5), 51.5 (4-CH2), 
61.9 (C3), 86.9, 117.5, 125.2 [3C (Pbf)], 126.6, 127.9-129.9 (20CH, Ph), 142.7 and 139.9 (4C, 
Ph), 132.7, 135.6, 138.7, 158.7 [4C (Pbf)], 155.9 [NHC(NH-Bn)=N)], 170.5 (C2); ES-MS m/z 
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827.04 [M+1]
+
; Anal. calcd. for C50H59N5O4S: C, 72.70; H, 7.20; N, 8.48. Found: C, 72.89; 
H, 7.31; N, 8.25. 
4.13.4. (5S,3S)-1,4-Dibenzyl-3-(3-(3-benzyl-2-((2,2,4,6,7-pentamethyl-2,3-dihydro-
benzofuran-5-yl)sulfonyl)-guanidino)propyl)-5-phenethyl-2-oxopiperazine [(S)-41a] 
Amorphous solid (24 mg, 14 %)); HPLC-MS [Sunfire C18 (4.6  50 mm, 3.5 μm), 10-
100% gradient of solvent A in B, 5 min] tR 5.63 (70%) and 5.84 (30%) min;
 1
H NMR [500 
MHz, (CD3)2CO] δ (ppm): 1.41 and 1.43 [2s, 6H, 2CH3 (Pbf)], 1.54-1.76 [m, 4H, -H and -
H (Arg)], 1.57 and 1.82 [2m, 2H 1-H (phenethyl)], 2.01 [s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 
(Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.47 [m, 2H, 2-H (phenethyl)], 2.83 (m, 1H, 5-H), 2.95 [s, 2H, 
CH2 (Pbf)], 3.02-3.16 [m, 2H, -H (Arg)], 3.18-3.28 (m, 2H, 3-H and 6-H), 3.48 and 3.51 (2d, 
1H, J = 5 and 13 Hz, 6-H), 3.67, 3.72 and 3.79 (3d, 2H, J = 14 Hz, 4-CH2), 4.42 [d, 2H, J = 6 
Hz, NHC(NH-CH2)=N], 4.57 (s, 2H, 1-CH2), 7.08-7.35 (m, 20H, Ph); 
13
C NMR [125 MHz, 
(CD3)2CO] δ (ppm): 12.5, 18.3, 19.5 [3CH3 (Pbf)], 26.7 [Cγ (Arg)], 28.7 [2CH3 (Pbf)], 31.1 
[Cβ (Arg)], 32.8 [C2 (phenethyl)], 35.8 [C1 (phenethyl)], 41.8 [C (Arg)], 43.6 [CH2 (Pbf)], 
45.3 (NHC(NH-CH2)=N), 48.0 (C6), 50.2 (1-CH2), 57.5 and 57.7 (C5), 59.3 (4-CH2), 64.2 
(C3), 86.9, 117.5, 125.2 [3C (Pbf)], 126.5, 127.9-129.9 (20CH, Ph), 140.4, 140.5 and 142.8 
(4C, Ph), 132.8, 135.6, 138.7, 158.8 [4C (Pbf)], 155.9 [NHC(NH-Bn)=N)], 171.1 (C2); ES-
MS m/z 827.04 [M+1]
+
; Anal. calcd. for C50H59N5O4S: C, 72.70; H, 7.20; N, 8.48. Found: C, 
72.87; H, 7.33; N, 8.31. 
4.13.5. (5R,3S)-1,4-Dibenzyl-5-(2-(1-(tert-butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-
oxopiperazine [(R)-42a] 
White solid (40 mg, 22 %)); [α]D
20
 -8.4 (c 1, CHCl3); Mp: 106-108 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 80-100% gradient of solvent A in B, 5 min] tR 4.06 min;
 1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.44 [s, 6H, 2CH3 (Pbf)], 1.67 (s, 9H, Boc), 1.55-2.03 [m, 6H, 1-
H (phenethyl), -H and -H (Arg)], 2.07 [s, 3H, CH3 (Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.57 [s, 
3H, CH3 (Pbf)], 2.47-2.62 and 2.64-2.78 [2m, 2H, 2-H (phenethyl)], 2.90 [s, 2H, CH2 (Pbf)], 
2.85-3.04 [m, 2H, -H (Arg)], 3.05-3.31 (m, 4H, 3-H, 5-H, 6-H), 3.38 and 3.81 (2d, 2H, J = 
13 Hz, 4-CH2), 4.42 and 4.69 (2d, 2H, J = 14 Hz, 1-CH2), 6.04 and 6.19 [2br s, 3H, 
NHC(NH2)=N], 7.12-7.24  (m, 13H, Ar), 7.32 [d, 1H, J = 7.5 Hz, 7-H, (Ind)], 8.01 [br s, 1H, 
4-H, (Ind)]; 
13
C NMR (100 MHz, CDCl3) δ (ppm): 12.6, 18.0, 19.4 [3CH3 (Pbf)], 21.7 [C2 
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(phenethyl)], 25.7 [Cγ (Arg)], 28.4 [3CH3 (Boc)], 28.7 [2CH3 (Pbf)], 29.8 [Cβ (Arg)], 31.9 [C1 
(phenethyl)], 40.6 [C (Arg)], 43.3 [CH2 (Pbf)], 47.5 (C6), 50.2 (1-CH2), 50.4 (C5), 51.3 (4-
CH2), 61.1 (C3), 83.8 (C, Boc), 86.3, 117.4, 124.6 [3C (Pbf)], 115.4, 118.9, 120.0, 122.5, 
124.5, 127.6-129.0, 130.3, 135.5 (15 CH, Ar), 130.3, 133.2 (2C, Ind), 136.6, 138.4 (2C, Ph), 
132.3, 135.6, 138.3, 158.6 [4C (Pbf)], 149.9 (CO, Boc), 156.2 [C (NHC(NH2)=N)], 171.0 
(C2); ES-MS m/z 876.11 [M+1]
+
; Anal. calcd. for C50H62N6O6S: C, 68.62; H, 7.14; N, 9.60. 
Found: C, 68.92; H, 7.25; N, 9.52. 
4.13.6. (5S,3S)-1,4-Dibenzyl-5-(2-(1-(tert-butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-
oxopiperazine [(S)-42a] 
White solid (77 mg, 42 %)); [α]D
20
 +7.7 (c 1, CHCl3); Mp: 96-98 ºC; HPLC-MS [Sunfire 
C18 (4.6  50 mm, 3.5 μm), 40-100% gradient of solvent A in B, 5 min] tR 6.43 min; 
1
H NMR 
(400 MHz, CDCl3) δ (ppm): 1.46 [s, 6H, 2CH3 (Pbf)], 1.68 (s, 9H, Boc), 1.53-1.99 [m, 6H, 1-
H (phenethyl), -H and -H (Arg)], 2.08 [s, 3H, CH3 (Pbf)], 2.53 [s, 3H, CH3 (Pbf)], 2.59 [s, 
3H, CH3 (Pbf)], 2.47-2.56 [m, 2H, 2-H (phenethyl)], 2.77 (m, 1H, 5-H), 2.79 [s, 2H, CH2 
(Pbf)], 2.96 [m, 2H, -H (Arg)], 3.08 (dd, 1H, J =8.5 and 13 Hz, 6-H), 3.19-3.28 (m, 2H, 3-H,  
and 6-H), 3.60 and 3.62 (2d, 2H, J = 14 Hz, 4-CH2), 4.43 and 4.49 (2d, 2H, J = 14 Hz, 1-
CH2), 6.01 and 6.12 [2br s, 3H, NHC(NH2)=N], 7.05-7.23  (m, 14H, Ar), 7.99 [br s, 1H, 4-H, 
(Ind)]; 
13
C NMR (100 MHz, CDCl3) δ (ppm): 12.6, 18.0, 19.4 [3CH3 (Pbf)], 21.3 [C2 
(phenethyl)], 25.9 [Cγ (Arg)], 28.3 [3CH3 (Boc)], 28.6 [2CH3 (Pbf)], 29.8 [Cβ (Arg)], 30.4 [C1 
(phenethyl)], 40.8 [C (Arg)], 43.3 [CH2 (Pbf)], 47.4 (C6), 50.1 (1-CH2), 56.8 (C5), 58.8 (4-
CH2), 63.6 (C3), 83.7 (C, Boc), 86.3, 117.4, 124.5 [3C (Pbf)], 115.3, 118.8, 120.0, 122.3, 
122.5, 127.5-128.9 (15 CH, Ar), 130.3, 133.3 (2C, Ind), 135.5, 138.9 (2C, Ph), 132.3, 136.4, 
138.4, 158.6 [4C (Pbf)], 149.8 (CO, Boc), 156.2 [C (NHC(NH2)=N)], 171.2 (C2); ES-MS m/z 
876.11 [M+1]
+
; Anal. calcd. for C50H62N6O6S: C, 68.62; H, 7.14; N, 9.60. Found: C, 68.82; 
H, 7.22; N, 9.47. 
4.13.7. (5R,3S)-1,4-Dibenzyl-5-(2-(1-(tert-butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(3-benzyl-2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-
oxopiperazine [(R)-44a] 
Amorphous solid (20 mg, 10 %)); HPLC-MS [Sunfire C18 (4.6  50 mm, 3.5 μm), isocratic  
95 % of solvent A in 5% of B] tR 2.32 (73%) and 2.47 (27%) min;
 1
H NMR [500 MHz, 
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(CD3)2CO] δ (ppm): 1.39 and 1.42 [2s, 6H, 2CH3 (Pbf)], 1.64 (s, 9H, Boc), 1.55-2.03 [m, 6H, 
1-H (phenethyl), -H and -H (Arg)], 1.99 [s, 3H, CH3 (Pbf)], 2.45 [s, 3H, CH3 (Pbf)], 2.51 
[s, 3H, CH3 (Pbf)], 2.59-2.78 [m, 2H, 2-H (phenethyl)], 2.92 [s, 2H, CH2 (Pbf)], 3.06 [m, 2H, 
-H (Arg)], 3.13 (m, 1H, 3-H), 3.20 and 3.38 (2m, 2H, 6-H), 3.34 (m, 1H, 5-H), 3.41 (d, 1H, J 
= 14 Hz, 4-CH2), 3.91 (m, 1H, 4-CH2), 4.42 [d, 2H, J = 6 Hz, NHC(NH-CH2)=N], 4.53, 4.55, 
4.60 and 4.65 (4d, 2H, J = 14 Hz, 1-CH2), 7.12-7.37  (m, 18H, Ar), 7.49 and 7.53 (2d, 1H, J = 
8 Hz, 7-H, (Ind)], 8.12 [d, 1H, J = 7.5 Hz, 4-H, (Ind)]; 
13
C NMR [125 MHz, (CD3)2CO] δ 
(ppm): 12.4, 18.1, 19.4 [3CH3 (Pbf)], 22.0 [C2 (phenethyl)], 24.7 [Cγ (Arg)], 28.1 [2CH3 
(Pbf)], 28.5 [3CH3 (Boc)], 27.6 [Cβ (Arg)], 28.4 [C1 (phenethyl)], 41.4 [C (Arg)], 43.4 [CH2 
(Pbf)], 47.9 (C6), 50.1 (1-CH2), 51.2 (C5), 51.5 (4-CH2), 61.8 and 61.9 (C3), 83.9 (C, Boc), 
86.7, 117.3, 124.9 [3C (Pbf)], 115.8, 119.8, 121.2, 123.0, 124.9, 125.1, 127.7-129.6 (20 CH, 
Ar), 131.2, 135.5 (2C, Ind), 136.3, 138.5, 139.7 (3C, Ph), 132.6, 135.4, 138.7, 158.7 [4C 
(Pbf)], 150.1 (CO, Boc), 155.7 and 156.5 [NHC(NH-Bn)=N)], 170.6 (C2); ES-MS m/z 965.96 
[M+1]
+
; Anal. calcd. for C57H68N6O6S: C, 70.93; H, 7.10; N, 8.71. Found: C, 70.82; H, 7.14; 
N, 8.82. 
4.13.8. (5S,3S)-1,4-Dibenzyl-5-(2-(1-(tert-butoxycarbonyl)-indol-3-yl)ethyl-3-(3-(3-benzyl-2-
((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)propyl)-2-
oxopiperazine [(S)-44a] 
Amorphous solid (16 mg, 8 %)); HPLC-MS [Sunfire C18 (4.6  50 mm, 3.5 μm), isocratic  
95 % of solvent A in 5% of B] tR 2.36 (75%) and 2.52 (25%) min;
 1
H NMR [500 MHz, 
(CD3)2CO] δ (ppm): 1.41 [s, 6H, 2CH3 (Pbf)], 1.65 (s, 9H, Boc), 1.67-1.91 [m, 6H, 1-H 
(phenethyl), -H and -H (Arg)], 2.00 [s, 3H, CH3 (Pbf)], 2.43 [s, 3H, CH3 (Pbf)], 2.51 [s, 3H, 
CH3 (Pbf)], 2.58 [m, 2H, 2-H (phenethyl)], 2.91 [s, 2H, CH2 (Pbf)], 2.96 (m, 1H, 5-H), 3.12 
[m, 2H, -H (Arg)], 3.29 (m, 1H, 3-H), 3.27 and 3.59 (2m, 2H, 6-H), 3.78 (m, 1H, 4-CH2), 
4.42 and 4.56 [2d, 2H, J = 5.5 Hz, NHC(NH-CH2)=N], 4.51 and 4.67 (2d, 2H, J = 14.5 Hz, 1-
CH2), 7.12-7.37  (m, 18H, Ar), 7.41 (d, 1H, J = 7.5 Hz, 7-H, (Ind)], 8.09 [d, 1H, J = 7.5 Hz, 4-
H, (Ind)]; 
13
C NMR [125 MHz, (CD3)2CO] δ (ppm): 12.2, 18.0, 19.3 [3CH3 (Pbf)], 21.9 [C2 
(phenethyl)], 26.7 [Cγ (Arg)], 28.0 [2CH3 (Pbf)], 28.3 [3CH3 (Boc)], 31.0 [Cβ (Arg)], 33.5 [C1 
(phenethyl)], 41.8 [C (Arg)], 43.3 [CH2 (Pbf)], 45.3 (1-CH2), 48.0 (C6), 57.6 (C5), 59.2 (4-
CH2), 64.2 (C3), 84.0 (C, Boc), 86.9, 117.5, 125.0 [3C (Pbf)], 115.9, 119.9, 121.4, 123.2, 
125.0, 125.2, 127.9-129.8 (20 CH, Ar), 131.3, 135.7, 135.1 (2C, Ind), 136.4, 138.4, 140.5 
(3C, Ph), 132.8, 135.6, 138.7, 158.8 [4C (Pbf)], 150.3 (CO, Boc), 155.9 and 156.5 [NHC(NH-
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Bn)=N)], 171.2 (C2); ES-MS m/z 965.96 [M+1]
+
; Anal. calcd. for C57H68N6O6S: C, 70.93; H, 
7.10; N, 8.71. Found: C, 71.07; H, 7.19; N, 8.60. 
4.14. Platelet aggregation inhibition assay 
Whole blood was obtained from human volunteers who were not taking any platelet 
altering drugs for two weeks prior to donation. Blood was collected by venous puncture into 
2.7 mL vacutainer tubes containing 3.2% buffered sodium citrate. Blood was centrifuged at 
250×g for 7 min to obtain platelet rich plasma (PRP). After removal of PRP, the blood was re-
centrifuged at 900×g for 10 min to obtain platelet poor plasma (PPP). The PPP was used as a 
reference in the optical aggregation and as a diluent to achieve a final platelet concentration of 
200.000 platelet/μL in PRP. Tests were performed in an optical aggregometer (Chrono-Log 
Model 440 Four Channel). Briefly, a 0.5 mL sample of diluted PRP was added to a glass 
cuvette and incubated with either vehicle (DMSO solution) or tested compound, at a 0.1 
mg/mL concentration, for 5 min at 37 ºC. At the beginning of each experiment, aggregation 
response to SFLLRN (30μM) was evaluated and the maximum aggregation value at the end 
of 5 min was recorded. Aggregation response to SFLLRN plus compound was recorded and 
compared to control (SFLLRN/vehicle) to determine the % of inhibition. Each compound was 
tested twice and the results are the mean of the two assays. 
4.15. Cytotoxicity assays 
A colorimetric assay, using the sulforhodamine B (SRB) reaction, was adapted for a 
quantitative measurement of cell growth and viability, following the technique described by 
Skehan, P. A. et al. [59]. Cells (MDA-MB-231, A549 and HT-29) were seeded in 96 well 
microtiter plates, at 5103 cells per well in aliquots of 195 μL of RPMI medium, and they 
were allowed to attach to the plate surface by growing in drug free medium for 18 h. 
Afterwards, samples were added in aliquots of 5 μL [dissolved in (3:7) DMSO/H2O]. After 48 
h exposure, cells were fixed by adding 50 μL of cold 50% (wt/vol) trichloroacetic acid, and 
incubating at 4 ºC for 60 min. Then, the plates were washed with deionized H2O and dried. 
100 μL of SRB solution (0.4% wt/vol in 1% acetic acid) was added to each microtiter well 
and these were incubated at room temperature for 10 min. Unbound SRB was removed by 
washing with 1% acetic acid, the plates were air dried, and the bound stain was solubilized 
with Tris buffer. Optical densities were read on an automated spectrophotometer plate reader 
at a single wavelength of 490 nm. Data analysis was automatically generated by the high 
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throughput screening LIMS implemented at the laboratory. The three response parameters 
GI50 (50% cell growth inhibition), LC50 (50% lethal concentration), and TGI (total growth 
inhibition) were extracted from concentration-response curves by linear interpolation, 
according to the National Cancer Institute (NCI) protocols [60]. 
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